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Section 1 Introduction 
 
Cigarette smoking is anecdotally seen more often amongst schizophrenic than 
well subjects. Research has suggested a variety of explanations which are 
discussed; the role of genetics, psychosocial explanations and smoking as self-
medication. The financial, physical health and treatment options of and for 
nicotine dependence are also examined with reference to schizophrenia. 
 
Section 2 Systematic Review of Cigarette Smoking and Schizophrenia 
 
50 studies were identified with a mean prevalence rate of smoking in 
schizophrenic populations of 66%. Male schizophrenics had a significantly 
higher (p=0.04) rate of smoking and smoked more heavily (p=0.01) than 
females. Different settings were also examined. 
 
Section 3  Meta-Analysis of Case-Control Studies examining the 
Prevalence of Smoking in Schizophrenia 
 
11 studies were identified that could be examined in a meta-analysis comparing 
prevalence rates of smoking. Schizophrenic patients were found to be nearly 3 
times more likely to smoke than controls. 
 
Section 4 Investigation into Patterns of Cigarette Smoking in 
Schizophrenia Using Data from the Edinburgh High-Risk 
Study (EHRS) 
 
At first interview there was a tendency (p=0.18) for high-risk group members 
with psychotic symptoms to have ever smoked compared to other high-risk and 
control subjects. Schizophrenic controls had a significantly higher prevalence of 
ever smoking compared to the high-risk and control groups (p=0.01). At the 
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fourth interview there was a trend for high-risk subjects showed a non-
significant difference in the rates of ever smoking compared with the controls 
(p=0.16). Those subjects who developed schizophrenia showed a clear trend 
(p=0.07) towards ever smoking  
 
Sections 5/6 Synthesis and Discussion of Results/Conclusion 
 
Explanations for the findings are presented. Although schizophrenia and 
cigarette smoking are inextricably linked, further studies are necessary if we are 
to more fully understand the nature of this association. 
 























The research carried out for this M Phil has focussed on the intersection between 
schizophrenia and cigarette smoking. It is almost a truism now that patients with this 
illness smoke more cigarettes than both the normal population and those who suffer 
from other psychiatric disorders. This has always left the question of ‘why so?’. 
 
A variety of explanations have been offered to this question, which will be outlined 
in the systematic review of the literature the author has done, including 
institutionalisation, self-medication, neurobiology and genetic factors. In addition to 
searching the evidence base, information from the unique ‘Edinburgh High-Risk 
Study’ on schizophrenia has been collated and analysed to see if there are further 
answers to the question posed above.  
 
The thesis itself is divided into introductory sections on schizophrenia, cigarette 
smoking and their interactions all with an unashamed neurobiological spin. The 
author shall then describe the hypotheses that have been tested and what meaningful 
questions can be arrived at from these.  
 
The middle section of the work is divided into the High risk experimental research 
followed by a systematic review of the literature on cigarette smoking and 
schizophrenia with a meta-analysis of the data where this was possible. 
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Finally there is a discussion of how what has been found may be integrated together 





SECTION 1.1.1 What is Schizophrenia? 
 
Current concepts regarding the aetiology, symptom constellation and management of 
schizophrenia have changed radically from when Emil Kraeplin (Kraeplin E., 
1919/1971) first delineated it from the manic-depressive psychoses. He described a 
disease entity with “symptoms of mental and emotional infirmity”. His foundation, 
inherited from Morel (Morel BA., 1860), Kahlbaum (Kahlbaum K., 1863) and 
Hecker (Hecker E., 1871) has proved a fruitful starting point for researchers since.  
 
The initial dichotomy he outlined in 1896 enabled Bleuler (Bleuler E., 1911/1950) to 
chart the first classification of schizophrenia into the four A’s of autism, 
ambivalence, affective incongruity and association of thought disturbances. In 
conjunction with the work of Kurt Schneider, notably his recognition of the 
symptoms of first rank, this set of symptoms has persisted in some form into the 
present day nosological tools of ICD-10 (World Health Organisation, 1992) and 
DSM-IVR (American Psychiatric Association., 1994). 
 
This standardisation of the diagnosis of schizophrenia has allowed the academic 
community to begin work on establishing the aetiology, pathogenesis and, ultimately, 










Table 1  Symptomatic Criteria for Schizophrenia in ICD-10 
The normal requirement for a diagnosis of schizophrenia is that a minimum of one 
very clear symptom (and usually two or more if less clear-cut) belonging to any one 
of the groups listed as (a) – (d) below, or symptoms from at least two of the groups 
referred to as (e) – (h), should have been present for most of the time during a period 
of one month of more. 
(a) Thought echo, thought insertion or withdrawal and thought broadcasting. 
(b) Delusions of control, influence or passivity, clearly referred to body or limb 
movements or specific thoughts, actions or sensations; delusional perception. 
(c) Hallucinatory voices giving a running commentary on the patient’s behaviour or 
discussing the patient among themselves or other types of hallucinatory voices 
coming from some part of the body. 
(d) Persistent delusions of other kinds that are culturally inappropriate and 
completely impossible. 
(e) Persistent hallucinations in any modality, when accompanied either by fleeting or 
half-formed delusions without clear affective content or by persistent over-valued 
ideas or when occurring every day for weeks or months on end. 
(f) Breaks or interpolations in the train of thought, resulting in incoherence or 
irrelevant speech, or neologisms. 
(g) Catatonic behaviour, such as excitement, posturing, or waxy flexibility, 
negativism, mutism and stupor. 
(h) ‘Negative’ symptoms such as marked apathy, paucity of speech, and blunting or 
incongruity of emotional responses, usually resulting in social withdrawal and 
lowering of social performance; it must be clear that these are not due to depression 
or neuroleptic medication 
(i) A significant and consistent change in the overall quality of some aspects of 
personal behaviour, manifest as loss of interest, aimlessness, idleness, a self-




SECTION 1.2.1 Current Aetiological Theories of Schizophrenia 
 
Since the work of Kraeplin numerous studies have investigated the aetiopathogenesis 
of schizophrenia. Numerous hypotheses have been put forward from the 
psychodynamic to the genetic. Two models have superseded these now, namely the 
dopaminergic and neurodevelopmental hypotheses. The author shall elucidate them 
briefly below to provide a backdrop for the rest of the work within the thesis. It is 
these two models which have the most explanatory powers when considering the 
possible links between smoking and schizophrenia. 
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SECTION 1.2.2 The Dopaminergic Hypothesis of Schizophrenia 
This hypothesis proposes that overactivity of dopamine (DA) systems within the 
brain is the central component of the pathogenesis of schizophrenia. It is one of the 
earliest, most enduring and influential of the modern neurochemical theories of 
mental disorder (Baumeister AA. & Francis JL., 2002). Two lines of research have 
converged on dopamine, firstly the psychotogenic action of amphetamine and 
secondly the fact that antipsychotic drugs all share, as their primary effect, dopamine 
receptor blocking actions which correlate with improvements in psychotic 
symptoms. 
The first line of evidence is that amphetamine and other related psychostimulants, all 
of which enhance dopaminergic neurotransmission via presynaptic mechanisms in 
central synapses, can induce a psychosis in normal subjects that is similar to 
schizophrenia (Griffith JD., Cavanaugh J., Held J., et al, 1972) in terms of its clinical 
presentation, course and response to antipsychotics (Sato M., Numachi Y. & 
Hamamura T., 1992). Furthermore these drugs can activate psychotic symptoms in 
patients with schizophrenia at lower doses than are required for normal patients to 
become unwell (Lieberman JA., Kinon BJ. & Loebel AD., 1990) and after an 
amphetamine challenge there is a greater release of dopamine in schizophrenic 
patients than in controls (Laruelle M. & A, 1999). 
The second line of evidence shows that the majority of antipsychotic medications 
which improve symptoms block dopaminergic neurotransmission by binding to DA-
D2 receptors with an occupancy level of between 60%-80%, the exceptions being 
clozapine and quetiapine which bind ‘loosely’ (that is that they have a comparable 
occupancy but it is for a shorter duration) (Kapur S., 1998) and aripirazole which 
acts as a partial agonist (Lieberman JA., 2004). Other pharmacological evidence that 
has been established is that alpha-flupenthixol, an effective dopamine antagonistic 
agent, has significant antipsychotic activity whilst its stereo-isomer, delta-
flupenthixol, which does not have receptor blocking properties, is therapeutically 
impotent (Johnstone EC., Crow TJ., Frith CD., et al, 1978). 
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Direct evidence for dopaminergic dysfunction being the biochemical lesion for 
schizophrenia has come mainly from post-mortem brain studies. These have reported 
increased dopamine receptor density in the caudate nucleus, putamen and nucleus 
accumbens (Owen F., Cross AJ., Crow TJ., et al, 1978) as well as increased 
concentrations of DA in the left amygdala and caudate nuclei  (Reynolds GP., 1983) 
of schizophrenic patients. Interestingly it is these very regions in the 
mesocorticolimbic system that have also been implicated in leading to nicotine 
dependence in humans as will be outlined in the section below titled ‘The Reward 
Hypothesis’. 
The above account of the pathogenesis of schizophrenia is not definitive however as 
there remain a number of problems with the evidence. The changes noted in post-
mortem studies could be a consequence of antipsychotic treatment which has been 
shown to increase DA-D2 receptor binding in animal studies (Kornhuber J., Riederer 
P., Reynolds GP., et al, 1989). The pharmacological evidence is blurred in some 
cases, for example Clozapine has relatively weak DA-D2 receptor blocking 
properties (Meltzer HY., 1991) and is, as yet, the only weapon in the armamentarium 
for ‘treatment-resistant’ schizophrenia (Kane JM., Honigfield G., Singer J., et al, 
1988). 
 
SECTION 1.2.3 The Neurodevelopmental Hypothesis of Schizophrenia 
Schizophrenia has increasingly been recognised as a disorder of the brain 
(Weinberger DR., 1995). From this the neurodevelopmental hypothesis of 
schizophrenia has been proposed which suggests that brain damage, which later 
results in the constellation of symptoms listed above, has occurred early in foetal life 
(Weinberger DR., 1987). Evidence thus far for these cytoarchitectural changes has 
been predominantly neuropathological in nature (Akbarian S., Bunney WE., Potkin 
SG., et al, 1993) though clinical studies such as the Edinburgh High-risk Study 
(EHRS) are changing this. 
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It has been shown that in the period prior to an individual developing the complete 
illness they differ from normal controls both phenotypically and behaviourally 
(Baum K. & Walker EF., 1995; Langsley N., Miller P., Byrne M., et al, 2005) yet 
somehow there is a delay due to a compensatory mechanism of some kind 
(Weinberger DR., 1995). This delay is postulated to occur as a result of the ‘faulty 
wiring’ which is laid down as a result of abnormal neurodevelopment which is only 
exposed after synaptic reorganisation occurs in late adolescence (Buckley PF., 1998).  
Further evidence for the hypothesis is garnered from the retrospective accounts of 
patients and third-parties in describing aberrant phenomenology in the months or 
years preceding the onset of a diagnosable schizophrenic illness (Chapman J., 1966). 
This work has been furthered more recently by the EHRS which showed that in those 
genetically predisposed to schizophrenia but still well (mean time to diagnosis 929 
days) they showed prominent affective and perceptual changes prior to moving into 
the prodromal phase or the illness itself (Owens DGC., Miller P., Lawrie SM., et al, 
2005). 
 
The theory is not without its problems though as the relative contribution of 
neurodevelopmental dysfunction to the aetiology of schizophrenia remains 
undetermined as yet (Buckley PF., 1998). Encouragingly, if the dysfunction is 
regarded as part of a cascade leading to the endpoint of schizophrenia then 
neurodevelopmental stigmata, such as minor physical anomalies (MPAs), should be 
observed at an excess rate across the ill population which is indeed the case (Lane A., 




SECTION 1.3.1  Nicotinic Receptors, Cognition, Information Processing 
Abnormalities and Schizophrenia
  
Schizophrenia has classically been regarded as a disease consisting of the positive 
and negative symptoms described in the codices of ICD-10 and DSM-IV. It has also 
become apparent that the course of the disease is marked by certain abnormalities of 
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cognition, broadly defined as the information-handling aspects of behaviour, 
including information processing abnormalities (Adler LE., Hoffer LD., Wiser BA., 
et al, 1993), working memory dysfunction (Revzani AH. & Levin ED., 2001) and 
poor reaction times (De Amicis LE., Wagstaff DA. & Cromwell RL., 1986). These 
constructs have often been studied as the major foci of neuropsychiatric disorders 
due to their broad based effects on higher intellectual functions. 
 
It is these particular cognitive processes that have consistently been marked out, by 
both clinical and animal studies, as being ‘under the influence’ of nicotine as a core 
neurotransmitter or neuromodulator (Revzani AH. & Levin ED., 2001). There is also 
anecdotal and research evidence showing that those affected with schizophrenia 
smoke a great deal more than those unaffected (Hughes JR., Hatsukami DK., 
Mitchell JE., et al, 1986) and inhale more deeply to gain more nicotine per cigarette 
than normal smokers (Olincy A., Young DA. & Freedman R., 1997). What then is 
the role of nicotinic-acetylcholinergic receptors (nAchRs) in the pathogenesis of 
schizophrenia?  
 
Nicotine administration and smoking have been shown to have a role in improving 
the aforementioned cognitive deficits, including sustained attentional function on a 
variety of neuropsychological tests of attention and vigilance, in normal subjects 
(Levin ED., Conners CK., Silva D., et al, 1998) and those suffering from 
neuropsychiatric illnesses. Attentional, memory and information processing 
improvements with administration of nicotine have been noted in those with 
Alzheimer’s disease (Sahakian B., Jones G., Levy R., et al, 1989) as well as 
schizophrenia (Levin ED. & Resvani AH., 2002). Thus the higher smoking rates 
found in the schizophrenic population may reflect intentional or inadvertent self-
medication of their symptoms. 
 
These more recent studies have been reviewed in light of the work on behavioural 
phenotypes as foci for studying schizophrenia by Venables (Venables P., 1964). He 
proposed that sensory overloading, or ‘flooding’, could be a result of a defect in 
critical brain mechanisms which regulated the perception of incoming sensory 
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stimuli. These mechanisms were felt to make up an inhibitory filter which might be 
at fault in schizophrenia particularly with regards to symptoms of paranoia and 
delusions as patients focus on details that normal people would ignore thus leading to 
an altered perception of the environment (Ripoll N., Bronnec M. & Bourin M., 
2004).  
 
The three phenotypes which are most often studied, including for tobacco research, 
are smooth pursuit eye movements using an infrared photoelectrode limbus detection 
device (Tregellas JR., Tanabe JL., Miller DE., et al, 2004) and prepulse inhibition 
(PPI) of startle responses (Braff DL., Geyer MA., Light GA., et al, 2001) which is 
the phenomenon of, in normal subjects, a diminished startle response to a louder 
startling sound if it has been preceded, approximately 100ms earlier, by a softer 
sound (Freedman R., Adler LE., Bickford P., et al, 1994). The final phenotype is 
auditory sensory gating (Adler LE., Hoffer LD., Wiser BA., et al, 1993) which is 
measured using an auditory evoked potential (AEP) with a conditioning/testing 
paradigm. Electrodes on the scalp record a wave with a 50ms latency (P50) 
following paired auditory stimuli which are given 500ms apart. The normal response 
is for the subject to have a reduction in the amplitude of the second of the two-paired 
click stimuli through the action of an inhibitory pathway activated by the first 
stimulus however in schizophrenia the response to the two sounds is nearly equal 
(Leonard S., Adler LE., Benhammou K., et al, 2001).  
 
It is these filtering mechanisms which seem to be at fault in schizophrenia and lead to 
the appearance of hypervigilance and corresponding problems with sustained 
attention. Patients have reported difficulties with maintaining concentration as they 
feel their sense of awareness overloaded by sensory stimuli which the non-
schizophrenic person will automatically screen out as irrelevant background 
information (Freedman R., Adams CE. & Leonard S., 2000). To illustrate this 
Freedman et al use the example of a ‘patient [who] came to the hospital, terrified the 
CIA was pounding on her front door every day in an attempt to attack her. A home 
visit revealed that the pounding noise came from a wrecking crane demolishing some 
adjacent buildings.’ (Freedman R., Adler LE., Bickford P., et al, 1994). 
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Evidence for the nAchRs’ involvement in the aetiology and pathogenesis of 
schizophrenia is also found in neurobiological models that implicate them in the 
control of response to sensory stimuli due to their activating function on 
hippocampic interneurones (Freedman R., Adler LE., Bickford P., et al, 1994). Using 
radio-labelled alpha-bungarotoxin it was shown that in seven out of eight 
schizophrenic subjects studied there was decreased labelling on these cells compared 
to the brains of matched subjects (Freedman R., Adler LE., Bickford P., et al, 1994). 
This paper also hypothesises that this is a result of one or a combination of three 
possible faulty neurodevelopmental processes. These are namely failure to migrate, 
death by apoptosis or neurones lying dormant or inadequately activated by afferent 
pathways (which cigarette smoking may provide agonism to). Alternatively 
hippocampal interneuron dysfunction may be the final common pathway for several 
types of pathophysiology associated with psychosis (Freedman R., Adler LE., 
Bickford P., et al, 1994). 
 
The above work also provides a possible explanation for the finding that these 
neuropsychological deficit endophenotypes are found in many unaffected relatives of 
schizophrenic probands (Blackwood DH., St Clair DM., Muir WJ., et al, 1991; 
Siegel C., Waldo M., Mizner G., et al, 1984). Gating deficits have been demonstrated 
in more than 80% of probands but are also present in 50% of their first-degree 
relatives and at a much lower rate than in the general population (Waldo MC., Carey 
G., Myles-Worsley M., et al, 1991). This loss of inhibition has been shown to be 
inherited in an autosomal dominant fashion (Freedman R., Adams CE. & Leonard S., 
2000). Genetic linkage analysis, using a genome-wide screen, has found that there is 
significant linkage only at the chromosome 15q13-14 (Freedman R., Coon H., 
Myles-Worsley M., et al, 1997) region which also corresponds with the locus for the 
alpha7-nicotinic receptor gene. As an addendum to this work, it has been suggested 
that those relatives with a P50 deficit who do not develop schizophrenia have 
compensatorily larger hippocampal volumes (Freedman R., Adler LE., Bickford P., 
et al, 1994). It may be that to develop the illness a person has to have a failure of the 
inhibitory gating mechanism with consequent sensory ‘flooding’ which results in 
psychosis only if they have diminished data-processing capabilities reflected in the 
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smaller hippocampal volumes found in schizophrenic patients (Weiss AP., DeWitt I., 
Goff D., et al, 2005). 
 
Interestingly successful clozapine treatment has been shown to normalise P50 gating 
dysfunction in schizophrenic patients. This is not the case with typical antipsychotic 
drugs which have no effect on this (Freedman R., Adler LE., Bickford P., et al, 
1994). It may be that, because there are relatively few dopaminergic fibres within the 
hippocampus, the typical DA-D2 receptor blockers have little direct effect on 
hippocampal function but may partially help information-processing difficulties 
upstream (without normalising P50 gating). It is unknown, as yet, whether this 
accounts for the relative differences in efficacy between clozapine and these other 
medications. 
 
It is important to note that the above story is not restricted to schizophrenia since the 
electrophysiological and genetic findings are similar with respect to bipolar affective 
disorder (Freedman R., Adler LE., Bickford P., et al, 1994; Turecki G., Grof P., Grof 
E., et al, 2000). It may be that sensory gating deficits are a common aetiological 
factor in these conditions (McIntosh AM., Forrester A., Lawrie SM., et al, 2001). 
 
As well as an integral role in cognition, nicotinic receptors can modulate the 
rhythmic activity of the hippocampus and other cerebral regions. In addition they can 
activate a transcriptional factor, CREB, which is felt to be important for developing 
synaptic plasticity and neuronal development (Dani JA., 2001) as well as providing a 
possible neuroprotective effect in neurodegenerative diseases including Alzheimer’s 









SECTION 1.4.1 Cigarettes – What Are They and What Do They Do? 
 
 
SECTION 1.4.2 The Rise and Rise of the Cigarette 
 
The first known ethnic group to use tobacco were the Native Americans who were 
found smoking it by the Europeans who arrived in America. These early settlers in 
the New World learned to smoke and brought the practice back to Europe with them 
where it became increasingly popular up to its present day levels of consumption.  
 
The Native Americans generally did not use tobacco recreationally as at extremely 
high doses tobacco becomes hallucinogenic and therefore it was used as an 
entheogen. Usually this practice of use was performed only by experienced shamans 
or medicine men. In addition to being smoked, the uncured tobacco was often eaten, 
drunk as tobacco juice or even used in the form of an enema preparation. Early 
missionaries exploring the continent often reported on the state caused by tobacco 
but as it spread more widely it was no longer used in such large quantities or for 
spiritual purposes but became a recreational drug of sorts. Despite this global change 
in the pattern of its use the religious consumption of tobacco is still common among 
many indigenous peoples, particularly those in South America.  
 
From the beginnings of colonial America, long before the creation of the United 
States, tobacco played a major part in fuelling the colonization of what was to 
become the American South. The idea that ‘America was built on tobacco’ is 
reasonably accurate as the initial colonial expansion was driven by a desire to 
increase tobacco production which was, at the time, a major source of revenue for the 
European powers. Ultimately the tobacco crop caused the first colonial conflicts with 
Native Americans and also led to the use of African slaves for cheap labour in the 
fields of places such as Virginia from 1619 until their freeing at the end of the 
American Civil War. 
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In 1609 John Rolfe arrived at the Jamestown Settlement in Virginia where he was the 
first man to successfully raise tobacco. The tobacco grown there prior to his arrival, 
Nicotiana Rustica, was not to the liking of the European market but luckily for Rolfe 
he had brought some seed for the Nicotiana Tabacum species with him from 
Bermuda. Although most of the settlers would not touch his tobacco crop, Rolfe was 
able to make his fortune farming it.  
 
Shortly before his arrival to Virginia his first wife died and he remarried the 
legendary Pocahontas, a daughter of Chief Powhatan. When he left for England with 
her he was now wealthy but unfortunately she died so he returned to his farm and 
slowly improved the quality of the tobacco. Eventually by 1620, approximately 
18000 kilograms of tobacco had been shipped to England and by his death in 1622 
Jamestown was thriving as a production capital of tobacco. 
 
The importation of tobacco into Europe was not without resistance and controversy 
even in the 17th century. King James I of England published the famous polemic 
titled A Counterblaste to Tobacco in 1604. In this essay the king denounced tobacco 
use as "[a] custome lothsome to the eye, hatefull to the Nose, harmefull to the braine, 
dangerous to the Lungs, and in the blacke stinking fume thereof, neerest resembling 
the horrible Stigian smoke of the pit that is bottomelesse." In that same year, an 
English statute was enacted that placed a heavy protective tariff on every pound of 
tobacco brought into England. 
 
Throughout the 17th and 18th centuries, tobacco continued to be the leading cash 
crop of the Virginia Colony. Large warehouses filled the areas near the wharfs of 
new thriving towns such as Richmond and Manchester at the fall line on the James 
River and Petersburg on the Appomattox River. Until 1883, tobacco excise tax 
accounted for one third of internal revenue collected by the United States 
government (Wikipedia, 2005b).  
 
Cigarettes themselves became increasingly popular in Europe during the Crimean 
War when British troops saw their Ottoman Turkish comrades smoking tobacco 
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rolled up in newsprint. From there the practice has become increasingly widespread 
throughout the world (Wikipedia, 2005a).  
 
The World Health Organisation estimates 5700 billion cigarettes are now smoked 
annually every year globally (World Health Organisation., 2004) with 1 million 
deaths per year reported as being a direct effect of tobacco within the European 




SECTION 1.4.3 What Do Cigarettes Actually Do to Smokers’ Brains?  
 
Nicotine is a tertiary amine composed of a pyridine and pyrrolidine ring which may 
exist in either D- or L- stereoisomeric forms.  Tobacco contains L-nicotine which is 
the most pharmacologically active form (Dursun SM. & Kuchter S., 1999) and is felt 
to be the primary psychotropic compound delivered by the cigarette despite its 
smoke containing 4800 different compounds (Hoffmann D., Hoffmann I. & El-
Bayoumy K., 2001). Therefore for the purposes of this thesis it will be regarded that 
the effects of cigarette smoking within the central nervous system (CNS) are as a 
result of nicotine mediated by high-affinity nicotinic-cholinergic receptors. 
 
The psychoactive and peripheral effects of nicotine are largely attributable to its 
molecular similarity to acetylcholine (Watkins S., Koob GF. & Markou A., 2000) 
with consequent impact on this system. CNS nicotinic-cholinergic receptors are a 
family of ligand-gated cation channels which are known to be heterogenous due to 
differences within their subunit compositions (Weiland S., Betrand D. & Leonard S., 
2000). . Interestingly, the nicotinic receptor itself was the first neurotransmitter 
receptor to be identified as a molecular entity and reconstituted in artificial 






Figure A – Diagram illustrating the nicotinic acetylcholine receptor (www.cnsforum.com, 2005b) 
 
 
The nAchrRs  are distributed throughout the brain with the main pathways being the 
cortical projections from the nucleus basalis magnocellularis and diagonal band 
(Dursun SM. & Kuchter S., 1999)(see figure B below). They have been implicated in 
two roles of signal transduction namely in fast synaptic transmission and presynaptic 
transmitter release modulation (Weiland S., Betrand D. & Leonard S., 2000). The 
latter affecting a variety of neurotransmitters including acetylcholine, dopamine, 
serotonin and noradrenaline (Dursun SM. & Kuchter S., 1999) which shall be 
elucidated in turn.  
 
Nicotine has marked cholinergic effects including causing reduced acetylcholine 
activity with consequent decreased cortical activity (Armitage AK., Hall GH. & 
Morrison CF., 1968) and subsequent cortical arousal after nicotine exposure 










Figure B – The distribution of cholinergic receptors through the brain (www.cnsforum.com, 2005a) 
 
 
Nicotine’s actions through the dopaminergic mesolimbic pathways have been 
implicated in the behavioural reinforcing effects of nicotine (Corrigall WA., Franklin 
KBJ. & Coen KM., 1992). Rat studies have shown that ingesting doses of nicotine, 
which are equivalent to smoking cigarettes, initially activate neurones in these 
pathways and then produce desensitisation and up-regulation of nicotinic receptors 
after prolonged exposure (Pidoplichko VI., DeBias M., Williams JT., et al, 1997). 
This may account for tolerance to the psychopharmacological effects of nicotine in 
people over time as well as being of relevance to nicotine-craving behaviour 
(Fagerstrom K., 2002). 
 
The raphe nuclei of the lower brain stem contain the majority of serotonin neuron 
cell-bodies. Their projections emanate from the rostral portion and provide for 
diffuse innervation of the cortex (see figure C). Nicotine’s effects on this system are 
complex. Animal models have shown that acutely nicotine enhances serotonin 
release but with chronic administration there is a decrease in serotonin concentration 
and synthesis within the hippocampus (Foulds J., 1999). Post-mortem studies in 
humans support the idea of an interaction between nicotine and serotonin receptor 
subtypes. Chronic smokers have a decreased concentration of brain serotonin and 
5HIAA as well as reduced binding of the 5HT-1A agonist 8-OH-DPAT in the 
hippocampus (Benwell MEM., Balfour DJK. & Anderson JM., 1990). From this it 
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would seem that there is a reciprocal interaction more generally between the 
nicotinic and serotonergic systems. 
 
 
Figure C  - The serotonergic pathways in the brain (www.cnsforum.com, 2005d) 
 
 
The noradrenergic system is constructed within the CNS by ascending fibres, in the 
medial forebrain bundle (MFB), from the locus coeruleus. These innervate the 
ventral horns of the spinal cord, the cerebellar and cerebral cortices. Hypothalamic 
and preoptic noradrenergic networks stem from axons which also traverse in the 
MFB but arise from cell groups of the medulla and pons (see figure D). Nicotine 
administration, even at low doses, has been shown to increase the firing rate of locus 
coeruleus noradrenergic neurons (Svensonn T. & Enberg G., 1980). This, as well as 
evidence that chronic administration of nicotine leads to a reduction in frontal cortex 
noradrenergic activity (Kirch DG., Gerhardt GA., Shelton RC., et al, 1987), lends 
credence to the hypothesis that acute nicotine administration is associated with 
noradrenergic turnover increases and chronic infusions cause reduced noradrenaline 
turnover by desensitisation (Balfour DJK., 1989). 
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Figure D  - The noradrenergic pathways of the brain (www.cnsforum.com, 2005c) 
 
 
The majority of the studies described above have been reliant on animal experiments 
to identify the effects on the brain of nicotine or smoking. Advances in techniques 
over recent years, particularly functional magnetic resonance imaging, have 
demonstrated that nicotine affects the same brain regions in humans as it does in 
animals. The first such study, albeit limited by its high dosages of nicotine which 
were given intravenously rather than by smoking, showed dose-dependent increases 
in neuronal activity. These changes were found in brain regions including the nucleus 
accumbens, amygdala and frontal lobes (Stein EA., Pankiewiz J., Harsch HH., et al, 
1998). This work has been furthered showing a biphasic relationship between 
reticular activation and nicotine dose which in the right hemisphere correlated with 
nicotine-cravings. It also demonstrated that nicotine increased regional cerebral 
blood flow (rCBF) in the left frontal region and decreased rCBF in the left amygdala 
(Rose JE., Behm FM., Westman EC., et al, 2003). 
 
As well as these functional imaging studies there has also been recent work 
published which examined post-mortem brain tissue from the hippocampi of 
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schizophrenic smokers and non-smokers in comparison with smoking and non-
smoking well controls (Mexal S., Frank M., Berger R., et al, 2005). More 
specifically the investigators in this study were attempting to identify functionally 
related genes that were differentially expressed between smokers and non-smokers in 
addition to the effects of psychopathology on these results. In all 277 genes were 
expressed differently in smokers compared with non-smokers regardless of mental 
health status of which significant over-representation was found in areas of cell 
motility, immune responses genes and NMDA post-synaptic density (NMDA-PSD). 
The latter was felt by the authors to support the hypothesis of a close interaction 
between nicotinic and glutamatergic function which was in turn suggestive of a 
marked change in excitatory neurotransmission in smokers’ brains.  
  
Such a change in neurotransmission might have beneficial effects on sensory 
processing (Leonard S., 2003) or cognition (Levin ED. & Simon BB., 1998). One of 
the former study’s authors, Sherry Leonard, has suggested that “one reasons persons 
with schizophrenia smoke is that they are self-regulating. Gene expression seems to 
be normalized by smoking [in these individuals]” (Kuehn BM., 2006). The self-
medication hypothesis is one I will elucidate in further detail later in the thesis. 
 
From the above it is clear that cigarettes, as nicotine delivery devices, are potent 
psychotropic instruments particularly in the domains of arousal and reward. 
 
 
SECTION 1.5.1 Nicotine Dependence and Why Do People Smoke?
 
All tobacco products contain nicotine which is readily absorbed in the lungs, mouth 
and nose before being rapidly transferred via the pulmonary alveolar circulation to 
and across the blood-brain barrier within 10-20 seconds of administration 
(Henningfield JE., Stapleton JM., Benowitz NL., et al, 1993). Its propensity to lead 
to addiction is beyond dispute as can be seen from the huge numbers who continue to 
smoke (World Health Organisation., 2004) in the face of consistent health warnings.  
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The awareness of this has led to its use, abuse and dependence being classified in 
both the ICD-10(World Health Organisation, 1992) and DSM-IV (American 
Psychiatric Association., 1994) (see table 2 below). 
 
 
Table 2   Symptomatic Criteria for Nicotine Dependence in ICD-10 
(1) A strong desire or sense of compulsion to take the substance 
(2) Difficulties in controlling substance taking behaviour in terms of its onset 
termination or levels of use 
(3) Physiological withdrawal state when substance use has ceased or been reduced,    
evidenced by either of the following: the characteristic withdrawal syndrome for 
the substance or  use of the same (closely related) substance with the intention of 
relieving or avoiding withdrawal symptoms 
 
(4) Evidence of tolerance, such that increased doses of the psychoactive substance 
are required in order to achieve the effects originally produced by lower doses 
(5) Progressive neglect of alternative pleasures or interests because of psychoactive    
substance use and increased amount of time necessary to obtain or take the 
substance or to recover from its effects 
(6) Persisting with substance use despite clear evidence of overtly harmful 
consequences (physical or mental) 
 
 
As a preamble to some of the explanations that follow in this introductory section it 
is worth bearing in mind Orford’s (Orford J., 1985) comment which warns against 
adopting a unitary theory of addiction or dependence.  
 
“[Appetitive behaviour] can serve many different functions for different people and 
in addition it can serve different functions for a single individual”. 
 
Such functions may be biological, psychological, social or a combination of these 
three in nature. For the purposes of this introduction I will outline the major models 
of addiction and dependence as they pertain to nicotine generally rather than 
concentrating on this chemical’s interaction with schizophrenia specifically as this 
will be dealt with fully in the discussion section to allow comparison with the 




SECTION 1.5.2 Genetic Factors and Their Effects on Liability to Nicotine 
Dependence in the Normal Population 
 
There have been a number of family, adoption and twin studies that have reported a 
genetic influence on smoking. One family study reported that in subjects aged 
between 20 and 60 years old those whose parents’ smoked during the subject’s 
adolescence were more likely to be smokers (52%) than those (20%) whose parents’ 
did not smoke during the same period (Hughes JR., 1986). This study however was 
limited by the possible confounding effects of non-genetic factors. More conclusive 
genetic evidence is found from a recent adoption study which showed there was a 
moderate to strong association between adoptees’ smoking and that of their 
biological siblings. It also demonstrated a similar link between male adoptees’ and 
their biological mothers’ smoking (Osler M., Holst C., Prescott E., et al, 2001). 
 
Twin studies, which compare the concordance of behaviours in monozygotic twin 
pairs with the same behaviours in dizygotic twins, have estimated the heritability of 
initiation of regular smoking in a range of  37% (Kaprio J., Sarna S., Koskenvuo M., 
et al, 1978) to 84% (Heath AC., Cates RC., Martin NG., et al, 1993) in women and 
28% (Heath AC., Cates RC., Martin NG., et al, 1993) to 84% (Heath AC., Cates 
RC., Martin NG., et al, 1993) in men. In the more powerful research design of 
studies where twins have been reared apart, one of the most methodologically 
rigorous studies concluded that 60% of the variance in regular tobacco use amongst 
men and women born after 1940 was attributable to genetic factors (Kendler KS., 
Thornton LM. & Pedersen NL., 2000). 
 
The two main possible explanations for how smoking behaviour, as an 
endophenotype, is determined by the individual’s genotype are felt to be variations 
between personalities and differential responses to nicotine between smokers and 
non-smokers. 
 
 A number of personality traits have been identified which predict future smoking 
and appear to have a genetic basis, namely extroverted / neurotic traits (Eysenck HJ. 
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& Eaves EJ., 1980) and antisocial traits (Hughes JR., 1986). Smokers also score 
higher on Eysenck’s psychoticism (reflecting emotional coldness, egocentricity and 
hostility), extroversion and, in some cases, neuroticism scales even on a prospective 
basis (Cherry N. & Kiernan K., 1976). This may occur because smoking decreases 
their higher anxiety (reflected in the elevated neuroticism score) as well as increasing 
their ability to concentrate on their environment (Hughes JR., 1986). The studies 
about antisocial personality and smoking are still confounded by whether or not such 
traits cause smoking or are as a result of a genotype that causes both antisocial traits 
and substance use. 
 
Recent research has demonstrated differences between individuals in the structure 
and expression of the DA-DR2 receptor gene on human chromosome 11q23 
(Eubanks JH., Djabali M., Selleri L., et al, 1992). Such polymorphisms result in 
alterations of dopamine availability from tobacco smoking which in turn may lead to 
alterations within the reward system of the brain. Those with an enhanced reward 
when exposed to the dopaminergic agent, i.e. a cigarette, may end up being more 
prone to nicotine dependence (Noble EP., 2000) 
 
In a recent review on the genetic influences of smoking behaviour and nicotine 
dependence it was noted that some of the genes which are considered to be 
associated with schizophrenia overlap with some of those that are connected with 
nicotine dependence. These include those that encode for the DA-D2 receptor, as 
above, which allows for the hypothesis that “smoking among family members with 
genetic loading for schizophrenia may be a risk factor for [getting] the disease” 
(Yoshimasu K. & Kiyohara C., 2003) though the author acknowledges the role of 
environmental factors in the strong relationship between schizophrenia and smoking. 







SECTION 1.5.3 The Self-Medication Hypothesis 
 
This theoretical model has been regarded as one of the most intuitively appealing 
ideas about why people abuse substances (Glass R., 1990). It provides a possible link 
between an individual’s biological or psychological vulnerabilities and their 
substance of choice’s effect on ameliorating these problems (Khantzian EJ., 1997). 
This model initially was developed from Khantzian’s psychodynamic 
psychotherapeutic approach (Khantzian EJ., 1985) but has increasingly been 
recognised as being partly related to the negative reinforcement process as users take 
drugs to avoid specific mood states (Eissenberg T., 2004) and, in the case of 
schizophrenia, partly related to treatment of its underlying cognitive processing 
difficulties and other problems associated with the disorder and its treatment 
(Leonard S., Adler LE., Benhammou K., et al, 2001) (McEvoy JP., Feudenreich O., 
Levin ED., et al, 1995). 
 
In the general population a significant association has been shown between nicotine 
dependence, depression and other measures of subjective distress. One of the studies 
in this area demonstrated that smoking rates rose and quit rates fell as depressive 
symptoms increased (Anda RF., Williamson DF., Escobedo LG., et al, 1990). Such 
studies though do still leave the essential question for the self-medication hypothesis 
as to which direction the line of causality moves in. Does smoking precipitate mental 
illness and subjective distress; do the latter lead to initiation of the former or have the 
two occurred together coincidentally? Prospective studies have begun to look at this 
question, one of which illustrated that increased rates of smoking in normal teenagers 
correlated with greater levels of emotional distress 2 years previously (Orlando M., 
Ellickson PL. & Jinnett K., 2001) though this work noted that tobacco itself may 
cause affective distress. Recent work (Riala K., Hakko H., Isohanni M., et al, 2005) 
looking prospectively at rates of cigarette smoking in a large Finnish birth cohort 
showed that initiation of regular smoking was significantly more closely related to 
the onset of schizophrenia as compared to other psychoses. Despite such results 
authors have, as yet, been unable to conclusively answer (Eissenberg T., 2004) this 
chicken or egg dilemma but it remains one of the foci of this thesis. 
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As with measures of subjective distress and their interface with the possible role of 
cigarette smoking as an attempt at self-medication, the role of nicotine as a cognitive 
performance enhancer has been extensively investigated in normal and unwell 
subjects (Glautier S., 2004) (and see section 1.4.3). These studies have been noted to 
be confounded in some cases by a failure to isolate the contaminating effects of 
nicotine withdrawal (Glautier S., 2004) which causes attentional impairments 
(Hatsukami D., Fletcher L., Morgan S., et al, 1989).  Thus to negate this effect 
research has been focussed on non-smokers and the effects of transdermal nicotine 
patches rather than cigarettes, due to the obvious ethical dilemmas posed by making 
non-smokers smoke. This research has shown that low dose patches (7mg/day) 
significantly improve performance on the Conners  Continuous Performance Task 
(CPT) in such a group (Levin ED., Conners CK., Silva D., et al, 1998). Another 
study has added to this work demonstrating that alcohol consumption, which disrupts 
performance on a number of cognition tasks, increases smoking behaviour in normal 
subjects which may be as a means of compensating, or medicating, for these 
disruptions (Glautier S., Clements K., White JA., et al, 1996). 
 
As has been suggested in section 1.3.1, the deficits in information processing that are 
present in schizophrenia as well as the affective changes that are recognised as 
components of the illness (World Health Organisation, 1992) may provide enough 
impetus in those with it to attempt, despite the concomitant risks involved, to self-




SECTION 1.5.4 The Reward Hypothesis – The Role of Positive 
Reinforcement in Maintaining Cigarette Smoking 
 
Reinforcement is said to occur when an animal’s behaviour yields an outcome that 
increases the likelihood of that behaviour in the future. In nicotine’s case it can be 
positive, meaning that the behaviour of cigarette smoking produces a rewarding 
event that would not have occurred otherwise or negative such that the behaviour 
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leads to termination or avoidance of an adverse event (Eissenberg T., 2004). I shall 
discuss the former in this section and the latter in the next. 
Nicotine produces many positive rewarding and reinforcing effects on administration 
to humans including inducing mild euphoria (Pomerleau OF. & Pomerleau CS., 
1992), increasing energy, heightening arousal, reducing stress and alleviating anxiety 
(Jarvik ME. & Schneider NG., 1992). In addition to these positive effects there has 
been the characterisation of a nicotine abstinence syndrome after chronic nicotine 
exposure (Hughes JR., Gust SW., Skoog K., et al, 1991) which has both somatic and 
affective components. In the acute phases of withdrawal the somatic elements 
include bradycardia, gastrointestinal discomfort with increased appetite and often 
weight gain. The affective symptoms include depressed mood, dysphoria, irritability, 
anxiety, with elevated reactivity to environmental stimuli and concentration 
difficulties (American Psychiatric Association., 1994; Hughes JR., Gust SW., Skoog 
K., et al, 1991). Continued abstinence carries with it enduring withdrawal symptoms 
such as depressed mood (Hughes JR., Gust SW., Skoog K., et al, 1991) and strong 
cravings for tobacco (Hughes JR., Hatsukami DK., Pickens RW., et al, 1984). 
 
The acute positive reinforcing effects are vital in establishing self-administration 
behaviour but how this leads from the first puff of a cigarette to drug dependence is 
still not clear. It has been hypothesised that it may involve neuroadapation within 
neural circuits that leads to positive reinforcement and in turn a negative affective 
state upon discontinuation of nicotine that acts as a negative reinforcer (Koob GF., 
1996). 
 
The mesocorticolimbic dopaminergic system that projects from the ventral tegmental 
area (VTA) to the nucleus accumbens (NA) and prefrontal cortex (PFC) (Corrigall 
WA., Franklin KBJ. & Coen KM., 1992) has been found to be an important 
neurological substrate for the euphoriant and reinforcing effects of addictive drugs 
(Watkins S., Koob GF. & Markou A., 2000). Animals will self-stimulate these 
regions with electrical intra-cranial current thus implicating them for having hedonic 
potential as well as the fact that all drugs of abuse increase dopamine in the NA 
(Milner PM., 1991). The stimuli that do induce relapse of abstinence such as stress, 
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drug-associated cues and small priming doses as well as the fact that dopamine 
agonists induce craving for nicotine in humans are further evidence for this system’s 
role in causing dependence(Chambers RA., Krystal RH. & Self DW., 2001). 
 
More specifically, neurobiological animal studies of nicotine reinforcement using 
intravenous self-administration of nicotine have shown that nicotine activates 
nicotinic acetylcholinergic receptors in the mesocorticolimbic system. Other non-
dopaminergic systems such as the cholinergic, glutamatergic, gamma-aminobutyric 
acid (GABA) and opioid peptide systems may influence nicotine reinforcement 
systems but much of the data to date indicates that all of these ultimately interact 
with the midbrain dopamine system (Watkins S., Koob GF. & Markou A., 2000).   
 
The dopaminergic system seems to be critical in mediating the acute positive 
reinforcing effects of nicotine, a hypothesis that is supported by the studies that 
showed that systemic administration of nicotine produces a dose-dependent increase 
in extracellular dopamine levels in the NA, a neurochemical effect shared by other 
positive-reinforcer drugs. Nicotine also seems to cause a greater dopamine release by 
direct binding on nAchRs within the VTA than by direct infusion into the NA (Nissel 
M., Nomikos GG. & Svensson TH., 1994).  This nAchR activation in the VTA is 
also followed by desensitization which occurs at different rates suggesting that there 
are multiple classes of the receptors with different activation-sensitization profiles 
(Pidoplichko VI., DeBias M., Williams JT., et al, 1997). This may be why smokers  
report the first cigarette of the day as being the most pleasurable (Russell MA., 1989) 
as their recovered nAchRs in the VTA, when re-activated during the morning, give a 
greater dopamine release than later on (Watkins S., Koob GF. & Markou A., 2000).  
 
Cholinergic interaction with the mesolimbic dopamine systems may be part of the 
key which allows nicotine to open the door on dopamine release. In rats (Corrigall 
WA., Coen KM. & Adamson KL., 1994) administration of mecylamine, a non-
competitive nAchR antagonist, blocks nicotine self-administration which indicates 
that activation of nAchRs is part of the reinforcing action of nicotine. However the 
same animal study showed that partial lesions of the pedunculopontine nucleus failed 
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to block self-administration of nicotine showing that cholinergic input alone may not 
be needed for the reinforcing actions as exogenously administered nicotine may 
directly stimulate nAchRs in the VTA which in turn affect dopamine release and 
transmission. 
 
The role of the glutamatergic system in the positive reinforcing effect of nicotine has 
been increasingly investigated in recent years particularly the excitatory role that N-
methyl-D-aspartate (NMDA) receptors in the VTA have to play in modulating the 
nicotine-dopamine diathesis (Watkins S., Koob GF. & Markou A., 2000). Nicotine 
activates nAchRs found on presynaptic glutamatergic terminals causing increased 
glutamate release (McGehee DS., Heath MJS., Gelber S., et al, 1995) which has a 
knock-on excitatory action at NMDA receptors situated on VTA dopaminergic 
neurons leading to dopamine release in the NA (Hu XT. & White FJ., 1996). 
 
Support for GABA affecting dopaminergic neurotransmission is found in a number 
of studies. Most notable is that enhancement of GABAergic neurotransmission 
through giving gamma-vinyl-GABA (GVG), an irreversible inhibitor of GABA 
transaminase and hence an indirect GABA agonist, stopped nicotine induced 
dopamine rises in the NA and hence its positive reinforcing effects (Dewey SL., 
Brodie JD., Gerasimov M., et al, 1999). 
 
The impact of the opioid peptides on the reward hypothesis are less clear cut 
however nicotine does affect their release as has been shown by raises in opioid 
peptide tissue levels in the NA post administration of nicotine (Houdi AA., 
Pierzchala K., Marson L., et al, 1991) where it is postulated they occupy high-
density mu-opiod receptors (Watkins S., Koob GF. & Markou A., 2000). Beyond this 
mesolimbic area of positive reinforcement there may be a parallel reward system 
situated in the hypothalamus (Houdi AA., Pierzchala K., Marson L., et al, 1991). 
nAchRs in this region are stimulated by exogenous administration of nicotine which 
leads to the release of the pro-opiomelanocortinin peptide group which includes the 
precursor to beta-endorphin. It is this latter chemical which is thought to be 
rewarding in that it may decrease the stress response and facilitate relaxation (Herz 
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A., 1997). As a counterpoint to the above, attempts at using naloxone, an opiod 
receptor antagonist, have proved fruitless on changing smoking behaviours (Nemeth-
Coslett R. & Griffiths RR., 1986). 
 
The serotonergic system has been shown to have some interactions with nicotine and 
nAchRs throughout the CNS, as described in section 1.4.3, which would provide a 
potential neurological substrate for positive reinforcing effects but there has been 
limited evidence for this as yet (Watkins S., Koob GF. & Markou A., 2000). More 
clear is their possible effect when smokers quit which the author shall delineate in 
the following section. 
 
 
SECTION 1.5.5 The Reward Hypothesis – The Role of Negative 
Reinforcement  
 
As stated above nicotine can be regarded as a negative reinforcer (Eissenberg T., 
2004) with abstinence from its chronic administration providing a readily observable 
withdrawal syndrome (Hughes JR., Gust SW., Skoog K., et al, 1991) which subjects 
will perform drug self-administration to reduce or terminate (Levin ED., Westman 
EC., Stein RM., et al, 1994). 
 
One model within this theory is the opponent-process model first articulated by 
Solomon and Corbit (Solomon RL. & Corbit JD., 1973) which describes internal 
processes that regulate an organism’s affective state and/or reward threshold as 
running awry after repeated drug administration (Eissenberg T., 2004). Hence when 
nicotine is taken via a cigarette it is hypothesised that there is a temporary reduction 
in the reward threshold leading to more neutral events seeming more rewarding 
(Koob GF. & Le Moal., 1997). However other internal processes, namely changes in 
neurobiological circuitry (Watkins S., Koob GF. & Markou A., 2000), begin to 
oppose this drug-induced reduction in reward threshold by working to increase it 
therefore leading to a more permanent change in the ‘hedonic set-point’ (Koob GF. 
& Le Moal., 1997). This increase means that when the drug is discontinued events 
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that were mildly rewarding seem only neutral and events that were previously only 
mildly unpleasant become markedly unpleasant resulting in avoidance of the 
negative affective state of withdrawal by smoking (i.e. negative reinforcement) 
(Eissenberg T., 2004). 
 
On a molecular level during chronic nicotine exposure nAchRs become desensitized, 
inactivated and finally upregulate after chronic exposure to nicotine to maintain a 
baseline level of synaptic activity (Dani JA., 1996). This process may occur on 
reward or non-reward-related cholinergic pathways so that when the smoker quits the 
recovery of receptors may contribute to the negative affective and somatic 
withdrawal states which may be being self-medicated against during addiction (Dani 
JA., 1996). 
 
Neurochemically there are also adaptations after chronic nicotine exposure to the 
dopaminergic system with decreased tissue levels of dopamine in the nucleus 
accumbens found after spontaneous withdrawal (Fung YK., Schmid MJ., Anderson 
TM., et al, 1996). This reduction has been proposed to be due to nicotinic receptor 
desensitisation leading to decreased neuronal firing which has been noted in the VTA 
after chronic continuous nicotine infusion (Watkins S., Koob GF. & Markou A., 
2000). Alongside this and in accordance with the opponent-process model 
intracranial self-stimulation reward thresholds are elevated in rats during nicotine 
withdrawal (Watkins S., Stinus L., Koob GF., et al, 2000). This may reflect changes 
in their dopaminergic systems as they are not receiving enough nicotinic agonist to 
activate nAchRs in the pedunculopontine nucleus which would activate 
dopaminergic neurones in the VTA (Watkins S., Koob GF. & Markou A., 2000).  
 
Further clarification of the pharmacological mechanism of withdrawal and it’s 
consequent impact as a negative reinforcer can be found by looking from the other 
end of the telescope at drugs that have been used to aid smoking cessation. 
Bupropion is one such drug which, since its introduction in 1989, has clearly 
demonstrated efficacy as an “atypical” antidepressant with a good tolerability profile 
(Feighner JP., Gardner EA., Johnstone JA., et al, 1991). It is of the aminoketone 
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class (Wikipedia, 2006) and as such is chemically unrelated to either the tricyclic 
antidepressants, monoamine oxidase inhibitors or selective serotonin reuptake 
inhibitors (Stahl SM., Pradko JF., Haight BR., et al, 2004). Bupropion’s mechanism 
of action has been shown in animal studies to be not the serotonergic  system but 
rather it (and its active metabolite hydroxybupropion’s) efficacy derives from their 
ability to dually reduce noradrenergic and dopaminergic reuptake (Feighner JP., 
Gardner EA., Johnstone JA., et al, 1991). Furthermore acute administraion of 
bupropion reduced firing of dopamineregic and noradrenergic neurons in a dose 
dependent manner (Ascher JA., Cole JO., Colin J-N., et al, 1996) which is consonant 
with the activation of an inhibitory feedback loop that would occur as synaptic levels 
of dopamine and noradrenaline increase.  
  
It is these latter properties of noradrenergic and particularly dopaminergic reuptake 
inhibition that are of interest for this thesis as bupropion is licensed not only as an 
antidepressant but also as an aid to smoking cessation. Its anti-craving and anti-
withdrawal effects for cigarettes, the reason for its licensure, are felt to be due to its 
actions on the dopaminergic system (Stahl SM., Pradko JF., Haight BR., et al, 2004). 
As there is a reduction in dopaminergic tissue levels in the nucleus accumbens during 
spontaneous smoking cessation (Fung YK., Schmid MJ., Anderson TM., et al, 1996) 
and the administration of bupropion has been shown to increase extracellular levels 
of dopamine and noradrenaline in this area in rats (Nokikos GC., Damsma G., 
Wenkstern D., et al, 1989) there may be a possible mechanism for reducing the 
symptoms associated with withdrawal with this drug.  
  
The above is in accord with the idea of the “hedonic set-point” (Koob GF. & Le 
Moal., 1997), mentioned earlier in section 1.5.5, with bupropion providing a means 
of ‘lowering the hedonic thermostat’ to a point whereby cravings and withdrawal 
effects might be easier to endure as has indeed proved to be the case (Johnston JA., 
Schmidt G., Ascher JA., et al, 2002). 
 
The glutamatergic system is also affected by nicotine withdrawal with increases in 
the acoustic startle response (Helton DR., Tizzano JP., Monn JA., et al, 1997, a 
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measure which is also increased in schizophrenia and reflects reactivity to 
environmental stimuli. This evidence was supported by the finding that a pre-
synaptic group II metabotropic glutamate receptor agonist completely blocked this 
response {Helton DR., 1997 #147) presumably as it reversed over-excitation of the 
glutamatergic system due to chronic nicotine exposure (Watkins S., Koob GF. & 
Markou A., 2000). 
 
The opioid peptide system also appears to undergo neuroadaptation, most probably 
receptor downregulation (Watkins S., Koob GF. & Markou A., 2000), during chronic 
nicotine exposure. Naloxone has also been shown to reduce self-reports of affective 
and somatic symptoms of nicotine withdrawal in humans (Krishan-Sarin S., Rosen 
MI. & O'Malley SS., 1999). During nicotine withdrawal there are similarities in rat 
studies with somatic signs of opiate withdrawal in addition to behavioural changes 
which are mediated by reduced opioid neurotransmission rather than reduced 
cholinergic neurotransmission (Watkins S., Stinus L., Koob GF., et al, 2000).  
 
In view of the affective changes associated with nicotine withdrawal it is 
unsurprising to note that there is a component of altered serotonergic 
neurotransmission in nicotine withdrawal. Chronic nicotine use gives a decrease in 
the hippocampal concentration of 5HT as well as increasing 5HT-1A receptor 
numbers in the same area which is purportedly due to a reduction in the activity of 
serotonergic neurones within the median raphe nucleus (Benwell MEM., Balfour 
DJK. & Anderson JM., 1990) as reported in section 1.4.3. Hence with this decrease 
in serotonergic function there may be an increase in depressed mood, impulsivity and 
irritability which would act as negative reinforcers.  
 
Serotonin’s actions may not end there though as 5HT-1A antagonists have been 
shown to significantly reduce the startle response found in nicotine withdrawal 
(Rasmussen K., Kallman MJ. & Helton DR., 1997) which may itself be due to the 
reduction in serotonin’s inhibitory action on startle (Watkins S., Koob GF. & Markou 
A., 2000). Again the connection with schizophrenia and its associated abnormalities 
of startle response is present. 
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The final component of nicotine and the effects of its withdrawal on maintaining 
smoking is found with the idea that corticotrophin-releasing factor may underlie 
some of the negative affective symptoms reported by smokers. This is based on the 
observation that during the acute withdrawal period from nicotine there is an increase 
in circulating corticosterone (Benwell ME. & DJK., 1979). 
 
 
SECTION 1.5.6 Psycho-Social Explanations for Cigarette Smoking 
Behaviours 
 
Psychological explanations for why people smoke were, unsurprisingly for the time, 
influenced heavily by psychoanalytic theory in the middle of the twentieth century. 
This suggested that smoking was rewarding as it produced pleasant or irritating 
sensations around the mouth leading to ‘oral erotic gratification’ in individuals who 
had been ‘orally frustrated’ during childhood perhaps in relation to the weaning 
process or through inadequacies in the mother-child relationship (Bergler E., 1953). 
They then might seek symbolic satisfaction as an adult through an oral 
preoccupation, such as smoking (Jacobs MA., Knapp PH., Anderson LS., et al, 
1965). 
 
The aforementioned model was then supplanted during the 1960s and 1970s with one 
that favoured integration into a more bio-psycho-social approach. Social and cultural 
effects including the influence of family and friends, the cultural stereotype of the 
smoker and the social rewards of smoking do seem to be important in initiating and 
allowing the persistence of nicotine dependence (Lohr JB. & Flynn K., 1992). 
 
Socio-economic and environmental factors have also been shown to have 
implications for who smokes with social class, occupation, work stress and area of 
residence being chief among these (Lohr JB. & Flynn K., 1992). The greatest 
prevalence of smoking has been found to be in social class V with the lowest in 
social class I (Capell PJ., 1978). Smokers also tend to have less education and lower 
levels of academic achievement while in school (Bewley and Bland 1977 cited in 
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(Lohr JB. & Flynn K., 1992)). The parallels with what is known about the 
epidemiology of schizophrenia are unmissable but despite these socio-economic and 
lifestyle considerations the schizophrenic population still has an extremely high 
prevalence of smoking (Hughes JR., Hatsukami DK., Mitchell JE., et al, 1986). 
 
As has been alluded to in the earlier section on the genetic implications for nicotine 
dependence there are personality differences between well smokers and non-
smokers. Studies have found an association between cigarette use and higher levels 
of neuroticism, anxiety and psychoticism (Cherry N. & Kiernan K., 1976) as well as 
risk taking and impulsivity (Williams AF., 1973). It is not unreasonable to think that 
these trait differences, especially the former three, may predispose people with 
schizophrenia to smoke. 
 
‘The Psychological Tool Model’ (Myrsten AL., Andersson K., Frankenhauser M., et 
al, 1975) is a further theory that has been proposed which suggests that cigarette 
smoking behaviour allows the user to manipulate their psychological state under 
many environmental conditions by the dose-dependent, stimulant-depressant actions 
of nicotine. Nicotine, as stated above, can cause stimulation of ‘pleasure-centres’, 
increase alertness and enhance cognitive performance. Other beneficial short-term 
psychological effects include maintaining levels of performance in the face of 
monotony and fatigue, elevating attention selectivity and attenuating stress (Eysenck 
HJ., 1973). Smokers can use cigarettes to both calm and stimulate themselves on 
different occasions as nicotine is one of the few drugs that can act as a stimulant or a 
depressant (Schelling TC., 1992). It may be, as is outlined in the discussion, that 
schizophrenic patients may be using cigarettes in just this way, as self-medication, 
much as those without the illness report that smoking is pleasurable and helps them 
feel less anxious, angry, depressed and more alert (Jarvik ME. & Schneider NG., 
1992). 
 
As can be seen from the above there are complex interactions between the 
dopaminergic and other central nervous system neurotransmitters and it is not 
unreasonable to begin to think that the twin processes of cigarette smoking and 
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schizophrenia are linked somehow. Particular ideas that will be developed in the 
discussion will be how the reward hypothesis fits with what is already known about 
the negative symptoms of schizophrenia, the link between the self-medication model 
and schizophrenia, how psycho-social factors impact on the interface between 




SECTION 1.6.1 So Why Investigate Schizophrenia and Smoking?
 
 
SECTION 1.6.2 Previous Epidemiological Evidence Has Shown an 
Elevated Prevalence Rate of Smoking in Schizophrenic 
Patients 
 
Multiple studies have detailed epidemiological data showing that psychiatric 
patients, including those with a diagnosis of schizophrenia, have elevated rates of 
being smokers compared with non-psychiatric populations (Hughes JR., Hatsukami 
DK., Mitchell JE., et al, 1986; Leonard S., Adler LE., Benhammou K., et al, 2001; 
Masterson E. & O'Shea B., 1984). The largest and most recent of these studies 
encompassed 42 other pieces of research in a meta-analysis showing that there is an 
association between tobacco smoking behaviours and schizophrenia (De Leon J. & 
Diaz FJ., 2005). The author has aimed to expand on this figure in my systematic 
review as well as conduct a meta-analysis where possible.  
 
Such research has been carried out across the globe in differing settings but not 
specifically within a “high-risk” group. The study for this thesis carried out in this 
type of population may allow for a predictive diagnostic value to be placed on 
smoking prior to subjects developing the full clinical syndrome of schizophrenia. 
 
Both of these arms, in conjunction with the systematic review, may allow some of 
the answers to be formulated to the ‘why do schizophrenics smoke more?’ question 
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SECTION 1.6.3 Acetylcholine May Have a Role in the Pathogenesis of 
Schizophrenia 
 
As has been outlined in the preceding sections on the role of central nicotinic 
receptors in cognition, particularly in the domain of information processing, and the 
possible abnormalities that can occur in this system in schizophrenia, the author felt 
it would be important to investigate what information there is within the literature to 
correlate such dysfunction with what is known about the pathogenesis of this illness. 
 
Such an investigation lends itself to considering what strategies may be available to 
alleviate the putative increase in symptoms that has been suggested to occur with 
cessation of smoking in schizophrenic patients (Dalack GW., 1996) as well as to 
evaluate how current treatments interact with the nicotine - schizophrenia diathesis. 
This latter point is most clearly illustrated with the observation that clozapine, as 
well as being an effective treatment for schizophrenia, also reduces smoking rates in 




SECTION 1.6.4 Cigarette Smoking has a Financial and Health Impact for 
Patients 
 
Cigarette smoking is a costly habit to engage in with a total expenditure per 
individual, assuming a 20 cigarette per day habit in the UK, amounting to £1650 per 
year (Action on Smoking and Health UK., 2004). A 1995 study in the United States 
(Lohr JB. & Flynn K., 1992) conservatively (original author’s description) estimated, 
using early 1990s population data, that approximately 19 720 800 patients with 
schizophrenia smoked, consuming on average, 1.5 packs per day. This results in 
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nearly $20 billion dollars worth of cigarettes smoked by the people who are often 
least able to afford it. 
 
In addition to the financial implications of smoking there are marked consequences 
of smoking from a general health perspective also. From Doll’s first evidence that 
smoking increases the risk of developing lung cancer (Doll R. & Hill A., 1950) to his 
more recent work that demonstrated a rise in vascular, neoplastic and respiratory 
deaths in smokers (Doll R., Peto R., Boreham J., et al, 2004) there can now be no 
ambivalence about how dangerous a pursuit it is. Research within purely 
schizophrenic populations has confirmed these findings in the main (Masterson E. & 
O'Shea B., 1984). 
 
If it transpires that schizophrenic patients are self-medicating or smoking for reasons 
other than those found in the well population then it behoves the medical profession 
to establish why and what can be done to furnish them with an alternative, certainly 
less carcinogenic, treatment. 
 
 
SECTION 1.6.5 Treatment Options for Schizophrenia and Cessation 
Programmes for Smoking 
 
In view of the financial and health problems associated with cigarette smoking it 
would seem that helping schizophrenic patients to stop smoking would be a priority 
for psychiatrists. This is not confirmed by the literature with only 1 out of 35 (2.39%) 
patients being advised to stop or reduce their smoking in one Scottish study (Lawrie 
SM., Buckley LA., Ulyatt BC., et al, 1995) and only 12.4% of patients were 
counselled about smoking by a visiting psychiatrist in the American National 
Ambulatory Medical Care survey (Himelhoch S. & Daumit G., 2003). 
 
This reluctance to counsel patients regarding their smoking needs to be addressed as 
patients with persistent major mental illness are, in the wide majority (87%), aware 
that smoking is detrimental to their physical health (Van Dongen CJ., 1999) and a 
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substantial proportion, in one study at a level of 40% (Forchuk C., Norman R., Malla 
A., et al, 2002), wish to quit the habit. In one study of those that did wish to stop and 
who were furnished with a reasonable cessation programme then reasonable 
abstinence rates were reported with 42% at 7 weeks and 12% at 6 months 
(Addington J., El-Guebaly N., Campbell W., et al, 1998). 
 
The medical implications of smoking are now being increasingly monitored at a 
society-wide level. The implementation of the smoking ban in public places 
throughout the UK which will also affect psychiatric hospitals in Scotland early in 
2005 (McConnell J., 2004) may have an effect on patients not only in terms of 
improving their physical health but also in affecting their mental health. 
In the light of these policy changes it felt reasonable to examine the prevalence of 
smoking within the schizophrenic population, establish what can be done to alleviate 
the problem and begin to examine why it exists in the first place. 
 
SECTION 1.6.6 Anecdotal Evidence 
 
Throughout the 5 years that the author has been working in the field of psychiatry it 
has been impossible to ignore the consistent ebb and flow of those who suffer from 
serious mental illness in and out of smoking rooms in hospital. Colleagues and the 
author have remarked that there must be some explanation for this ranging from 
those who feel it is an effect of the patients’ social milieu to the more biologically 
inclined explanations that it must relate to their neuropathology. This thesis aims to 









SECTION 1.7.1 Hypotheses 
 
1. Patients with schizophrenia who are inpatients will be more likely to be 
smokers than their outpatient counterparts. 
 
2. Male patients with schizophrenia will have a higher prevalence rate of 
smoking compared with female patients. 
 
3. Schizophrenic smokers will have a higher prevalence rate of being heavy 
smokers than normal smokers. 
 
4. Male schizophrenic smokers will have a higher prevalence rate of being 
heavy smokers compared to female smokers. 
 
5. Schizophrenic patients are significantly more likely to be smokers than 
individuals in the well population. 
 
6. The schizophrenic group in the Edinburgh High-Risk Study will have a 
higher prevalence rate of cigarette smokers compared with the normal 
population and high-risk groups. 
 
7. Patients at high-risk of developing schizophrenia will have a higher 
prevalence rate of cigarette smokers compared with the normal control group. 
 
SECTION 1.7.2 Questions  
 
1. Are schizophrenics more likely to smoke than other groups and, if yes, why? 
 
2. Are high-risk subjects more likely to smoke than their counterparts who are 
not at high-risk, and if this is so, why? 
 





A SYSTEMATIC REVIEW OF CIGARETTE SMOKING 
AND SCHIZOPHRENIA  
 
 
SECTION 2.1.1 INTRODUCTION 
 
As the initial outline of this thesis was being constructed it became apparent that it 
would be important to place the results obtained from the Edinburgh High-Risk 
Study regarding schizophrenia and cigarette smoking in the wider context of what 
has already been established regarding the association between these two entities. 
 
Therefore the author felt it would be prudent to review the studies that have already 
been presented regarding the prevalence data of cigarette smoking in schizophrenia 
as well as extracting any other meaningful portions of data that were available from 
these. This has allowed for some statistical analyses of differences and similarities 
within the schizophrenic populations studied. However, in view of the EHRS’ focus 
on what is different about those who are at high-risk of developing schizophrenia 
compared with those who are not, it also seemed an integral part of this work to 
analyse studies which have examined cases and controls together. This latter research 
forms the body of section 3 which is a meta-analysis comparing cigarette smoking 









SECTION 2.2.1 METHOD 
 
 
SECTION 2.2.2 Search Strategy 
 
To enable the greatest cross-section of relevant articles to be available for review a 
broad search strategy was employed. Electronic searches on online databases was 
achieved by using the OVID gateway to gain access to -   
 
Journals at Ovid Full Text (as of May 18th 2005) 
EBM Reviews – ACP Journal Club (1991 – May 2005) 
EBM Reviews – Cochrane Central Register of Controlled Trials (2nd Quarter 2005) 
EBM Reviews – Cochrane Databases of Systematic Reviews (2nd Quarter 2005) 
EBM Reviews – Databases of Abstracts of Reviews of Effects (2nd Quarter 2005) 
EBM Reviews Full Text – Cochrane DSR, ACP Journal Club and DARE 
EMBASE (1980 – 2005 Week 20) 
Ovid MEDLINE (1966 – May Week 2 2005) 
Ovid OLDMEDLINE (1950 – 1965) 
PsycINFO (1872 – 1966) 
PsycINFO (1967 – May Week 2 2005) 
 
A purposefully wide set of search headings were used due to the variety of ways in 
which cigarette smoking was seen, from preliminary reading around the topic, to be 
discussed in the literature. As stated above the primary focus for the review was to 
isolate epidemiological data on the topic which is shown by the lower half of the 






















MAJOR CLINICAL STUDY 
 
No language restrictions were applied to the search initially but due to logistical 
problems (i.e. lack of translation facilities!) I had to exclude most of the studies 
which were not in English. A number of studies were also unable to be located 
despite communication with the British Library. 
 
In addition to the electronic search references were hand-searched from this first 
round of picks and collated a further list of journal articles to be found from these. 
This process was repeated a further two times. Unfortunately due to time constraints 
the author was unable to hand-search further journals or communicate with any of 
the authors of papers’ to establish if they had unpublished data which may have been 
of value to the review. 
 
Where data was reported in more than one article the author extracted the data from 
either the original study or from the most recent report. If there were uncertainties 
regarding the data then it was excluded as a whole from the review to ensure non-
contamination of the data. 
 
 
SECTION 2.2.3 Study Eligibility 
 
From the above pool of studies a further selection process was undertaken using the 
following criteria: 
 
1. Patients must have had a diagnosis of schizophrenia as a pure entity insofar as 
this was possible to be determined. Clear evidence of mixing of schizophrenic 
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with schizo-affective, or other psychiatric diagnosis, populations led to exclusion 
from the review. 
 
2. At least 90% of the participants were aged 16 or over. 
 
3. In the first arm of the review studies were only included if they had data for 
current rates of smoking amongst the schizophrenic group to enable comparisons 
to be made and total rates of prevalence to be calculated. 
 
4. In the meta-analysis, case-control studies were included only if they had data for 
current rates of smoking, again to allow comparisons to be made between groups. 
 
 
SECTION 2.2.4 Data Extraction 
 
From all studies a variety of variables were extracted where possible: 
 
1. Socio-demographic data including gender, inpatient/outpatient status and country 
of origin of the study. 
 
2. Current, former, never and ever rates of smoking as totals and by gender where 
possible. 
 
3. Number of cigarettes smoked with an arbitrary division of this variable into those 
smoking 1-19 cigarettes per day (CPD) and those smoking 20 or more cpd. Data 
regarding Fagerstrom Test of Nicotine Dependence (FNTD) results was collected 
as well as mean CPD smoked though these were not used in the analysis. 
 
4. Schizophrenia subtype data as well as symptomatology scores (e.g. according to 
the Positive and Negative Syndrome Scale (PANSS) (Kay SR., Fiszbein A. & 
Opler LA., 1987) where extractable. 
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5. Age of onset of smoking and schizophrenia where found. 
 
6. Medication doses and type of drug used where found. 
 
Two arms were set up to allow some meaningful analysis of the data to be done. The 
first of these, found in section 2, looked at prevalence rates of current smoking 
amongst schizophrenic patients across a variety of settings and countries. The second 
arm, found in section 3, looked at case-control studies to compare rates of smoking 
between schizophrenic patients, normal controls and other psychiatric patients. This 
last group was also separated into one group with a mix of diagnoses and another 
with purely affective disorders. Unfortunately due to a lack of data these results have 
not been presented here. 
 
 
SECTION 2.2.5 Statistical Analysis 
 
Study results from this arm of the study were analysed using the Statistical Package 
for the Social Sciences (SPSS) for Windows version 12.0. This allowed calculation 
of prevalence rates of smoking within each study’s schizophrenic population as a 
whole to be compared as well as examining male and female data where available.  
 
Throughout the proceeding analyses the prevalence rate of smoking is the number of 
current smokers with schizophrenia divided by the total number of schizophrenic 
patients in the sample. The same method was applied across the genders. Both 
schizophrenia and current smoking are as defined by the studies themselves.  
 
Data from the tables below were compiled in SPSS thus allowing calculation of 
descriptive statistics and Mann-Whitney tests where appropriate and applicable. In 
addition data was then represented within a box and whisker plot form (Figure E) to 




SECTION 2.3.1 RESULTS 
 
From the total amount of studies identified there were 50 that met the systematic 
review criteria (Table 3). The main reasons for excluding studies identified from 
within the original search were as follows;  
 
1. Duplication of studies from original search strategy from internet databases and 
Reference Manager version 10.0 (RefMan) software. 
 
2. Papers did not deal with smoking cigarettes but instead concentrated on other 
substances. This was particularly a problem with smoking as it related to 
cannabis use. 
 
3. Nicotine as a search term picked up a large number of studies focussing on 
nicotinic acid. 
 
4. Epidemiological data was either not present in the study or was not extractable. 
 
5. Data on schizophrenic patients was not classified separately but was aggregated 
with schizoaffective disorder or other psychotic disorders more generally. 
 
6. A number of papers were review articles which contained data I had isolated 
from the original article reported in the review. 
 
 
SECTION 2.3.2 Analyses of prevalence rates of smoking in schizophrenia 
across 3 settings 
In total 50 studies (table 3) were appropriate for analysis in this section. The table 
below also illustrates the variability in recording methods for cigarette smoking and 
for making the diagnosis of schizophrenia. Of these 26 examined patients in 
outpatient settings, 15 in inpatient settings and 9 in mixed settings. 
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Table 3 Studies with complete data sets for prevalence rates of smoking in schizophrenic populations 
Study 
 

























Egypt SCID-I SCID-I 
(DSMIV) 
OP 100 76 0.76 
(Bejerot S., 
2003) 
Sweden >1cpd for 
6mths 









OP 306 224 0.73 
(Brown S., 
1999) 
Scotland SCAN SCAN OP 102 64 0.63 
(Chong 
SA., 1996) 
China ≥5cpd for 
6mths 






Chart Dx OP 43 27 0.63 
(Diwan A., 
1998) 
USA Questionnaire Own 
psychiatrist 
report 







DSMIII-R OP 106 65 0.61 
(Fowler 
IL., 1998) 





SCID OP 78 58 0.74 
(Hamera 
E., 1995) 










OP 64 41 0.64 
(Hughes 
JR., 1986b) 
USA Questionnaire DSMIII OP 24 21 0.88 
(Itkin O., 
2001) 
Israel FTND DSMIV OP 64 29 0.45 
(Kelly C., 
1999) 
Scotland Questionnaire ICD9 OP 135 78 0.58 
(Lyons 
MJ., 2002) 
















OP 102 71 0.70 
(Mori T., 
2003) 
Japan DSMIV DSMIV OP 137 47 0.34 
(Srinavasan 
TN., 2002) 
India Questionnaire DSMIV OP 286 109 0.38 
(Taiminen 
TJ., 1998) 
Finland Self-report Drug trial 
selection 
OP 88 49 0.56 
(Uzun O., 
2003) 
Turkey DSMIV SCID 
(DSMIV) 







OP 623 393 0.63 
(Chiles JA., 
1993) 
USA Pack years 
smoked 
DSMIIIR OP 80 70 0.87 
(Menza 
MA., 1991) 




Chile Not specified Not specified IP 96 78 0.81 
(Challis 
GB., 1999) 
Canada Not specified Not specified IP 51 32 0.62 
(De Leon 
J., 1995) 
USA Staff estimate 
of smoking 
DSMIII-R IP 237 201 0.85 
(Llerena 
A., 2003) 
Spain Not specified Clinical Dx 
(DSMIII-R) 















IP 449 335 0.75 
(Liao D-H., 
2002) 






DSMIV IP 30 22 0.73 
(McEvoy 
JP., 1999) 
USA Not specified Not specified IP 22 17 0.77 
(Patkar 
AA., 2002) 
USA FTND DSMIV IP 87 66 0.76 
(Sandyk R., 
1991) 
USA Self report / 
Staff 
observation 




/ Staff report 
DSMIII IP 111 71 0.64 
(Lawrie 
SM., 1995) 
Scotland Questionnaire DSMIII-R IP 15 12 0.80 
(O'Farrell 
TJ., 1983) 
USA Interview with 
head nurse 
Not specified IP 207 182 0.88 
(Masterson 
E., 1984) 









DSMIV MIX 133 IP 
273 OP 
 




USA Questionnaire DSMIII-R MIX 41 IP 
18 OP 




Australia DSMIII-R DIP (DSMIII-
R) 
MIX 430 320 0.74 
(Poirier M-
F., 2002) 
France Questionnaire DSMIII-R MIX 207 136 0.66 
(Calabresi 
M., 1991) 
Italy Not specified DSMIII-R MIX 71 57 0.80 
(Akvardar 
Y., 2004) 
Turkey FTND SCID MIX 49 34 0.69 
(Ucok A., 
2004) 
Turkey Regular cpd 
>1mth 
SCID MIX 66 38 0.58 
(Riala K., 
2005) 
Finland Questionnaire DSMIII-R MIX 67 32 0.48 
(De Luca 
V., 2004) 
Canada Questionnaire SCID-IP MIX 177 108 0.61 
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As can be seen from the below (figure E, table 4) there is a non-significant difference 
between the settings in terms of the rate of smoking within their respective 
schizophrenic populations. This can be seen from the clear overlap of the 95 percent 
confidence intervals. 





Table 4 - Mean prevalence rates of smoking in schizophrenic groups between settings 
Setting Mean N Std. Deviation 
OP 0.65 26 0.17 
IP 0.72 15 0.13 
MIX 0.66 9 0.11 



















Prevalence rate of schizophrenic smokers
33
 OP (n=26) IP (n=15) Mixed (n=9) 
Setting
These results show that more people with schizophrenia smoke as inpatients (mean 
value 72%) than as outpatients (mean value 64%) in this sample though this is not a 
statistically significant finding. Those studies which contained a mixture of inpatients 
and outpatients had a mean rate of smoking (66%) which lay between the other 2 
groups’ values. 
 
The prevalence rate for cigarette smoking when all 3 settings were analysed together 
was 67% (table 4). The outlier shown (figure E – marked as 33) is the prevalence rate 
from a Chinese study based in Taiwan (Liao D-H., Yang J-Y., Lee S-M., et al, 2002). 
This value is markedly lower due to the low prevalence of smoking in the female 
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schizophrenic smokers within the study. The base rate of smoking in the female 
general population in this region, at 5 percent (Liao D-H., Yang J-Y., Lee S-M., et al, 
2002), is much lower than in comparison to western countries. As a result even 
though this study showed an elevated rate of smoking amongst Chinese female 
schizophrenic patients the overall mean was lowered in relation to the other, 
predominantly western, studies. 
 
 
SECTION 2.3.3 Analyses of prevalence rates of smoking in schizophrenia 
by gender and across settings 
 
From the original set of 50 studies which had data that would allow for calculation of 
prevalence rates only the 13 listed in table 5 had results that could give a comparison 
between male and female groups. 
 
Table 5   Studies containing complete data sets for schizophrenic smokers by gender 


















rate of female 
schizophrenic 
smokers 
(Bejerot S., 2003) OP 161 89 72 79 37 42 0.51 0.47 
(Brown S., 1999) OP 102 48 54 64 37 27 0.69 0.56 
(Chong SA., 1996) OP 195 99 96 62 52 10 0.54 0.1 
(El Guebaly N., 1992) OP 106 49 57 65 39 26 0.68 0.53 
(Kelly C., 1999) OP 135 62 73 78 52 26 0.71 0.42 
(Mori T., 2003) OP 137 71 66 47 30 17 0.45 0.24 
(De Leon J., 1995) IP 237 87 150 201 140 61 0.93 0.7 
Llerena A., 2003 #274} IP 100 16 84 70 68 2 0.81 0.13 
(De Leon., 2002) IP 449 114 335 335 236 99 0.7 0.87 
(Liao D-H., 2002) IP 257 130 127 105 90 15 0.71 0.12 
(Masterson E., 1984) IP 100 50 50 83 42 41 0.84 0.82 
(Akvardar Y., 2004) MIX 49 23 26 34 18 16 0.69 0.7 







Table 6 Descriptive statistics for prevalence rates of smoking in schizophrenic populations by gender 
 
Setting 
Prevalence rate of male schizophrenic 
smokers 
Mean (s.d.) 
Prevalence rate of female schizophrenic 
smokers 
Mean (s.d.) 
OP (n=6) 0.6 (0.11) 0.39 (0.18) 
IP (n=5) 0.8 (0.10) 0.52 (0.38) 
Mixed 
(n=2) 0.67 (0.27) 0.59 (0.15) 
Total 
(n=13) 0.69 (0.13) 0.47 (0.26) 
 
Again, similarly to table 4, it can be seen that the prevalence rates of smoking in both 
male and female outpatients’ groups (60% and 39% respectively) have a lower rate 
of smoking than both genders of inpatients (males 80% and females 53%). Studies 
with a mixed population lay in-between these values for men (67%) but for women 
there was a higher rate of smoking in this combined setting (59%). 
 
From these results it can be seen that there is a lower prevalence rate for female 
schizophrenic patients, in this sample, to be smokers compared with their male 
counterparts across the 3 settings. This is not statistically significant by individual 
setting however there is greater variation within the female population which may 
reflect cultural norms in different countries (Liao D-H., Yang J-Y., Lee S-M., et al, 
2002). 
 
Table 7, below, demonstrates that there is a significant difference (p=0.04) between 
the prevalence rates of smoking amongst schizophrenic populations when they are 
differentiated by gender. This data is pooled from across the three settings described 
in table 6. 
 
Table 7   Mann-Whitney U-Test results comparing prevalence rates of smoking in schizophrenic                    
populations by gender  
Ranks 
 Sex Number of studies Mean Rank Sum of Ranks 
Prevalence rates of smoking 
within schizophrenic 
populations 
Male 13 16.62 216.00 
 Female 13 10.38 135.00 




 Prevalence rates of smoking within schizophrenic populations by gender 
Mann-Whitney U 44.00 
Wilcoxon W 135.00 
Z -2.08 
Asymp. Sig. (2-tailed) .04 
Exact Sig. [2*(1-tailed 
Sig.)] .04(a) 




SECTION 2.3.4 Analyses of heavy smoking rates in schizophrenia by 
gender and across settings 
 
For this analysis heavy smoking is defined as smoking more than 20 cigarettes per 
day. The prevalence rate was calculated by dividing the number of schizophrenic 
patients who were ‘heavy’ smokers by the total number of schizophrenic smokers. 
 
A total of 12 studies had data that would allow the calculations to be performed for 
the total number of smokers and of these 5 would allow differentiation by gender 
also (see table 8). 
Table 8   Studies containing data for heavy smoking rates (defined as greater than 20 cigarettes per   
    day) as totals and by gender                            
Study Setting 
Total number 












































more than 20 
cpd 
(Brown S., 1999) OP 64 53 33 20 0.89 0.74 0.83 
(Dickerson FB., 2002) OP 27 9 . . . . 0.33 
(El Guebaly N., 1992) OP 65 53 31 22 0.79 0.85 0.82 
(Fowler IL., 1998) OP 144 136 . . . . 0.94 
(Herran A., 2000) OP 41 18 . . . . 0.44 
(McCreadie RG., 2003) OP 71 38 . . . . 0.54 
(Srinavasan TN., 2002) OP 109 26 . . . . 0.24 
(Uzun O., 2003) OP 58 18 . . . . 0.31 
(Challis GB., 1999) IP 32 10 . . . . 0.31 
(De Leon J., 2002) IP 201 90 68 22 0.49 0.36 0.45 
(Llerena A., 2003) IP 70 28 27 1 0.4 0.5 0.4 
(Masterson E., 1984) IP 83 59 34 25 0.81 0.61 0.71 
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Table 9 Descriptive statistics for prevalence rates of heavy smokers in schizophrenic populations by 
                 setting and totals 
Setting 
Prevalence rate of male 
schizophrenic smokers who 
smoke more than 20 cpd 
 
Mean (s.d.) 
Prevalence rate of female 
schizophrenic smokers who 
smoke more than 20 cpd 
 
Mean (s.d.) 
Prevalence rate of all 
schizophrenic smokers who smoke 





(n=2) 0.84 (0.69) 0.79 (0.07) 0.56 (0.27) 
IP (n=3) 0.56 (0.22) 0.49 (0.12) 0.47 (0.17) 
Total 
(n=13) 0.68 (0.22) 0.61 (0.19) 0.52 (0.24) 
 
Unfortunately due to paucity of data (i.e. 2 outpatient studies with a combined n of 
106 and 3 inpatient studies with a combined n of 177) meaningful statistical analyses 
with this data set was not possible beyond these descriptive remarks. Table 9 shows 
an opposing result to those in tables 4 and 6 with outpatients of both genders having 
a higher rate of smoking heavily (84% of male smokers and 79% of female smokers) 
than male (56%) and female (49%) inpatients. The same applies when the results for 
the 12 studies with across gender data are analysed with 56% of outpatients smoking 
more than 20 cigarettes per day compared with 47% of inpatients. 
 
These previous results are in the main not statistically significant as can be seen by 
the standard deviation values in table 9. It still remains worth highlighting the 
marked difference between the larger prevalence of female heavy smokers in 
outpatient settings as compared with the smaller rate in inpatient settings. 
 
 
Table 10 Mann-Whitney U-Test comparing the prevalence rates of heavy smoking (i.e. >20cpd) by 
gender regardless of setting of study 
Ranks 
 sex Number of studies Mean Rank Sum of Ranks 
male 5 8.00 40.00 
female 5 3.00 15.00 
Prevalence rate 
of smoking more 













Mann-Whitney U .00 
Wilcoxon W 15.00 
Z -2.62 
Asymp. Sig. (2-tailed) .01 
Exact Sig. [2*(1-tailed 
Sig.)] .01(a) 
a  Not corrected for ties. 
  
Table 10, above, shows the results of a Mann-Whitney U-Test which compares the 
prevalence rates of heavy schizophrenic smokers by gender and regardless of setting. 
Here there is a statistically significant difference (p=0.01) with male schizophrenics 
having a greater rate of heavy smokers compared to female schizophrenics. 
 
 
SECTION 2.3.5 Further analysis of data 
 
Of the initial 50 studies there were 8 that gave data for mean number of cigarettes 
smoked with only 1 of these providing gender data for this. 4 studies gave data on 
when the patients studied developed schizophrenia with only 2 of these providing 
gender data. Details for this are given in table 11 with descriptive statistics in table 
12. 
Table 11 Studies with either mean cigarette per day (cpd) values or those which specified the age of 
   onset of schizophrenia in study participants 







Age of onset of 
schizophrenic 
illness 








(Altamura AC., 2003) OP . . . 21.9 20.7 24.2 
(Goff DC., 1992) OP 28.9 . . . . . 
(Hamera E., 1995) OP 31.3 . . . . . 
(Itkin O., 2001) OP . . . 26.6 25.7 27.5 
(McCreadie RG., 2003) OP 27 . . . . . 
(Mori T., 2003) OP 22.6 . . 24.7 . . 
(Uzun O., 2003) OP 24.9 . . . . . 
(Beratis S., 2001) MIX 31.5 33.5 26.3 . . . 
(Glynn SM., 1990) MIX 21.8 . . . . . 
(Akvardar Y., 2004) MIX . . . 23.5 . . 
(Ucok A., 2004) MIX 34.5 . . . . . 
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Table 12 Descriptive statistics for data in table 11  
 Number of studies Minimum Maximum Mean 
Standard 
Deviation 
Onset age of schizophrenia 4 21.9 26.6 24.175 1.9822 
Onset age of schizophrenia 
for  males 2 20.7 25.7 23.200 3.5355 
Onset age of schizophrenia 
for females 2 24.2 27.5 25.850 2.3335 
Mean cigarettes smoked per 
day 8 21.8 34.5 27.815 4.5398 
Mean cigarettes smoked per 
day by male schizophrenics 1 33.5 33.5 33.500 . 
Mean cigarettes smoked per 
day by female schizophrenics 1 26.3 26.3 26.300 . 
 
 
As is to be expected from previous research (Hafner H., Riecher A., Maurer K., et al, 
1989), even with a small number of studies, the mean onset age for schizophrenia 
was lower in males (mean 23.2 years) than in females (25.85 years) by 2.65 years. 
From the four studies that had data for the age of onset of illness the mean age of 
onset, irrespective of gender, was 24.18 years.  
 
Only one study had data comparing the mean cpd by gender which showed that 
males smoked more (mean cpd of 33.5) than females (mean cpd of 26.3).  A total of 





SECTION 2.3.6 SUMMARY OF RESULTS 
 
1. The mean value for the rate of ever smokers in the studies found (n=50) in the 
systematic review was 66%. 
 
2. A non-significant result was found showing that there was a tendency for 
inpatients (72%) with a diagnosis of schizophrenia to smoke more than their 
outpatient counterparts (64%) with the figure lying at 66% for those studies 
which had mixed inpatient and outpatient group. These differences were not 
statistically significant. 
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3. Male schizophrenic patients had a significantly higher prevalence rate of 
ever-smoking status (p=0.04) compared to female schizophrenic patients but 
this did not hold true when the results were examined by setting. 
 
4. There was evidence that males (84% of outpatient smokers, 56% of inpatients 
smokers) smoked more heavily than their female counterparts (79% of 
outpatient smokers, 49% of inpatients smokers) and this result was 
statistically significant if the setting of the study was disregarded (p=0.01).  
 
5. There was some evidence, again not significant, suggesting that of the 
outpatients who smoked they had a higher rate of heavy smoking compared 
to the inpatient group.  
 
6. From a limited number of studies (table 12) there were as expected results 
showing that males’ onset age for schizophrenia was lower than females. 
 
 
SECTION 2.4.1 DISCUSSION OF SYSTEMATIC REVIEW RESULTS 
 
 
SECTION 2.4.2 HYPOTHESIS 1 - Patients with Schizophrenia Who Are 
Inpatients Will be More Likely to be Smokers than their 
Outpatient Counterparts 
 
This question was based on the premise that schizophrenic patients who were 
currently being managed within a hospital setting would be more unwell than those 
patients who were managing to live within the community. This hypothesis was 
rejected as there was no statistical difference between inpatient (n=26) or outpatient 
(n=15) study groups in terms of the prevalence rate of ever smoking. There was 
however a higher mean value of ever smokers in the inpatient group (72%) compared 
with the outpatient group (64%) with mixed setting (n=9) studies lying between these 
values at 66%. 
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SECTION 3.4.3 HYPOTHESIS 2 - Male Patients with Schizophrenia Will 
Have a Higher Prevalence Rate of Smoking Compared 
with Female Patients. 
 
Worldwide data regarding the gender differences in smoking prevalence has 
consistently shown that males have a higher rate of smoking (42%) than females 
(12%) (World Health Organisation, 2003). This hypothesis was mooted in response 
to these figures to ascertain whether this followed suit in the schizophrenic 
population. In total 13 studies were identified across 3 settings which had prevalence 
rates which could be examined by gender (Table 6). When examined by individual 
setting there was a difference between genders with females proving to be 
consistently less likely to be smokers though it was clearly not statistically 
significant.  
 
When the 3 settings were aggregated and the prevalence rates compared only by 
gender (Table 7) there was a statistically significant difference (p=0.04) between 
male and female schizophrenics with the former having a higher rate which allowed 
this hypothesis to be accepted. This is in keeping with global data however both male 
and female groups far exceeded the WHO statistics described above with the mean 
rate for schizophrenic men at 68.7% (s.d. 13.1%) and schizophrenic women at 47.2% 
(s.d. 26.4%).  
 
 
SECTION 2.4.4 HYPOTHESIS 3 - Schizophrenic Smokers Will Have a 
Higher Prevalence Rate of Being Heavy Smokers than 
Normal Smokers 
 
Unfortunately due to a paucity of control data within these studies the author was 
unable to give a direct comparison between the normal and schizophrenic 
populations for this question. However if a comparison is made between the total 
mean prevalence rate of smokers who smoke more than 20 cpd (i.e. are heavy 
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smokers) and the prevalence rate found in studies looking at the normal population 
there is a marked difference between the 2 groups. 
 
The mean heavy smoking rate from this systematic review (Table 9) was 68% in 
males, 61% in females with a combined rate of 53%. As a comparison a general 
population study conducted during 2001 in the north-west of England (Frank PI., 
Morris JA., Frank TL., et al, 2004), which has the highest rate of smoking in the UK 
(Walker A., Maher J., Coulthard M., et al, 2001), found heavy smoking prevalence 
rates (as a proportion of total rates of ever smokers) to be 38.4% in males and 30.1% 
in females. The latter figures demonstrate that there may well be a higher prevalence 
rate of heavy smokers within the schizophrenic population though this answer is 
given tentatively in view of there not being a direct case-control study method 
applied.  
 
As an addendum to this part of the review it is important to note the non-significant 




SECTION 2.4.5 HYPOTHESIS 4 - Male Schizophrenic Smokers Will Have 
a Higher Prevalence Rate of Being Heavy Smokers 
Compared to Female Schizophrenic Smokers 
 
This question was raised in the light of studies which have reported males to be more 
likely to be heavy smokers than females within normal populations (Frank PI., 
Morris JA., Frank TL., et al, 2004). The hypothesis was confirmed with the same 
result holding true within the schizophrenic populations analysed with males having 







A META-ANALYSIS OF CASE-CONTROL STUDIES 




SECTION 3.1.1 INTRODUCTION 
 
Although the systematic review results have shown with some clarity the increased 
prevalence rates of cigarette smoking amongst schizophrenic populations both in and 
out of hospital; the question as to how this compares with smoking in the normal 
population still remained to be answered. This would allow a description of the 
amount of risk that being a cigarette smoker confers on being schizophrenic also. 
 
To allow an adequate representation of this comparison it was felt appropriate to 
compile a meta-analysis from the case-control studies that had been found, in the 
most part, from the systematic review. This had initially been intended to include 
case-control studies which had had schizophrenic patients smoking rates compared 
with both normal and other psychiatric diagnoses control groups however there were 
insufficient numbers of the latter type of study to allow for meaningful statistical 
analysis with this technique. 
 
SECTION 3.2.1 METHODS 
 
SECTION 3.2.2 Study Selection 
 
From the original set of 50 papers that had been obtained by the process of 
systematic review (Table 17) there were 5 (De Leon., 2002) (Herran A., Santiago A., 
Sandoya M., et al, 2000) (Hughes JR., Hatsukami DK., Mitchell JE., et al, 1986) 
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(Lyons MJ., Kremen WS., Eisen SA., et al, 2002) (McReadie RG., 2002) that were 
able to be examined in a meta-analysis due to the presence of a control group. The 
remaining 45 studies had no control group or no extractable control data. In addition 
to these 5 studies a further 6 were discovered by using identical search criteria as 
those in section 2.2.2 of the systematic review. The characteristics of each of these 
schizophrenic and control groups are outlined in Table 13.  
 
Table 13 Descriptive table outlining the features of the studies found in the systematic review that  
were included in the meta-analysis. 
 




Characteristics of Control group 
(Beratis S., 2001) MIX Greece 
Smoked >100 cigarettes 
and still smoking (or 
only quit in last month) 
DSMIII-R / IV Age/Sex/Setting all matched Occupation/Education most matched 
(De Leon J., 2002) IP USA Questionnaire/FTND DSMIV >18yo, Community sample 
(De Leon., 2002) IP USA Questionnaire/ERBS DSMIII-R Non-schizophrenic psychiatric pts 
(Degenhardt L., 2001) OP Australia Questionnaire CIDI (DSMIII-R) Community sample 
(Herran A., 2000) OP Spain Questionnaire/FTND DSMIV 24-44yo subjects from (Diez-Manrique JF., 1996) 
(Hughes JR., 1986b) OP USA Questionnaire DSMIII Community sample 
(Lyons MJ., 2002) OP USA DSMIII-R DISII-R VET registry 
(McCreadie RG., 2002) OP Scotland Questionnaire ICD-10 Age/Sex/Postcode matched 
(Calabresi M., 1991) MIX Italy Questionnaire Unknown Non-schizophrenic psychiatric patients 
(Ucok A., 2004) MIX Turkey Regular smoking every day for >1month SCID 
Healthy relatives of neurological 
dept outpatients 
(Riala K., 2005) MIX Finland Questionnaire DSMIII-R Healthy controls from Northern Finland 1966 Birth Cohort 
 
OP – Outpatient populations 
IP – Inpatient populations 
Mix – Mixed populations with n’s provided where given in studies 
DSM  – Diagnostic Statistical Manual of Mental Disorders (version indicated by roman numerals) 
ICD – International Classification of Diseases (version  indicated by integer) 
SCID - The Structured Clinical Interview for DSM-IV 
FTND – Fagerstrom Test of Nicotine Dependence 
ERBS – Elgin Repetitive Behaviours Scale 
CIDI – Composite International Diagnostic Interview 
DISIII-R – Diagnostic Interview Schedule Version III-Revised 







SECTION 3.2.3 Data Extraction 
 
For studies to be included in the meta-analysis a set of entry criteria was applied which 
was the same as for the initial review (see section 2.2.3) with an additional clear focus on 
comparing the prevalence rates of current smoking among control groups as well as adult 
schizophrenic populations, as defined by operationalised criteria (except in the case of  
(Calabresi M., Casu G. & Dalle Luch R., 1991) where no criteria was able to be found 
within the paper). In addition studies had to include data for the total number of subjects 
in each group as well as the total number of current smokers within each group. 
 
Quantitative data extracted from retrieved articles included both data to allow assessment 
of potential sources of heterogeneity for example age, gender, illness characteristics, 
family history and other lifestyle factors such as use of drugs or alcohol. Where possible, 
data was tabulated for the amount smoked by the subjects and what proportion of them 
smoked. This allowed for the calculations detailed in Table 14, below.  
 
 
SECTION 3.2.4 Statistical Analysis 
 
SECTION 3.2.4a Effect size 
 
STATA software was used for all data storage and statistical analyses.  Estimates of Odds 
Ratios and their variance were estimated using the Mantel-Haenszel method. Subgroup 
and overall estimates of effect size were estimated using random effects meta-analysis by 
using the DerSimonian and Laird moment-based estimator of between-study variance.  
The direction of the effect size was negative if the schizophrenic group had a lower 
prevalence of smoking when compared to controls.   
 
SECTION 3.2.4b Heterogeneity of Effect Size 
 
Heterogeneity of effect sizes was tested using the Q statistic, with P<0.10 as the cut off 
level of significance.  Because tests of heterogeneity may be underpowered if the number 
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of studies is small, we also explored its magnitude using the I-squared statistic.  This 
quantity estimates the percentage of total variation across studies due to heterogeneity.   
Meta-regression was used to explore age and gender effects for any variable which 
showed greater than 20% of variation in effect size due to heterogeneity. 
 
The summary statistics show that a random effects analysis was employed due to there 
being significant heterogeneity between the studies which also negated the problems that 
can be associated with fixed effects modelling, namely the assumption that each study is 
an estimate of a single underlying effect rather than assuming that all included studies are 
a true random sample of all possible studies. (Lawrie SM., McIntosh A. & Rao S., 2000). 
 
SECTION 3.2.4c Publication Bias 
 
Publication bias was assessed graphically using funnel plots of standardised mean 
difference versus its standard error. The Egger test was used to formally test for the 
presence of publication bias, by estimating the intercept of the regression line fitted to 
Galbraith Radial Plot.   
 
 
SECTION 3.3.1 RESULTS 
 























(Beratis S., 2001) 406 406 237 172 1.908 1.44 - 2.52 11.89 
(De Leon J., 2002) 66 404 55 105 14.238 7.18 – 28.23 8.55 
(De Leon., 2002) 449 127 335 70 2.393 1.59 – 3.60 10.91 
(Degenhardt L., 2001) 99 6722 59 1835 3.928 2.62 – 5.89 10.95 
(Herran A., 2000) 64 710 41 361 1.723 1.01 – 2.93 9.87 
(Hughes JR., 1986b) 24 411 21 123 16.39 4.80 – 55.96 4.9 
(Lyons MJ., 2002) 24 3347 20 2199 2.61 0.89 – 7.66 5.72 
(McCreadie RG., 2002) 250 250 162 99 2.808 1.95 – 4.04 11.28 
(Calabresi M., 1991) 71 29 57 19 2.143 0.82 – 5.62 6.43 
(Ucok A., 2004) 66 114 38 54 1.508 0.82 – 2.78 9.18 
(Riala K., 2005) 67 8041 32 2369 2.189 1.35 – 3.54 10.3 
        
D and L Pooled 
Odds Ratios     2.940 2.08 – 4.15 100.00 
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The following bullet points provide the summary statistics for the meta-analysis 
• Heterogeneity chi-squared =  47.55 (d.f. = 10) p = 0.000 
• I-squared (variation in OR attributable to heterogeneity) =  79.0% 
• Estimate of between-study variance Tau-squared =  0.2404 
• Test of OR=1 : z = 6.13 p = 0.000 
 
Figure F   Forrest Plot from meta-analysis data described in table 28 
 
 
Of all 11 studies only 3 have confidence intervals which at the lower end are less 
than 1 ((Lyons MJ., Kremen WS., Eisen SA., et al, 2002) (Calabresi M., Casu G. & 
Dalle Luch R., 1991) (Ucok A., Polat A., Bozkurt O., et al, 2004) that is to say are 
not statistically significant. The first of these studies (Lyons MJ., Kremen WS., Eisen 
SA., et al, 2002) may show less of an effect due to the small sample size of the 
schizophrenic population though this was not a factor for another of the studies with 
the same ‘n’(Hughes JR., Hatsukami DK., Mitchell JE., et al, 1986) in addition there 
is a higher prevalence rate of smoking in the control group (65.7%) of the former 
study. The work of (Calabresi M., Casu G. & Dalle Luch R., 1991) has a control 
group of non-schizophrenic psychiatric outpatients who have a higher prevalence 
rate of smoking (65.51%) than the normal control groups used in the majority of the 
other studies range (25.9% - 50.8%) which will reduce the odds ratio. The final non-
significant result was from the Turkish study (Ucok A., Polat A., Bozkurt O., et al, 
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2004) which states itself that there is a higher prevalence rate of smoking in the 
normal population than in other countries which affected their, and hence my, results. 
There are 2 outliers which show a more dramatic pattern of risk associated with 
cigarette smoking (De Leon J., Diaz FJ., Rogers T., et al, 2002; Hughes JR., 
Hatsukami DK., Mitchell JE., et al, 1986) with odds ratios of 14.24 (95%CI 7.18 - 
28.23) and 16.39 (95%CI 4.80 – 55.96) respectively. The former study appears to 
have no obvious explanation for the larger odds ratio especially in view of its 
relatively large sample size of the schizophrenic population (n=449) and the authors’ 
themselves provide no insight into why it might be high. The second study (Hughes 
JR., Hatsukami DK., Mitchell JE., et al, 1986) actually states that their results may 
be an underestimate of the amount of smokers in their schizophrenic population as 
self-reported prevalence is usually an underestimate of the true prevalence. 
 
 
SECTION 3.3.2 SUMMARY OF META-ANALYSIS RESULTS 
 
1. The D and L pooled odds ratio for this meta-analysis (n of studies=11) was 
found to be statistically significant. The value for the odds was high at 2.94 















SECTION 3.4.1 DISCUSSION OF META-ANALYSIS RESULTS 
 
 
SECTION 3.4.2 HYPOTHESIS 5 - Schizophrenic Patients are Significantly 
More Likely to be Cigarette Smokers than Individuals in 
the Well Population 
 
This question was posed to answer more conclusively that which has been suggested 
for years that there is an association between cigarette smoking and schizophrenia. 
From the results of the meta-analysis it is clearly shown that suffering from 
schizophrenia carries with it a significantly greater odds of being a current cigarette 
smoker than being a non-smoker (p<0.00).  
 
The actual elevation in the probability of being an ever smoker is demonstrated by a 
pooled odds ratio of 2.94 (95% CI 2.08 – 4.15) which equates to an almost 3 fold 
increase in that risk. The possible reasons behind these significantly raised odds will 















AN INVESTIGATION INTO PATTERNS OF 
CIGARETTE SMOKING IN SCHIZOPHRENIA USING 




SECTION 4.1.1 Introduction 
 
 
SECTION 4.1.2 What is the High-risk Study and how can it answer my 
questions? 
 
As has been outlined in the introductory section there is an increasing amount of 
compelling evidence for schizophrenia being a neurodevelopmental disorder of the 
brain (Weinberger DR., 1995). Direct evidence of this being the aetiology as well as 
establishing what might be the various risk factors that could point to what causes the 
developmental problems leading to schizophrenia requires a comparison between a 
normal control group and a group at a higher risk of developing the illness prior to its 
actual onset. With the lifetime risk of developing schizophrenia placed at around 1 
percent (Jablensky A., 1995) it is too infrequent to be pragmatically studied by using 
general population samples. It is, however, more practical to study individuals whose 
relatives have schizophrenia due to the increased odds ratio of them developing the 
illness being put at 16.2 (Kendler KS. & Gardner CO., 1997). 
 
In addition such studies allow for phenotypic and behavioural markers to be 
identified and, ultimately, therapeutic actions to be identified. 
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Previous prospective studies have had difficulties due to using infants of mothers 
with schizophrenia as there is a long wait between infancy and the subjects entering 
the period of being at most risk of developing the illness (Cornblatt B., 1997) most 
notably with the problems of high attrition in the study sample, problems with power 
calculations and dating of sampling instruments. 
 
The EHRS is, like the other High-risk studies, focussed on examining individuals 
who are at a greater genetic risk of developing schizophrenia but its design is 
different. It includes subjects who have at least 2 close relatives (defined as first or 
second degree) with schizophrenia but starts examining them from when they are in 
early adulthood thus eliminating the problems outlined above (Johnstone EC., 
Abukmeil SS., Byrne M., et al, 2000). Subjects were drawn from areas throughout 
Scotland and were drawn from an age range of between 16 to 25 years old ensuring 
that the study period is during the time of maximal risk of developing the illness. 
Initially it had been planned to follow them every 18 to 24 months over a 5 year 
period, as this was felt to allow interpretable numbers for the study to be gained due 
to the relatively narrow age of onset, or until they developed a clinically diagnosed 
psychotic illness. The study time has been lengthened as the follow-up work is still 
ongoing to this day (Johnstone EC., Miller P., Ebmeier KP., et al, 2005). 
 
The study is primarily organised and conducted from the University of Edinburgh’s 
Division of Psychiatry based at the Royal Edinburgh Hospital (Hodges A., Byrne M., 
Grant E., et al, 1999). 
 
The EHRS has afforded the author the opportunity of comparing whether and how 
much members of the 4 groups smoke; those with symptoms who are at ‘high risk’ of 
developing schizophrenia, those without symptoms who are at ‘high risk’, those who 
are normal controls and those who are schizophrenic controls. It also allows 
observation of at what points smoking rates change in the various samples. This 
should give answers to some of the questions and hypotheses outlined in sections 
1.7.1 and 1.7.2 and provide some idea of the line of causation between the illness and 
consumption of cigarettes. 
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SECTION 4.2.1 METHOD 
 
 
SECTION 4.2.2 Recruitment 
 
When the study was first started it had was hoped that the requisite number of 
subjects to make the study viable would be available within Lothian. Unfortunately 
sufficient numbers of young people with families multiply affected with 
schizophrenia were unavailable so a number of other centres were established 
including Argyll and Clyde, Highlands and Islands, Dumfries and Galloway, 
Borders, Forth Valley and Perth (Hodges A., Byrne M., Grant E., et al, 1999). 
 
As stated above subjects in the ‘high risk’ arm were required to have 2 close relatives 
with a diagnosis of schizophrenia which was made, where possible, using the 
Operational Criteria Checklist (McGuffin P., Farmer A. & I., 1991). Such families 
were found by examining psychiatric case notes of all patients with schizophrenia in 
individual hospitals. If there was data suggestive of the patient having a close relative 
affected with the illness then consent was obtained from that patient to have a 
healthy relative contacted. This person then was asked to detail a full familial 
psychiatric history with specific focus on whether there was a close relative to the 
patient aged between 16 and 24 years old.  
 
Permissions were sought throughout from involved clinical teams and relevant 
medical practitioners. Care and tact were clearly required when dealing with issues 
of familial psychiatric illness particularly when approaching individual young people 
who may not have been aware of their increased risk of developing schizophrenia. 
Initiation was, therefore, often through an older healthy relative (Hodges A., Byrne 
M., Grant E., et al, 1999). 
 
In total over 2500 sets of case files were reviewed and approximately 500 home 
visits were made to patients and their families (Hodges A., Byrne M., Grant E., et al, 
1999). By the end of the recruitment period in July 1999, some 229 high risk 
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participants were ascertained. Of these 163 had provided some data and 156 provided 
complete data (Johnstone EC., Miller P., Ebmeier KP., et al, 2005). From what is 
already known about the rates of illness within such families it was expected that 
between 20 and 30 would go on to develop schizophrenia (Kendler KS., Mcguire M., 
Gruenberg A., et al, 1993). This approximate figure was used to establish how large 
the other groups would need to be for statistical analysis. 
 
As well as the above arm, two further control samples were recruited for the EHRS. 
The well control group were recruited from the social network of the high risk 
individuals themselves. This enabled an improvement in matching for age and socio-
economic status. They had to have no personal or family history of psychotic illness 
but they could have second-degree relatives with other psychiatric illnesses (Hodges 
A., Byrne M., Grant E., et al, 1999). Beyond these criteria they were as similar as 
possible to the high risk subjects (Johnstone EC., Miller P., Ebmeier KP., et al, 
2005). 36 were eventually found and given the same battery of assessments over time 
as the high-risk portion (Johnstone EC., Abukmeil SS., Byrne M., et al, 2000). 
 
The second control group was comprised of first-episode schizophrenic patients 
enlisted from local hospitals in Scotland and were balanced group-wise for age and 
sex with the high risk individuals. In contrast to the other two groups the first-
episode arm subjects were only assessed at the first meeting (Johnstone EC., 
Abukmeil SS., Byrne M., et al, 2000). 
 
All the above was centred around enabling a comparison to be made between the 
premorbid states of the high-risk group who go on to develop psychosis, those who 
remain well and the two control groups thus allowing a delineation of variables 
which could provide clues about how the illness develops.  
 
SECTION 4.2.3 Data Collection 
 
The clinical, social and demographic information described within this study was 
collected from all the subjects at face-to-face interviews. Initially the Schedule for 
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Affective Disorders and Schizophrenia – Lifetime (SADS-L) (Spitzer RL., Williams 
VBW., Gibbon M., et al, 1987) was used to determine life-time psychopathology in 
the subjects. As stated in (Hodges A., Byrne M., Grant E., et al, 1999) the familial 
history of psychiatric disorder had been established by interviewing subjects’ 
relatives as part of the recruitment procedure.  
 
A developmental history, as well as establishing the presence of obstetric 
complications, was obtained by interviewing both the subjects and their mothers at 
length. This included questions about school career, social work involvement and 
periods in foster care. In addition to this a more general enquiry was carried out into 
the participants’ psychological and physical states. The primary tool for assessing 
psychopathology was the Present State Examination (PSE) (Wing JK., Cooper JE. & 
Sartorius N., 1974); this battery was carried out at entry, if the person presented to 
clinical services with the possibility of developing a psychiatric illness and at 
subsequent return interviews (Johnstone EC., Abukmeil SS., Byrne M., et al, 2000). 
The PSEs were not all videotaped due to the suspicions this aroused in some of the 
subjects who were becoming psychotic but were carried out usually apart from this to 
allow a clear definition of the development of schizophrenia on clinical and PSE / 
CATEGO grounds (Johnstone EC., Abukmeil SS., Byrne M., et al, 2000). 
 
From the PSE data a five point scale for psychopathology was developed (table 14) 
(Johnstone EC., Abukmeil SS., Byrne M., et al, 2000). 
 
Table 14 Five point scale for psychopathology in the EHRS 
 
Score Symptoms 
0 No psychotic or neurotic symptoms 
1 Neurotic symptoms only 
2 Partially held psychotic symptoms 
3 Definite but isolated and/or transient psychotic symptoms 
4 Schizophrenia as diagnosed by ICD-10(World Health Organisation, 1992) 
 
Psychotic illness of a non-schizophrenic nature is not covered by the above scale but 
did not occur in any case. Those with a score of 2 or 3 were combined into one 
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group, high risk with positive evidence of schizophrenic symptoms (HR+), and are 
referred to as having had psychotic or possibly psychotic symptoms (Johnstone EC., 
Miller P., Ebmeier KP., et al, 2005). This allowed a division and comparison 
between 4 groups for the purposes of the study.  
 
1. Normal Controls. 
2. High-risk subjects with no psychotic symptoms (HR-). 
3. High-risk subjects with psychotic symptoms (HR+) 
4. First episode schizophrenic patients. 
 
To obtain the data on the presence and quantity of cigarettes smoked I was granted 
access to the initial and return assessments for all these groups. I was blind at this 
stage to which groups the subjects were in and this remained the case until the data 
analysis was complete. From discussion with the interviewers, patients were asked as 
to whether they smoked and, if so, how many cigarettes were smoked per day. 
 
The recording of cigarette usage was not always present within the case records and 
these portions of the data set were left blank and unanalysed. Of the majority that did 
have answers there were variable ways in which the data was written down. To 
enable statistical analyses to be made a scale was developed to allow a cohesive 
grouping of the data. This broke down into 5 groups 
 
1. Never/rarely smoked. 
2. Ever smoked. 
3. 1-10 cigarettes per day (CPD) smoked. 
4. 10-20 CPD smoked. 
5. 20 or more CPD smoked. 
 
This process was repeated for the return assessments which were done to allow any 




SECTION 4.2.4 Data Analysis 
 
Throughout the results section for the work completed within the Edinburgh High-
risk Study the author used the Statistical Package for Social Sciences (SPSS) Version 
12.0 for Windows. Due to the nature of the data obtained non-parametric tests of 
significance were employed as the data was not normally distributed. Normality was 
assessed in all cases by using the Shapiro-Wilk test. 
 
Results for smoking have been recorded as ever or never smoking. The ever smoking 
group included those subjects who were current smokers also. This allowed for the 
clearest description of the data. Unfortunately there was variable recording of the 
actual quantity of cigarettes smoked per day in the assessment papers used for each 
subject at the various time points. This variation could not furnish enough detail for 





SECTION 4.3.1 RESULTS 
 
 
SECTION 4.3.2 Analyses of EHRS Data Comparing All Groups at the 
First Assessment Point 
 
Table 15, below, shows the prevalence rates of ever smoking for all the subjects in 
the study, where data was available barring those patients who were schizophrenic 
controls. Analysis of this data, shown in table 16, shows there is a non-significant 
(p=0.18) difference between those subjects who were at high risk of developing 
schizophrenia who had psychotic symptoms at the first assessment point to have ever 
smoked compared to those who in the same group who had not developed psychotic 




Table 15 A comparison of the rates of smoking between the control group and the high risk groups 







Count 77 51 128 
High risk -ve % within 
Group 60.2% 39.8% 100.0% 
Count 7 11 18 
High risk +ve % within 
Group 38.9% 61.1% 100.0% 
Count 23 13 36 
Group 
Control % within 
Group 63.9% 36.1% 100.0% 
Count 107 75 182 
Total % within 




Table 16 Pearson Chi-Square analysis of data from table 15 which demonstrates non-significant 
difference for high risk subjects with psychotic symptoms to be an ever smoker than high 
risk subjects without symptoms or the control group 
 
 Value df Asymp. Sig. (2-sided) 
Pearson Chi-Square 3.43 2 0.18 
Likelihood Ratio 3.37 2 0.19 
Linear-by-Linear 
Association 0.00 1 0.99 
N of Valid Cases 182   
 
0 cells (.0%) have expected count less than 5. The minimum expected count is 7.42. 
 
 
Figure E, below, allows for a more clear graphical representation of the differences 
in ever smoking prevalence rates between the high risk with symptoms group, high 







Figure E - Bar chart illustrating data from table 1 
Group

























Table 17, below, shows the results of a statistical analysis comparing those in the 
high risk group for schizophrenia without psychotic symptoms to the normal control 
group. There is clearly no statistically significant difference between these two 
groups (p=0.69) in terms of their smoking status at the first time they were assessed. 
 
Table 17 Mann-Whitney test data showing no significant difference when comparing numbers of 
subjects who ever smoked in HR- group compared to control group at 1st time point  
 
Ranks 
 Group N Mean Rank Sum of Ranks 
High risk -ve 128 83.17 10646.00 
Control 36 80.11 2884.00 Ever smoked 







 Ever smoked 
Mann-Whitney U 2218.00 
Wilcoxon W 2884.00 
Z -.40 
Asymp. Sig. (2-tailed) .69 
 
 
The following data set (Table 18) shows that there is a trend, which did not reach 
statistical significance (p=0.09), for those who had psychotic symptoms in the high-
risk group to be ever smokers compared with those without such symptoms in the 
high-risk group at the first time point to have ever smoked.  The crude unadjusted 
odds ratio for this result is 2.3725 with 95% confidence intervals of 0.9 to 6.5. The 
power is represented by the width of the 95%CI. 
 
Table 18 Chi-square test data showing a trend, but no significant difference, towards subjects in   the 
HR+ group having a higher rate of ever smoking compared with the HR- group  
 Group N Never Ever 
High risk –ve 128 77 51 
High risk +ve 18 7 11 Ever smoked 
Total 146   
 
Test Statistics 
 Ever smoked 
Pearson Chi square 2.921 
Df 1 
Asymp sig 0.087 
N of cases 146 
 
Table 19, see below, illustrates the results of a Mann-Whitney U test comparing the 
prevalence rate of ever smoking in the high-risk group with psychotic symptoms 
compared with those in the well control group. This shows a trend, although not 
statistically significant (p=0.08), for those in the HR+ group to have ever smoked at 
the time of the first assessment compared to those who were well and not at a high 
genetic risk of developing schizophrenia. 
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Table 19 Mann-Whitney test data showing no significant difference, but greater evidence of a trend 
compared to table 5’s chi-square analysis, for HR+ subjects to be ever smokers compared 
to the control group 
Ranks 
 Group N Mean Rank Sum of Ranks 
High risk +ve 18 32.00 576.00 
Control 36 25.25 909.00 Ever smoked 
Total 54   
 
Test Statistics 
 Ever smoked 
Mann-Whitney U 243.00 
Wilcoxon W 909.00 
Z -1.72 




Table 20 is a descriptive frequency table comparing the three initial broad groups 
with no subdivision of the high-risk set by symptomatology or consequent outcome. 
This data has been used for analysis in table 21. 
 
Table 20   Frequency table for all the high-risk subjects irrespective of outcome, controls and first 
episode schizophrenic patients for ever smoking rates at 1st round screening 
  




Count 84 62 146 
High risk % within 
Group 57.5% 42.5% 100.0% 
Count 23 13 36 
Control % within 
Group 63.9% 36.1% 100.0% 
Count 6 17 23 
Group 
Schizophrenic % within 
Group 26.1% 73.9% 100.0% 
Count 113 92 205 
Total % within 
Group 55.1% 44.9% 100.0% 
 
 
The following Pearson Chi-Square test (table 21) has been performed on the data 
from table 20. It shows that schizophrenic patients were significantly more likely to 
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have been ever smokers (p=0.01) than either the high-risk group as a whole or the 
control group. 
 
Table 21 Chi-Square test comparing all the high risk subjects irrespective of outcome with controls 
and first episode schizophrenic patients for ever smoking rates at 1st round screening (see 
table 9). This demonstrates a significantly higher presence of smoking amongst the 1st 
episode schizophrenic patients with no difference between the high risk and control 
subjects  
 
 Value df Asymp. Sig. (2-sided) 
Pearson Chi-Square 9.30(a) 2 .01 
N of Valid Cases 205   
 




SECTION 4.3.3 Analyses of EHRS Data Comparing All Groups at the 
Fourth Assessment Point 
 
The data set below (table 22) is a frequency table showing the number and associated 
percentage values for the full high-risk group (irrespective of outcome or symptom 
profile) and the control group at the fourth round of assessments. 
 
Table 22    Frequency table for all the high risk subjects irrespective of outcome and controls for ever 
smoking rates at 4th round screening 
 




Count 40 18 58 
High-risk % within 
Group 69.0% 31.0% 100.0% 
Count 17 3 20 
Group 
Control % within 
Group 85.0% 15.0% 100.0% 
Count 57 21 78 
Total % within 
Group 
73.1% 26.9% 100.0% 
 
 80
Table 23 shows the results of a Pearson Chi-Square analysis of the data from table 
22. This shows that there continues to be stability of there being no statistically 
significant difference between the whole group of those who were at high risk of 
developing schizophrenia compared with the normal control group for being ever 
smokers. It does, however, demonstrate a non-significant difference for the high-risk 
group to have been ever smokers (p=0.16). 
  
 
Table 23 Chi-Square test comparing all the high-risk subjects irrespective of outcome and controls 
for ever smoking rates at 4th round screening (see table 11). This demonstrates stability 
over time of there being no significant difference between the control and high-risk groups 
for ever smoking 
 
 Value df Asymp. Sig. (2-sided) 
Pearson Chi-Square 1.94(b) 1 .16 
N of Valid Cases 78   
 
b  0 cells (.0%) have expected count less than 5. The minimum expected count is 5.38. 
 
 
SECTION 4.3.4 Analyses of EHRS Data Using the High-Risk Group Data 
When Divided into Those Who Did and Did Not Go on to 
Develop Schizophrenia  
 
Table 24, below, gives a description of ever smoking rates, in terms of numbers in 
the groups as well as the corresponding percentages, for the normal control group in 
comparison with the high-risk group. The latter group has, however, been divided 
into those who went on to eventually develop schizophrenia by the fourth assessment 









Table 24 A comparison of the rates of ever smoking between the control group and the high-risk 
groups divided into those who did and did not develop schizophrenia by the 4th time point 
 










Group 61.1% 38.9% 100.0% 
Count 23 13 36 
Control group % within 
Group 63.9% 36.1% 100.0% 







Group 38.9% 61.1% 100.0% 
Count 110 75 205 
Total % within 




Table 25 is a Pearson Chi-Square analysis of the three groups delineated in table 24. 
This shows there is a result, which was not statistically significant though approaches 
a trend (p=0.11), for the portion of the high-risk group who developed schizophrenia 
to be more likely to have been ever smokers at the first assessment point compared 
with those who did not develop schizophrenia or the control group. 
 
Table 25 A comparison of the rates of smoking between the control group and the high-risk groups 
divided into those who did and did not develop schizophrenia by the 4th time point  
 
 Value df Asymp. Sig. (2-sided) 
 
Pearson Chi-Square 3.59 2 .11 






The below Pearson Chi-Square analysis (table 26) is comparing only those subjects 
who were at high risk of developing schizophrenia when divided into a group who 
did go on to develop schizophrenia compared to a group who did not go on to 
become schizophrenic. This shows a trend, though again not reaching true statistical 
significance (p=0.07), for those at high-risk who went on to become unwell to have 
been ever-smokers at the first time they were assessed for the EHRS. 
 
Table 26 A Chi-Square comparison of the rates of smoking between the high-risk groups only, 
divided into those who did and did not develop schizophrenia, by the 4th time point 
showing a strong tendency for those who developed schizophrenia to have ever smoked at 
the 1st round in comparison to those who did not. 
 
 Value df Asymp. Sig. (2-sided) 
 
Pearson Chi-Square 3.20 1 .07 
N of Valid Cases 185   
 
 
SECTION 4.3.5 Summary Of Ever Smoking Data at the First Assessment 
Point for All Possible Groups  
 
The bar chart below (Figure H) gives a clear illustration of how there is a trend for an 
increased percentage of ever smokers by groups. Normal control subjects have the 
lowest rate of being ever smokers at the first assessment followed by those high-risk 
subjects who had no symptoms, then by those with symptoms, then by those who 













Figure H - Bar Chart illustrating percentage of ever smokers within each possible group of the Edinburgh High-













have been ever 
smokers











SECTION 4.3.6 SUMMARY OF RESULTS 
 
1. There is a non-significant difference (p=0.18) for the rates of ever smoking 
between the high-risk group members with psychotic symptoms when 
compared with those in the high-risk group without such symptoms or the 
well control group at the first assessment point. However there was evidence 
of a trend (p=0.09) when the high-risk group with psychotic symptoms was 
compared only with the high-risk group without psychotic symptoms or only 
with the control group (p=0.08) for rates of ever smoking. The crude 
unadjusted odds ratio for the former result is 2.3725 with 95% confidence 
intervals of 0.9 to 6.5. The power is represented by the width of the 95%CI. 
 
2. There is no significant difference (p=0.69) for the high-risk group without 




3. The schizophrenic control group were significantly more likely to be ever 
smokers at the first time point than both the high-risk and control groups 
(p=0.01). 
 
4. At the fourth time point there continued to be no significant difference 
between those in the well control group and the high-risk groups for ever-
smoking status (p=0.16). 
 
5. When the high-risk group was divided into those who did and did not go on 
to develop schizophrenia there was a trend (p=0.07) for those who did 









SECTION 4.4.2 Methodological Problems 
 
 
SECTION 4.4.3 Recording of Cigarette Use 
 
As  alluded to earlier, when the author states the prevalence rates of smokers this has 
been in terms of had the subject ever smoked or never smoked. This was 
unfortunately due to the variable way in which cigarette consumption was recorded 
by the initial researchers. Although this allows a clear delineation of the categories it 
does mean that intensity of smoking data is lost as well as the ability to establish how 
smoking patterns changed over time to some extent. This is because once patients 
have been recorded as an ever smoker, even if they quit, this status does not change. 
However this method of recording is in keeping with the largest and most recently 
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published meta-analysis of this subject (De Leon J. & Diaz FJ., 2005) and as such 
will allow comparison with previous author’s results. 
 
Future studies may be improved by having a shift of focus from recording the 
number of cigarettes smoked to establishing the subject’s level of dependence on 
nicotine by using such instruments as the FTND (see table 27) which has been shown 
to be a valid measure of heaviness of smoking as measured by physiological and 
biochemical indices (Heatherton T., Kozlowski LT., Frecker RC., et al, 1991) as well 
as psychological measures (Dijkstra A. & Tromp D., 2002). This would allow a 
better investigation of the possible correlation between true dependence and 
schizophrenia rather than just using whether or not the patient has ever smoked that 
would thus allow a clearer examination of underlying abnormalities that may be 
present in both these problems. 
 
Table 27 Items and scoring for the Fagerstrom Test for Nicotine Dependence (FTND) 
Questions Answers Points 
1. How soon after you wake up do you smoke your first cigarette? Within 5 minutes 
6-30 minutes 
31-60 minutes 





2. Do you find it difficult to refrain from smoking in places where it 









4. How many cigarettes per day do you smoke? 10 or less 
11-20 
21-30 





5. Do you smoke more frequently during the first hours after waking 












SECTION 4.4.4 Heritability of Smoking as a Confound 
 
As described in section 1.5.2, there is evidence for tobacco smoking behaviours to be 
at least partly inherited via the genotype. To eliminate this as a potential confounder 
it would have been necessary to take a familial smoking history and, if possible, 
perform the FTND on all the subjects’ parents. Though this would not completely 
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eliminate the problem as it is suggested by some authors that schizophrenia and 
smoking behaviours may both occur due to a common shared genetic vulnerability 





SECTION 4.5.1 Evaluation of Hypotheses 
 
 
SECTION 4.5.2 Hypothesis 6 – The Schizophrenic Group in the Edinburgh 
High-Risk Study Will Have a Higher Prevalence Rate of 
Cigarette Smokers Compared with the Normal Population 
and High-Risk Groups 
 
From the data collated from within the Edinburgh High-Risk Study it was apparent 
that this hypothesis could be accepted. There was a clear (p=0.01, table 21) 
difference between the number of ever smokers in the schizophrenic group as 
compared to the control or high-risk groups at the first time point. This is in keeping 
with the results from my systematic review of the evidence base below and the 




SECTION 4.5.3 Hypothesis 7 – Patients at high-risk of developing 
schizophrenia will have a higher prevalence rate of 
cigarette smokers compared with the normal control group 
 
At the point of the first assessment this hypothesis must be rejected as there was no 
statistically significant difference between the high-risk and control groups. However 
there were clear trends demonstrated for the high-risk group with psychotic 
symptoms to have been ever smokers compared with the high-risk group without 
 87
symptoms (p=0.09, table 18) and compared with the control group (p=0.08, table 
19). When the former result was further analysed it was found that the crude 
unadjusted odds ratio for this result is 2.3725 with 95% confidence intervals of 0.9 to 
6.5. The power is represented by the width of the 95%CI. 
 
At the fourth time of assessment the hypothesis continues to be rejected as there is a 
no difference between the whole high-risk group’s rate of ever smoking compared to 
the control group (p=0.16, table 23). If the high-risk group is further divided into 
those who developed schizophrenia by this point compared with those who did not 
and the controls then a trend becomes evident (p=0.10, table 24). Furthermore if the 
comparison is limited to just the high-risk group who developed schizophrenia with 
those who did not develop schizophrenia then the significance becomes greater 




SECTION 4.5.4 SUMMARY 
 
The most valuable result from this arm of the study may be the one that shows a 
trend (p=0.07) for those who were at high-risk and went on to become schizophrenic 
to have a higher prevalence rate of being ever smokers than their counterparts who 
stayed well even at the first time of assessment.  This is because it suggests that there 
is a predictive value to determining whether or not someone has ever smoked if they 
are at a high genetic risk of developing schizophrenia. This would allow the clinician 
to make a reasonable, albeit not statistically significant, prediction that the individual 
concerned may go on to become unwell if they are an ever smoker who is already 
genetically predisposed to schizophrenia.  
 
These results answer the first 2 questions posed in the introduction namely ‘Are 
schizophrenics more likely to smoke than other groups?’ and ‘Are high-risk subjects 
more likely to smoke than their high-risk counterparts without symptoms?’. The final 
question is not wholly answerable from these results but if figure H is re-examined 
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then it can be seen that a preliminary affirmative answer is available to question 3, 
that is to say ‘does smoking correlate with illness severity?’, as the percentage of 
ever smokers in each group does show an almost linear progression with what could 
be regarded as ‘illness severity’ as there is a progression from normal controls 
through the high-risk no symptoms group, high-risk with symptoms group, high-risk 
who became ill group up to those who were schizophrenic at the first assessment. 
 
The trend for the high-risk subjects who became schizophrenic to smoke more also 
suggests that something untoward is happening at the first assessment point, i.e. 
when they were not schizophrenic, which is leading them to smoke more cigarettes. 
The question of course is ‘what is the nature of this disturbance?’ and how cigarette 
smoking might alleviate or exacerbate it. The author will tackle this subject in the 






















SECTION 5.1.1 SO WHY DO SCHIZOPHRENICS AND SOME OF 
THOSE WHO ARE AT HIGH-RISK OF DEVELOPING 
SCHIZOPHRENIA SMOKE MORE CIGARETTES 




SECTION 5.2.1 THE BIOLOGICAL MODELS  
 
 
SECTION 5.2.2 Cigarettes Improve Aberrant Information Processing 
Skills  
 
As far back as 1962 it has been hypothesised that there may be a ‘schizotaxic factor’ 
(Meehl PE., 1962) which leads to the inherited predisposition to schizophrenia and 
may involve an increased level of neuronal sensitivity to sensory stimuli. Such 
information processing deficits may account for the symptomatic problems patients 
have in interpreting sight and sound leading to the disorder’s characteristic visual and 
auditory hallucinations (Leonard S., Adams C., Breese CR., et al, 1996).  
 
The aforementioned factor has been preliminarily investigated in the work, outlined 
in section 1.3.1, involving the P50 auditory gating paradigm (Adler LE., Hoffer LD., 
Wiser BA., et al, 1993; Braff DL., Geyer MA., Light GA., et al, 2001) which has 
been shown to be defective in schizophrenic populations (Adler LE., Pachtman E., 
Franks R., et al, 1982) as well as their first degree relatives (Adler LE., Hoffer LD., 
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Griffith J., et al, 1992). Adler’s work showed that there was a significant reduction of 
the P50 gating ratio from >75% to 25% (normal subject value = 18% ) in 5 minutes 
or less after the first cigarette smoking session however the effect was no longer 
significant after a second session (P50 ratio approximately 65%) (Adler LE., Hoffer 
LD., Wiser BA., et al, 1993).  This problem is not repaired by the typical neuroleptic 
anti-dopaminergic drugs used to treat schizophrenia and as such cigarette smoking 
may represent an attempt by patients to treat it themselves (Adler LE., Olincy A., 
Waldo M., et al, 1998) and lead to the higher odds of them being smokers (OR=2.94) 
than the normal population as shown in section 3.3.2. 
 
This deficit may be due to a disturbance within the hippocampus. Within this 
structure lie areas CA1-CA4 but it is the CA3 region particularly that is a major point 
of convergence for cortical and brain-stem inputs. It has been suggested (Hasselmo 
ME., Schnett E. & Barkai E., 1995) that the utility of this network depends on 
precise regulation (or gating) of the intensity of synaptic input to it which is felt to be 
mediated by cholinergic inputs. These may inhibit afferent inputs to CA3 and hence 
perform a gating function. Unfortunately Hasselmo et al. were not able to determine 
which cholinergic receptor is the basis for this effect but it has been postulated that 
the absence of cholinergic activity caused by a cholinergic receptor reduction in 
schizophrenia would result in perceptual difficulties as the affected person would 
constantly be altering autoassociative memory by overstimulation instead of recalling 
previous memories to place the new sensory input in the context of prior experience 
(Adler LE., Olincy A., Waldo M., et al, 1998). The most obvious candidate for this, 
as yet unidentified receptor, would seem to be the alpha-7 subtype of nAchRs which 
is known to be dysregulated in schizophrenia and alters sensory physiology (Leonard 
S., Gault J., Hopkins J., et al, 2002). 
 
The increased prevalence of heavy smoking within the schizophrenic population, 
demonstrated by the acceptance of hypothesis 5, may also be tied in with this model. 
The alpha-7 nAchR is known to have a much lower affinity for nicotine than other 
subunits (alpha-2/3/4/5 and beta-2/3/4) (Seguela P., Wadiche J., Dinely-Miller K., et 
al, 1993). Most smokers, i.e.those within the general population who are not trying to 
 91
self-medicate for attentional deficits, probably use nicotine to stimulate the higher 
affinity receptors that aid the release of GABA and dopamine (Kirch DG., Gerhardt 
GA., Shelton RC., et al, 1987)giving the anxiety reduction and mood elevation that 
most smokers report (Jarvik ME. & Schneider NG., 1992). Therefore schizophrenic 
smokers, who tend to smoke more heavily (see section 2.4.4), may be targeting the 
defective lower affinity alpha-7 receptor which has also been shown to be present in 
decreased numbers in the hippocampi of schizophrenic patients. (Freedman R., Hall 
M., Adler LE., et al, 1995) 
 
The P50 attentional mechanism is not the only information-processing domain that is 
abnormal in schizophrenia. Smooth pursuit eye movements (SPEM) have also been 
documented as aberrant in this population (Levy DL., Holzman PS., Matthysse S., et 
al, 1994). A number of studies have reported that nicotine administration to 
schizophrenics, by smoking cigarettes (Klein C. & Andresen B., 1991) (Olincy A., 
Ross RG., Young DA., et al, 1998), improves SPEM performance. Furthermore 
improvements due to nicotine consumption in other areas of cognition have also been 
shown including in the Continuous Performance Task (CPT), a systematic measure 
of cognitive deficits in patients (Levin ED., Wilson W., Rose JE., et al, 1996) as well 
as in reducing antisaccade errors in task impaired schizophrenic subjects (Larrison-
Faucher AL., Matorin AA. & Sereno AB., 2004). In the latter study it was noted 
however that not all the ill subjects showed the antisaccade deficit but those that did 
tended to have a higher daily consumption of cigarettes. Again such findings would 
give credence to the idea that schizophrenic patients are more likely to smoke, as per 
the results of the meta-analysis and smoke more heavily (as was suggested in the 
results of hypothesis 3), to self-medicate for such abnormalities. 
 
The finding from hypothesis 7, that there is a clear trend for those at a higher risk of 
developing schizophrenia to be more likely to be ever smokers compared to the well 
controls, also correlates with what is known about the heritability of the P50 gating 
deficit (Waldo MC., Carey G., Myles-Worsley M., et al, 1991) as well as other 
attentional endophenotypes including the decreased P300 amplitude (Blackwood 
DH., St Clair DM., Muir WJ., et al, 1991) and abnormal SPEM (Holzman PS., 
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Kringlen E., Matthysse S., et al, 1988). These problems are found in about 50 
percent of the first degree relatives of the schizophrenic patients studied following an 
autosomal dominant pattern of inheritance. This suggests that the presence of, for 
example, the P50 gating deficit is not enough in itself to lead to the development of 
the full schizophrenic constellation of symptoms (Leonard S., Adams C., Breese CR., 
et al, 1996). A study of siblings discordant for schizophrenia and the P50 deficit was 
undertaken (Waldo MC., Cawthra E., Adler LE., et al, 1994) which showed that 
those who were ill had the P50 defect as well as a reduction in the volume of the 
hippocampus. Those who had the gating deficiency but a normal hippocampal 
volume were not affected meaning that expressed alone, neither abnormality was 
sufficient for disease development. This finding in first degree non-smoking relatives 
of schizophrenic probands, who were free of the possible confounding effects of 
neuroleptic and anticholinergic mechanisms, was also established by Adler et al. who 
showed that nicotine chewing gum could evoke the inhibitory mechanisms for the 
P50 system which were faulty in them (Adler LE., Hoffer LD., Griffith J., et al, 
1992).  
 
From the above therefore it may be that those from the EHRS who are at high-risk of 
developing schizophrenia and are smokers may well have the P50 gating deficit 
genotype, or other attentional endophenotype abnormality, and are treating 
themselves accordingly. Of these subjects it is possible that those who go on to 
become ill are unable to fully treat this deficit due to the lack of protective function 
afforded to them from a small hippocampus but they have a higher prevalence rate of 
being ever smokers as they must ‘work harder’ to overcome this. The group of those 
who are at high-risk with no psychotic symptoms may have a higher prevalence rate 
than the well controls as they are merely trying to self-medicate for the P50 deficit. 
The high-risk group with some psychotic symptoms but not the full syndrome of 
schizophrenia lie somewhere in-between these two phenotypes, and possibly 
genotypes, which reflects the complexity of this disorder. 
 
The final part of the P50 puzzle is the finding that clozapine normalises this gating 
deficit in those who respond to this medication as measured by an improvement in 
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their Brief Psychiatric Rating Scale (BPRS) (Overall JE. & Gorham DR., 1962) 
scores by 20 percent from when they were taking typical antipsychotic treatments 
(Nagamoto HT., Adler LE., Hea RA., et al, 1996). Further evidence for clozapine’s 
possible interaction with nicotinic systems is found in a study showing that 
schizophrenic patients actually decrease their cigarette smoking during clozapine 
treatment (McEvoy JP., Rose JE., Levin ED., et al, 1994) a finding that was added to 
by Procyshyn et al. who demonstrated that those patients who were on clozapine had 
lower expired carbon monoxide values as well as lower self-reported levels of 
smoking (Procyshyn RM., Ihsan N. & Thompson D., 2001). These results may 
suggest a strong cholinergic influence on the efficacy of antipsychotics as well as in 
the pathogenesis of schizophrenia but they must be tempered with the consideration 
that patients on typical neuroleptics may be smoking more cigarettes to self-medicate 
for these drugs' side-effects as the author will discuss below. 
 
 
SECTION 5.2.3 Schizophrenic Patients Are Smoking Cigarettes to Help 
Relieve the Negative Symptoms of Schizophrenia  
 
It has been asserted in recent years that neurobiological factors provide the strongest 
explanation for the connection between smoking and schizophrenia as direct 
neurochemical interactions can be investigated and demonstrated (Lyon ER., 1999). 
One such factor is that proposed by Dalack et al. (Dalack GW., 1998) 
who consider that cigarette smoking by schizophrenics may be an attempt to treat the 
negative symptoms of their illness including anhedonia, amotivation,  
social withdrawal and apathy which are present due to dysfunctions within the 
mesolimbic reward circuitry. Because of nicotine’s complex effects on the central 
dopaminergic system it might provide a way to activate this abnormal reinforcement 
/ reward system (Combs DR., 2000). 
 
The basis for this idea is that schizophrenia has been considered to be a disease 
caused by a hyper-dopaminergic state (see section 1.2.2) and as such, treatments, 
especially the typical neuroleptics, have been geared towards their dopamine receptor 
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blocking potential. Despite their relative success in treating the positive symptoms of 
schizophrenia, such as delusions and hallucinations, they have been less effective at 
remedying the negative symptoms (Johnstone EC., Crow TJ., Frith CD., et al, 1978) 
as these may be due to a reduction in dopaminergic transmission. This may be why 
other psychotropic chemicals, including amphetamines, have been shown to alleviate 
negative symptoms as they increase dopamine activity within the brain (Van 
Kammen DP. & Boronow JJ., 1988) and, indeed, such stimulants with dopaminergic 
properties are preferentially used by patients with schizophrenia (Patkar AA., 
Alexander RC., Lundy A., et al, 1999). Interestingly nicotine has also been shown in 
preclinical studies to be a promoter of dopamine release in the mesolimbic system 
(Imperato A., Mulas A. & DiChiara G., 1986) which has been suggested to be 
because it increases the release of dopamine with its action on presynaptic terminals 
(Svensonn T. & Enberg G., 1980). Tobacco smoke has also been shown to reduce the 
central activity of the monoamine-B (MAO-B) enzyme by up to 40% which would 
also lower the degradation of dopamine hence increasing nicotine’s pro-
dopaminergic activity (Fowler JS., Volkow ND., Wang G-J., et al, 1996). 
 
In conjunction with the above data nicotine has also been shown to induce a dose-
dependent increase in neuronal activity in some brain regions including the nucleus 
accumbens, amygdala, cingulate and frontal lobes (Stein EA., Pankiewiz J., Harsch 
HH., et al, 1998). This has relevance to the high prevalence rate of cigarette smoking 
in the schizophrenic population bearing in mind that schizophrenic patients display 
hypofrontality which has been reported to be associated with the negative symptoms 
of schizophrenia (Svensson TH., Grenhoff J. & Enberg G., 1990; Weinberger DR., 
1987). The latter study in rats found that nicotine produced a significant partial 
reversal of the dysfunction of mesolimbicocortical dopamine cells which had been 
induced by cold inactivation. It has been suggested that smoking may therefore 
represent an attempt to self-medicate the impaired influence of the frontal/prefrontal 
cortex on the mesolimbicocortical dopamine systems of schizophrenics which may 
be part of the explanation for the high prevalence rates found in the systematic 
review completed for this thesis.  
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Other clinical studies (Hall RG., Duhamel M., McClanahan R., et al, 1995), but not 
all (Herran A., Santiago A., Sandoya M., et al, 2000), have also demonstrated a link 
between negative symptoms and tobacco use. One such study found a positive 
association between severity of smoking, negative symptoms and other symptoms 
reflecting impairments in attention, orientation and thinking irrespective of possible 
confounders including medication dose and with no relationship found to positive 
symptoms (Patkar AA., Gopalakrishnan R., Lundy A., et al, 2002). The authors of 
this study raise the question of the line of causality between cigarette smoking and 
symptomatology, a problem that is evident throughout the papers examined for this 
thesis; they suggest that there are two alternative explanations for the association. 
The first is that patients are indeed self-medicating which would integrate well with 
what has already been detailed in this section regarding the neurobiology of 
schizophrenia as well as what patients subjectively report (Glassman AH., 1993). 
The second implies the reverse in that nicotine use worsens the clinical picture by 
exacerbating negative symptoms by desensitising nicotinic receptors therefore 
reducing cholinergic activity in the prefrontal cortex (Vezina P., Blanc Glowinsk J. 
& Tassin J., 1992).  
 
In addition to what has already been described in this section is the finding that 
tobacco addiction has been linked to an earlier age of onset in schizophrenia (Sandyk 
R. & Kay SR., 1991) which, in turn, has been found to have a significant association 
with the presence of negative symptoms (Johnstone EC., Owens DGC., Bydder GM., 
et al, 1989). Sandyk et al. suggest this association, which is due to an alteration in the 
function of the brain’s reward circuitry notably within the ventral tegmental area, is 
because of decreased dopamine activity in the mesolimbic system as a whole and 
therefore leads to compensatory excessive nicotine intake and ultimately addiction. 
In terms of the applicability of this to the EHRS sample, a recent study (Owens 
DGC., Miller P., Lawrie SM., et al, 2005) showed that those in the high-risk group 
who developed the full schizophrenic illness at the last assessment had a significantly 
worse rating in their negative symptom score from the PSE in comparison to those at 
high risk who remained well and by a greater amount than the well control group. 
This correlates with the data presented from the same sample in that the HR-ill group 
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show a trend of having more ever-smokers by the final assessment than either of the 
other two aforementioned groups. So it may be that those at high-risk are already 
self-medicating for their deficit. Unfortunately this potential answer is confounded 
however by the findings from Owens et al. that positive symptomatology followed 
the same pattern.  
 
All of the above has implications for what is known about the treatment of 
schizophrenia. Clozapine has been shown to reduce smoking rates in schizophrenic 
patients (Procyshyn RM., Ihsan N. & Thompson D., 2001) as well as having superior 
efficacy in treating negative symptoms and clearing hypofrontality (Shafari M., 
2005). It is not unreasonable to consider that the three effects are linked and that 
clozapine may prove an effective treatment for nicotine dependence in schizophrenia 
and provide clues to the aetiology of the condition. 
 
SECTION 5.2.4 Cigarettes Are Being Used by the Schizophrenic 
Population to Treat Their Positive Symptomatology 
 
A third explanation for the high prevalence rate shown for cigarette smoking in the 
schizophrenic populations studied (see section 2.3.6) as well as the significant odds 
ratio established by the meta-analysis conducted (see section 3.4.2) is that patients 
are treating their positive psychotic symptomatology with nicotine. 
 
The above may seem counter-intuitive however in light of what has been noted in the 
introductory sections of the thesis concerning how cigarettes affect smokers’ brains 
(see section 1.4.3) and the role of positive reinforcement in maintaining dependence 
(see section 1.5.4). This is particularly in relation to the effect that nicotine has in 
elevating extracellular levels of dopamine in the brain (Nissel M., Nomikos GG. & 
Svensson TH., 1994; Watkins S., Koob GF. & Markou A., 2000) when positive 
symptoms appear to be associated with a hyperdopaminergic state (Weinberger DR., 
1987). If this is true then what is the explanation for so many schizophrenics 
smoking so much? One author feels that any negative impact on positive 
symptomatology may be outweighed by the potential relief that cigarettes give to 
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negative symptoms (Forchuk C., Norman R., Malla A., et al, 1997) a subject that I 
elaborated on in the previous section. A neurobiological explanation may be possible 
as it has been demonstrated, in animal models, that chronic administration of nicotine 
leads to a desensitisation of central nicotine receptors and an overall decrease in 
dopamine release (Grenhoff J., Jannson AM., Svensson TH., et al, 1991; Kirch DG., 
Gerhardt GA., Shelton RC., et al, 1987; Lapin EP., Maker HS., Sershen H., et al, 
1989). These results have not been uniformly replicated as others have shown an 
increase in dopamine with chronic nicotine administration (Fung YK., 1988) and still 
others have demonstrated no change to dopamine levels (Lapin EP., Maker HS., 
Sershen H., et al, 1987). This makes the interpretation of such results and their link 
with a possible self-medication effect of nicotine on positive symptoms difficult at 
this time. It would be of interest though to examine how with chronic use of 
cigarettes the patient’s symptoms, both positive and negative, changed with time.  
As evidence for the potential interaction between the cholinergic and dopaminergic 
systems a model has been put forward about how they might interact to affect 
positive psychotic symptomatology. The proposers of this (Procyshyn RM., Patel K. 
& Thompson DL., 2004) noted that significantly more smokers were prescribed an 
anticholinergic agent than non-smokers and that the administration of such centrally 
acting agents results in unopposed nicotinic cholinergic receptor agonism by 
endogenous acetylcholine thus giving an amplification of positive symptoms 
secondary to increased dopaminergic activity. This increase is then attenuated by the 
desensitisation of nicotinic receptors described above. 
 
Clinical studies have also been performed in this field with the assumption that if 
self-medication is occurring then there should be a correlation between cigarette 
consumption and symptomatology. Goff et al. reported that smokers had a higher 
BPRS score for both positive and negative symptoms (Goff DC., 1992) while 
another study (Ziedonis DM., Kosten TR., Glazer WM., et al, 1994) found that 
smokers had more positive symptoms than non-smokers with the heaviest smokers 
having the highest levels of positive symptoms. These were both cross-sectional 
studies which limits the possibility of establishing a line of causality between the two 
factors so it may be that smoking is a marker of a patient trying to manage a worse 
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illness or it may be that cigarette smoking may worsen positive symptoms. This 
problem has been addressed in three case series, the first of which (Dalack GW., 
1996) noted that three subjects, albeit retrospectively, reported worsening of positive 
symptoms with cessation of smoking. Secondly Lawn et al. (Lawn SJ., Pols RG. & 
Barber JG., 2002) describe how smoking was perceived by more than half of the 
patients they studied to play a role in alleviating the positive symptoms of 
schizophrenia with a poignant description by one of their patients: 
 
“And at the moment there doesn’t seem to be any better solution to stopping the 
negative [psychotic] thoughts than smoking”. 
 
 The third (Hamera E., Schneider JK. & Deviney S., 1995) showed that there was an 
exacerbation of prodromal symptoms associated with less nicotine use. This last 
study has relevance to the results from the Edinburgh High-Risk study, presented in 
section 4.5.3, as it may explain why there is evidence of a trend for a higher 
prevalence rate of being an ever-smoker in those at high-risk of developing 
schizophrenia even when they have not gone on to develop the illness as yet. It is 
possible that the prodromal symptoms are already being managed in this group by 
cigarette smoking. 
 
The final finding which further corroborates the idea of self-medication for such 
symptoms is that a diagnosis of the paranoid subtype of schizophrenia significantly 
correlated with cigarette smoking whereas the other subtypes did not (Combs DR., 
2000). This subtype has a greater burden of positive symptomatology than the other 
subtypes and one answer to this could be that the increased smoking rates reflect this 
groups’ attempt to attenuate their paranoid symptoms. This is not the only possible 
explanation as dysphoria is particularly associated with positive symptoms of 
schizophrenia (Lysaker PH., Bell MD., Bioty SM., et al, 1995) and nicotine use may 
reflect an attempt to treat this affective abnormality due to cigarette’s potential 




SECTION 5.2.5 Antipsychotic Side-effects Can Possibly Be Helped by 
Smoking Cigarettes 
 
The antipsychotic drugs that are consistently used to treat schizophrenia have a 
number of unpleasant side effects, even in the normal population, where it can be 
seen that a single 5mg dose of oral haloperidol leads to a significant increase in 
nicotine intake (Dawe S., 1995). This suggests that there may well be a link between 
what medication is used and how much people smoke. It has been hypothesised that 
cigarettes may serve to reduce the side effects of antipsychotic treatments in two 
ways which may be a large incentive for patients to start or continue smoking.  
 
The first of these is that cigarettes have a pharmacokinetic interaction with 
neuroleptic treatment (Goff DC., 1992). This is not a nicotine specific effect but is as 
result of polycyclic hydrocarbons in cigarette smoke stimulating the hepatic 
microsomal system which induces enzymes to increase the metabolism of 
psychotropic medications (Ziedonis DM. & George TP., 1997). The putative enzyme 
is within the cytochrome P450 group, known to be involved in the oxidative 
metabolism of the majority of antipsychotics (Lyon ER., 1999), and has been 
suggested to be the 1A2 isoform (Nemeroff CB., DeVane CL. & Pollock BG., 1996). 
A number of studies have demonstrated an association between the clearance of 
haloperidol, as well as a reduction in it and its reduced form’s level in the 
bloodstream, with cigarette smoking (Jann M., Saklad SR., Ereshefsky L., et al, 
1986) (Miller DD., Kelly MW., Perry PJ., et al, 1990). This corroborates with other 
work that has shown that this reduced level then requires an increase in dosage to 
attain therapeutic levels of neuroleptics, for example the mean chlorpromazine 
equivalent in smokers is 590mg compared to 375mg for non-smokers (Ziedonis DM., 
Kosten TR., Glazer WM., et al, 1994). Other studies have reported a similar finding 
with smokers consistently prescribed a higher dosage of antipsychotics than non-




These findings though do not answer the question as to why the association persists. 
Is it due to the patient treating the side effects from their higher dosage of medication 
or are psychiatrists prescribing more medication to their schizophrenic smokers to try 
and counter the pharmacokinetic effects of cigarette consumption? One answer to 
this question may be found in work that has investigated the connection between 
specific antipsychotics and smoking behaviour. It has been noted that patients treated 
with haloperidol smoked more heavily, as measured by expired carbon monoxide 
measures, plasma nicotine and cotinine levels, than when they were drug free 
(McEvoy JP., Freudenreich O., McGee M., et al, 1995). The same group, and others 
(Procyshyn RM., Ihsan N. & Thompson D., 2001), have shown that clozapine users 
have lower prevalence rates of smoking which has been hypothesised to be due to the 
atypical agents elevating levels of cortical dopamine in a manner similar to nicotine 
(Moghaddam B. & Bunney BS., 1990). The older typical drugs effectively 
antagonise the central dopaminergic system meaning that this system could be being 
alternatively self-managed by the smoking schizophrenic as well as them reducing 
the actual blood levels of medication which would lead to less side effects (Lyon 
ER., 1999). This latter idea was considered in a study which demonstrated that 
smokers had lower levels of chlorpromazine-induced sedation than non-smokers, a 
finding that was attributed to lower plasma chlorpromazine concentrations (Swett 
CJ., 1974) in the smoking group due to their presumed activation of the hepatic 
microsomal enzyme system. 
 
Further to the above there is the second way that cigarettes may help schizophrenics 
manage medication related problems in the light of what is known about how 
nicotine exerts its effects on the dopaminergic function of the CNS and how this 
could influence the development and presentation of neuroleptic induced 
extrapyramidal movement disorders including parkinsonism and tardive dyskinesia 
(TD) (Lohr JB. & Flynn K., 1992).  
 
There are a number of reasons to consider a relationship between nicotine, dopamine 
and the dyskinesias. The first of which is the speculation that smoking may have a 
protective effect against the development of idiopathic Parkinson’s disease, which is 
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known to involve a loss of dopaminergic neurons in the substantia nigra leading to a 
net dopamine deficit, as has been suggested by a number of cross-sectional studies. 
One of these, Kessler at al., has shown that Parkinson’s disease is less likely to occur 
in smokers (Kessler II. & Diamond DL., 1971) and this may be due to nicotine’s 
agonist effect on the striatal dopamine system (Morens DM., Grandinetti A., Reed 
D., et al, 1995). A second reason for a possible interdependence between smoking 
and parkinsonism is that monozygotic twin studies have consistently shown that in 
Parkinson’s disease environmental factors outweigh genetic ones in its aetiology  
with affected co-twins being significantly less likely to be smokers than their 
unaffected siblings (Bharucha NE., Stokes L., Schoenberg BS., et al, 1986). In the 
light of such ideas it is not surprising to find that studies in this area have 
demonstrated that measures of neuroleptic-induced parkinsonism were lower in 
smokers than in non-smokers (Decina P., Caracci G., Sandyk R., et al, 1990) (Goff 
DC., 1992; Sandyk R., 1993). The last of these studies (Goff DC., 1992) showed that 
this effect was highly significant and appeared to be independent of gender, age and 
anticholinergic prescription with the number of cigarettes smoked daily having a 
significant correlation with parkinsonism ratings. Again the question arises of 
whether or not patients smoke in response to extrapyramidal side-effects or whether 
the protective antiparkisonian effect, as seen in the normal population, is at work. 
Goff et al. address this by stating that the smokers in their group started the habit on 
average 8 years before starting on neuroleptic treatment which would favour the 
latter explanation. 
 
Interestingly these findings in favour of smoking are in contrast to what has been 
seen in animal studies where smoking worsens extrapyramidal symptoms acutely as 
it induces catalepsy in mice (Baumann RJ., Jameson HD., McKean HE., et al, 1980) 
however with chronic administration of nicotine there is a protective effect against 
induced degeneration of nigrostriatal neurons (Janson AM., Agnati LF., Fuxe K., et 
al, 1988) which is an animal model for parkinsonism. This chronic ameliorating 
effect may be due to nicotine decreasing the vulnerability of nigrostriatal neurons by 
desensitising excitatory nicotinic receptors leading to reduced firing rates and lower 
energy demands on the neurons (Fuxe K., Janson AM., Jansson A., et al, 1990). In 
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addition it may be that after chronic nicotine administration the brain’s levels of 
acetylcholine are reduced (Balfour DJK., 1984). With the knowledge of all these 
actions that nicotine has on reducing the unpleasant side-effects of antipsychotic 
treatment it seems hardly surprising that there is such a high prevalence rate of 
smoking found in the systematic review and that the odds ratio within the meta-
analysis showed a significant association between smoking and schizophrenia. 
Schizophrenic patients, when they start smoking, do so often prior to being treated 
with neuroleptics, as has been noted above as would be the case in the high-risk 
group at the first assessment point of the EHRS. Hence medication may not be the 
initiator of the habit but would certainly seem to be a factor in the continuing 
persistence, and perhaps heaviness, of smoking when patients do start treatment with 
psychotropic medications. 
 
As has been outlined there are strong links between nicotine and dopamine which has 
led researchers to consider the interrelationship between cigarette smoking and 
tardive dyskinesia (TD) also. TD is characterised by involuntary movements of the 
orolingual, facial, truncal and extremity regions. Its incidence increases with duration 
of neuroleptic exposure and this has been hypothesised to be due to dopamine 
receptor supersensitivity which arises from chronic receptor blockade by 
antipsychotics (Lohr JB. & Flynn K., 1992; Ziedonis DM. & George TP., 1997). As 
the author has outlined previously nicotine administration may lead to dopamine 
release and as such it would be expected that smoking would therefore exacerbate 
TD or promote its emergence though studies conducted in this area have yielded 
differing results. Yassa et al. (Yassa R., Samarthji L., Korpassy A., et al, 1987) 
showed a significantly higher prevalence of TD in smokers compared to non-
smokers though they were on higher doses of neuroleptics presumably as a result of 
smoking’s effect on microsomal enzymes but Menza et al. (Menza MA., Grossman 
N., Van Horn M., et al, 1991) found that there was no difference between smokers in 
terms of the severity or frequency of TD. The latter study’s result fits with an 
alternative theory that has been suggested for the dopamine-nicotine interaction 
which is that chronic nicotine intake could reduce the risk of TD by blocking an 
increase in dopamine receptor density as has been demonstrated in a pre-clinical 
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study (Prasad C., Spahn SA. & Hiromasa I., 1989). This finding has been replicated, 
albeit in a case-control study of 1 smoker versus 1 non-smoker both of whom had 
been treated with haloperidol for some years, which showed that D2-dopamine 
receptor upregulation had not occurred in the smoker suggesting a protective effect 
of smoking on TD (Silvestri S., Negrete JC., Seeman MV., et al, 2004). 
 
The potential impact on the prevalence data within this thesis is that smoking, if it 
worsens TD, would intuitively mean that patients with schizophrenia would smoke 
less and vice versa. However, if the patient is already addicted to smoking and it’s 
potential beneficial effects, for example on negative and positive symptoms, 
outweigh the negative effect of developing tardive dyskinesia then it may be that the 
cost of giving up is greater than the cost of continuing. This is an area which 
highlights the need for a comprehensive cohort study looking at smoking behaviours 
and their interaction with all of the problems associated with schizophrenia to 
establish how they are temporally related. 
 
 
SECTION 5.2.6 Because The High-Risk Patients and Those with 
Schizophrenia Possess a Shared Vulnerability to Being 
Both Schizophrenic and Cigarette smokers  
 
As has been outlined in the above sections there has been a distinct lack of studies 
examining the temporal relationship between tobacco smoking and schizophrenia. 
Other diagnoses have had a greater exposure to this form of investigation most 
notably depression. Kendler et al. in the results of a twin study (Kendler KS., Neale 
MC., MacLean CJ., et al, 1993) theorised that genetic vulnerability could explain 
why depressed patients smoke approximately twice as much as the well population 
(Glassman AH., 1993). From this thesis it is apparent that the prevalence rate of 
cigarette smoking in the schizophrenic population is higher even than this.  
 
With the above in mind, as well as with the facts surrounding the heritability of the 
P50 gating (Adler LE., Hoffer LD., Griffith J., et al, 1992) and other attentional 
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deficits (Blackwood DH., St Clair DM., Muir WJ., et al, 1991), and with the 
knowledge that genetic linkage studies have supported a role for the alpha-7 nAchR  
within these faulty mechanisms in schizophrenia, as well as what was described in 
section 1.5.2 regarding the heritability of smoking in the normal population, it is not 
unreasonable to speculate that this high rate of cigarette consumption in 
schizophrenia may also be partly explained by genetic factors. Furthermore, work 
surrounding candidate gene investigations has identified putative genes such as the 
D2/D3/D4-dopamine receptor genes to be involved with the pathogenesis of 
schizophrenia and also with cigarette smoking (Yoshimasu K. & Kiyohara C., 2003).   
 
Following from this it has been noted that 50 percent of patients had started daily 
cigarette smoking prior to the onset of their first schizophrenic episode (De Leon J., 
1996). This result has been further confirmed in a number of other studies which 
showed a range of proportions (49-90 percent, mean 77%) for those who started 
smoking before the onset of their illness (Gurpuegui M., Martinez-Ortega JM., 
Aguilar MC., et al, 2005) (Campo-Arias A., Haydar-Ghidays R., Bermusdez-de-
Leon A., et al, 1998) (De Leon J., Diaz FJ., Rogers T., et al, 2002) (Uzun O., 
Cansever A., Basoglu C., et al, 2003) (Liao D-H., Yang J-Y., Lee S-M., et al, 2002) 
(Beratis S., Katrivanou A. & Gourzis P., 2001) (Kelly C. & McReadie RG., 1999). In 
one of these the mean smoking onset age preceded schizophrenia by 11 years (Kelly 
C. & McReadie RG., 1999). There is some debate in the literature as to whether this 
early initiation of smoking should be regarded as a symptomatological part of the 
prodrome of the illness (Riala K., Hakko H., Isohanni M., et al, 2005) or as an 
independent risk factor for schizophrenia itself (De Leon J. & Diaz FJ., 2005). If the 
latter view is considered then it would seem that those who are going to go on and 
develop schizophrenia may have some factor that makes them more vulnerable to 
start smoking. Such a factor may be genetic in nature as unaffected co-twins of 
schizophrenic probands have been shown (Lyons MJ., Kremen WS., Eisen SA., et al, 
2002) to have a high rate of ever smoking close (83%) to that of their affected co-
twins (86%). This would be in keeping with what I have suggested about how 
individual’s genotypes influence whether they smoke or not particularly in terms of 
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sensory and information processing abnormalities that are present throughout 
affected families. 
 
The alternative view of smoking as a symptom of the prodrome of the illness 
corresponds more with what has already been written above about how smoking may 
be used as a form of self-medication by patients. Both points of view require further 
investigation to take into consideration how genetic factors may influence 
vulnerability to start smoking or develop schizophrenia. One such investigation is 
found within this thesis.  
 
From the EHRS section it is apparent that there was a trend (p=0.09) for those who 
were at high risk of developing schizophrenia and had psychotic symptoms (HR+) at 
the first assessment point when compared with the group who were at high risk 
without psychotic symptoms (HR-). The crude unadjusted odds ratio for this data 
showed a result of 2.3725 (95% confidence intervals of 0.9 to 6.5). This would seem 
to correlate more with the self-medication argument in that the symptomatic group 
may be treating their prodromal symptoms whereas those who had no symptoms, but 
had the genetic vulnerability for schizophrenia, were no more likely to be ever 
smokers than the control group (p=0.69). 
 
In conjunction with these findings is that those who were at high-risk of developing 
schizophrenia and then went on to do so by the fourth timepoint had a near trend 
level (p=0.11) increase in their rate of ever smokers compared to those from the HR 
group who did not become unwell (p=0.07 when analysed alone with the ill group 
alone which indicates a statistical trend) or the control group. This may be because of 
an underlying additional vulnerability, beyond having a higher genetic risk, within 
the HR group who became ill that was not shared with the high-risk group who did 
not develop any or all of the full syndrome of schizophrenia. Alternatively it may 
again be that there is an underlying neurophysiological deficit that is being treated by 
those who become unwell at the first time point such as the P50 gating deficit.  
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As such, further investigation is required into this finding as it is possible that 
smoking may be a provocative factor for developing schizophrenia in the high-risk 
population as has been suggested by some who consider that repeated activation of 
the mesolimbic dopaminergic system over a long period by nicotine may precipitate 
the onset of schizophrenia in vulnerable individuals rather than reflecting an 
underlying shared vulnerability for nicotine dependence (Kelly C. & McReadie RG., 
1999). This hypothesis seems unlikely given the evidence for desensitisation of the 
dopaminergic system over time (Pidoplichko VI., DeBias M., Williams JT., et al, 
1997) though intermittent smoking or relapse of dependence after abstinence might 
worsen positive psychotic symptoms (Chong SA. & Choo HL., 1996; Foulds J. & 
Toone B., 1995). Therefore useful extensions of the work contained in this thesis 
would be to correlate symptomatology with smoking prevalence and to measure P50 
potentials and other attentional endophenotypes serially within high-risk populations. 
Other work could focus on neuroimaging to establish whether the development of 
schizophrenia correlated with cigarette smoking and another factor together such as 
hippocampal volume as was suggested earlier (Waldo MC., Cawthra E., Adler LE., 
et al, 1994). 
 
 
SECTION 5.3.1 But Maybe It’s Not All Biological 
 
Beyond the biological reasons for why those with schizophrenia and those at a higher 
risk for developing the illness might be more likely to be smokers are the ideas that 
have been put forward regarding how psychological and social factors might affect 
these prevalence rates. 
 
From this thesis it was apparent that there was a non-significant difference between 
the prevalence rates for smoking in inpatient and outpatient settings, which was 
postulated with hypothesis 1, but despite this finding some authors have suggested 
that there is a role played by institutions in maintaining smoking habits in the 
psychiatrically unwell. Masterson et al. suggest that ‘smoking is an important 
component of institutional life, cigarettes being widely used by the nursing staff as a 
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form of token economy’ (Masterson E. & O'Shea B., 1984) whilst another study 
found that a high percentage of psychiatric staff smoked and, more worryingly, 
almost a quarter of these staff denied that there were hazards in smoking (Mester 
RE., Toren P., Ben-Moshe Y., et al, 1993). This latter study also reported that a third 
of patients were aware that smoking by the staff encouraged them to do so, a fact that 
the employees were unaware of. Alongside this is what has been written in the 
section about cessation and treatment options (section 1.6.5) regarding the low 
percentage of patients who are counselled about smoking by psychiatric staff 
(Himelhoch S. & Daumit G., 2003) (Lawrie SM., Buckley LA., Ulyatt BC., et al, 
1995) which suggests that though patients may initiate smoking prior to 
hospitalisation, as has been stated earlier, those in the psychiatric profession and 
paramedical services may be doing little to reduce the prevalence of cigarette 
smoking once there is contact with them. 
 
The effect of institutionalisation has been refuted by others who note that the 
prevalence of smoking is raised in both in- and outpatient settings (Hughes JR., 
Hatsukami DK., Mitchell JE., et al, 1986) as I have shown also.  De Leon et al. note 
that non-schizophrenic psychiatric inpatients have a higher rate of smoking than the 
general population from which they come but not to the level shown in schizophrenia 
and thus discard institutionalisation as a factor (De Leon J., Dadvand M., Canuso C., 
et al, 1995). Further work from this group (De Leon., 2002) also suggests that long 
hospitalisation may even decrease smoking.  In reply to this argument it has been 
suggested that institutionalisation may affect schizophrenics differentially from non-
schizophrenics as the former may be anxious in response to being institutionalised 
and the latter may not be (Smith GL., 1996). As far as this debate’s relevance to 
those in the EHRS is concerned it is limited as those who were at high-risk and went 
on to develop the illness were already smoking more at the first assessment point 
prior to them becoming unwell and thus hospitalised. 
 
Further psychosocial interpretations of the elevated cigarette smoking rates in 
schizophrenia have been propounded including the ‘Psychological Tool Model’, the 
role of patient’s demographic and educational characteristics as well as the impact of 
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personality all of which have all been dealt with in section 1.5.6. As an addendum to 
these potential elevators of the prevalence rate is the role of gender in the results of 
hypotheses 4 and 6 which demonstrated that males were more likely to be smokers 
and to smoke more heavily than female smokers. As stated in these sections this is in 
keeping with what is known about patterns of smoking within the well population. It 
has however been suggested that the better pre- and post-morbid functioning of 
female schizophrenics may protect them from the need to smoke (Beratis S., 
Katrivanou A. & Gourzis P., 2001). 
 
The final psychological aspect for the smoking rate to be elevated in the 
schizophrenic population is the subjective reasons provided by the ill for their habit. 
There have been few studies in this area but those that have been published report 
that schizophrenic patients smoke for much the same reasons as those who are not 
schizophrenic - primarily ‘relaxation’ (80%), ‘habit’ (67%) and ‘calming nerves’ 
(52%) - with nearly a quarter concurring, without knowing it, with the self-
medication hypothesis and identifying psychiatric issues as influencing their smoking 
behaviour (Glynn SM. & Sussman S., 1990). A later study demonstrated that those 
with mental illness smoked in line with 4 major themes namely ‘habit and routine’ 
(58%), ‘socialisation’ (58%), ‘relaxation’ (42%) and ‘nicotine addiction’ (33%) (Van 
Dongen CJ., 1999) though this latter percentage may represent denial. 
 
Despite these varied psychological theories, which could as well be applied to the 
well population, it is hard not to think that the biological correlates I have discussed 
in this thesis might not be more applicable to the strong association between 












There has been a consistent theme in the results that the author have reported 
throughout this thesis which has been that cigarette smoking and schizophrenia are 
inextricably linked. The author has shown a clear and consistent association both in 
the systematic review and the meta-analysis that those who have schizophrenia are 
far more likely to smoke than those in the general population regardless of gender, 
setting or country. Furthermore it has been demonstrated, from the Edinburgh High-
Risk Study, results that show that those who have a genetic predisposition to 
becoming schizophrenic are already smoking more than their well and high-risk 
counterparts who stay well when they were first assessed for this study. So why is 
this? The answer seems to lie primarily in the neurobiology and neurophysiology of 
the illness. 
 
The presence of hard-wired information processing deficits in those who are 
schizophrenic and their first-degree relatives suggest that these groups are at a 
disadvantage when presented with the complex stimuli we find around us in the 
world. The author would suggest that these abnormalities may lie behind some of the 
characteristic symptoms we see in the disorder most probably in the domain of the 
perceptual disturbances that are almost its hallmark. This is because problems with 
managing incoming auditory data, in the case of the P50 deficit, and visual 
information, as with difficulties in tackling smooth-pursuit eye movement tasks, 
could lead to a lower threshold for the misinterpretation of such stimuli and hence 
auditory and visual hallucinations. Though these deficits alone are not enough to 
explain why schizophrenic patients are so much more likely to smoke cigarettes as 
their relatives with the same deficit do not manifest the same symptoms. As has been 
discussed in the sections dealing with information processing it seems to be the 
requirement of another abnormal factor to lead to the symptomatology being 
manifested such as a reduction in hippocampal volume that may lead to the full 
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syndrome of schizophrenia. Alternatively it may be that the processing problems tip 
the balance unfavourably towards psychosis and without smoking cigarettes the 
symptoms may be much worse or it may be that those who were at high-risk and do 
not become unwell are managing to keep the bar raised high enough for information 
to be handled in a normal fashion. 
 
This tendency for there to be the association described herein between positive 
symptoms of schizophrenia and cigarette smoking is difficult to interpret. There 
remains the continuing chicken and egg question in respect to both these symptoms 
and negative symptoms as they interact with the self-medication hypothesis. Elevated 
levels of positive symptoms are associated with elevated rates of smoking but is it 
because nicotine is having an agonist effect on the mesolimbic-mesocortical 
dopaminergic system or is it that positive symptoms, such as hallucinations, are 
being treated by the patients themselves with cigarettes which are causing a 
desensitisation of nicotinic receptors and hence a reduction in the activity of the 
dopaminergic system? This question requires more emphasis to be placed on 
prospective studies being carried out by researchers however studies such as the 
EHRS do afford the prospect of solving this puzzle as by studying the association of 
selected symptom profiles to cigarette smoking rates then it may become more 
obvious what leads to what. 
 
This problem with establishing the line of causality also presents itself when 
considering what the impact of negative symptoms are on cigarette smoking 
behaviours or vice versa. It would seem intuitively true that if patients are socially 
isolated, amotivational and dysphoric they would tend to sit for longer periods in 
hospital smoking rooms where company is at least more available. But when the 
evidence for the faulty reward system present in schizophrenia is considered, as well 
as the increasing knowledge of the role hypofrontality plays in the deficit state 
associated with this condition, it can seem even more intuitive that patients may be 
trying to counter these dysfunctional neural circuits by activating them with nicotine 
and its manifold secondary neurochemical effects. The complexity continues though 
as if the idea that patients are activating their brains with nicotine is true then are 
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they not placing themselves at more risk of worsening their psychotic symptoms? It 
would seem that neuroimaging methods, especially functional techniques, may 
provide a clearer explanation of this as it may be that the systems which underlie the 
pathogenesis of positive and negative symptoms are being differentially activated by 
cigarette smoking in schizophrenics and that there may be some or no trade-off 
between them. 
 
Finally on the neurobiological theme there is the suggestion that there is a shared 
vulnerability for tobacco dependence and schizophrenia. This seems to underpin 
much of what is known about the P50 deficits and other attentional endophenotypes 
that are found in schizophrenia and provides a plausible explanation for how the two 
disorders might be intertwined. If schizophrenia is a disorder that affects circuits in 
the brain that are linked to reward, information processing and motivation then it 
does not seem unreasonable for it to lead to problems with dependence on substances 
which also are linked to these areas. 
 
The illness itself is not the only explanation for why people with schizophrenia 
smoke though because it may be partly an iatrogenic effect. The side-effects of the 
medications that are primarily used to treat schizophrenia, namely neuroleptics, are 
no doubt a heavy burden for patients. The link between parkinsonism and cigarette 
smoking seems to suggest that nicotine may provide a helpful role in alleviating this 
problem but it does not explain why those in the EHRS who were smoking more at 
the first assessment point were doing so. In this case, as with the effects of 
institutionalisation, it cannot be the only explanation for why there is such a high 
prevalence rate as neither medication nor hospitalisation were part of the equation at 
the subjects’ first meeting with the interviewers. The author would suggest that it is 
the neurobiological substrates and symptoms that lead to the elevated initiation of 
cigarette smoking in schizophrenia and to some extent its persistence but when other 
non-schizophrenic groups might think of quitting those who have become unwell 
now have additional reasons to continue smoking such as medication, boredom or 
indeed worsening of symptoms with abstinence. Again, prospective studies may give 
the field of psychiatry a better understanding of how the processes are linked. 
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Whatever the reason for the association it still leaves the profession with the task of 
managing patients’ physical health which includes enabling them to stop smoking. 
Government initiatives are becoming increasingly preoccupied with getting the 
population to stop smoking also. If we and our patients are aware of the damage 
smoking is doing to their bodies then there must be a greater emphasis on smoking 
cessation which has been shown to be effective in psychiatric populations. However 
if nicotine is a potential therapeutic agent in schizophrenia, for all the possible 
reasons stated previously, then greater emphasis should be placed on finding a non-
carcinogenic alternative to cigarettes and then to provide it to patients.  
 
The final question that is raised by the consideration of nicotine as a potential 
weapon in the psychiatrist’s armamentarium is whether it may be appropriate for 
there to be a re-evaluation of the dopamine hypothesis of schizophrenia to increase 
its level of complexity to not only include serotonin, GABA and glutamate but also 
nicotine. The author has reported on many pre-clinical and clinical studies which 
show a clear line of evidence for nicotine’s role in pathological mechanisms in 
schizophrenia that may allow a new line of investigation to be set up to analyse what 
causes this distressing illness and how it can be treated. This after all is the Rosetta 























Action on Smoking and Health UK. (2004) Factsheet 16: The economics of 
tobacco. 
Addington J., El-Guebaly N., Campbell W., et al (1998) Smoking cessation 
treatment for patients with schizophrenia. American Journal of Psychiatry, 
155, 974-976. 
Adler LE., Hoffer LD., Griffith J., et al (1992) Normalisation of deficient auditory 
sensory gating in the relatives of schizophrenics by nicotine. Biological 
Psychiatry, 32, 607-616. 
Adler LE., Hoffer LD., Wiser BA., et al (1993) Normalization of Auditory 
Physiology by Cigarette Smoking in Schizophrenic Patients. American 
Journal of Psychiatry, 150, 1856-1861. 
Adler LE., Olincy A., Waldo M., et al (1998) Schizophrenia, Sensory Gating and 
Nicotinic Receptors. Schizophrenia Bulletin, 24, 189-202. 
Adler LE., Pachtman E., Franks R., et al (1982) Neurophysiological evidence for 
a defect in neuronal mechanisms involved in sensory gating in schizophrenia. 
Biological Psychiatry, 17, 639-654. 
Akbarian S., Bunney WE., Potkin SG., et al (1993) Altered distribution of 
nicotinamide-adenine dinucleotide phosphate diaphorase cells in the frontal 
lobe of schizophrenics implies distrubance of cortical development. Archives 
of General Psychiatry, 50, 169-177. 
Akvardar Y., Tumuklu M., Akdede BB., et al (2004) Substance use among 
patients with schizophrenia in a university hospital. Klinik Psikofarmakoloji 
Bueltini, 14, 191-197. 
Altamura AC., Bassetti R., Bignotti S., et al (2003) Clinical variables related to 
suicide attempts in schizophrenic patients: A retrospective study. 
Schizophrenia Research, 60, 47-55. 
American Psychiatric Association. (1994) The Diagnostic and Statistical Manual - 
IV. 
Anda RF., Williamson DF., Escobedo LG., et al (1990) Depression and the 
dynamics of smoking: a national perspective. Journal of the American 
Medical Association, 264, 1541-1545. 
Armitage AK., Hall GH. & Morrison CF. (1968) Pharmacological basis for 
smoking habit. Nature, 331-334. 
Asaad TAA., Okasha TA., El Khouly GA., et al (2003) Substance Abuse in a 
Sample of Egyptian Schizophrenic Patients. Addictive Disorders & Their 
Treatment, 2, 147-150. 
Ascher JA., Cole JO., Colin J-N., et al (1996) Bupropion: A review of its 
mechanism of antidepressant activity. Journal of Clinical Psychiatry, 56, 
395-401. 
 114
Balfour DJK. (1984) The effects of nicotine on brain neurotransmitter systems. In 
Nicotine and the Tobacco Smoking Habit (ed Balfour DJK.). New York: 
Pergamon Press. 
---- (1989) Influence of nicotine on the release of monoamines in the brain. Progress 
in Brain Research, 79, 165-172. 
Baum K. & Walker EF. (1995) Childhood behavioural precursors of adult symptom 
dimensions in schizophrenia. Schizophrenia Research, 16, 111-120. 
Baumann RJ., Jameson HD., McKean HE., et al (1980) Cigarette smoking and 
Parkinson's disease: a comparison of cases with matched neighbours. 
Neurology, 30, 839-843. 
Baumeister AA. & Francis JL. (2002) Historical Development of the Dopamine 
Hypothesis of Schizophrenia. Journal of the History of the Neuorsciences, 11, 
265-277. 
Bejerot S. & Nylander L. (2003) Low prevalence of smoking in patients with 
autistic spectrum disorders. Psychiatry Research, 119, 177-182. 
Benwell ME. & DJK., B. (1979) Effects of nicotine administration and its 
withdrawal on plasma corticosterone and brain 5-hydroxyindoles. 
Psychopharmacology, 63, 7-11. 
Benwell MEM., Balfour DJK. & Anderson JM. (1990) Smoking-associated 
changes in serotonergic systems of discrete regions of the human brain. 
Psychopharmacology, 63, 7-11. 
Beratis S., Katrivanou A. & Gourzis P. (2001) Factors affecting Smoking in 
Schizophrenia. Comprehensive Psychiatry, 42, 393-402. 
Bergler E. (1953) Smoking and its infantile precursors. International Journal of 
Sexology, 6, 214-220. 
Bharucha NE., Stokes L., Schoenberg BS., et al (1986) A case-control study of 
twin pairs discordant for Parkinson's disease: a search for environmental risk 
factors. Neurology, 36, 284-288. 
Blackwood DH., St Clair DM., Muir WJ., et al (1991) Auditory P300 and eye 
tracking dysfunction in schizophrenic pedigrees. Archives of General 
Psychiatry, 48, 899-909. 
Bleuler E. (1911/1950) Dementia praecox or the group of schizophrenias. New 
York: International Universities Press. 
Braff DL., Geyer MA., Light GA., et al (2001) Impact of prepulse characteristics 
on the detection of sensorimotor gating deficits in schizophrenia. 
Schizophrenia Research, 49, 171-178. 
Brown S., Birtwhistle J., Roe L., et al (1999) The unhealthy lifestyle of people with 
schizophrenia. Psychological Medicine, 29, 697-701. 
Brown S., Inskip H. & Barraclough B. (2000) Causes of the excess mortality of 
schizophrenia. British Journal of Psychiatry, 177, 212-217. 
Buckley PF. (1998) The Clinical Stigmata of Aberrant Neurodevelopment in 
Schizophrenia. The Journal of Nervous and Mental Disease, 186, 79-86. 
Calabresi M., Casu G. & Dalle Luch R. (1991) La prevelenza del fumo di tabacco 
nei pazienti psichiatri; L'influenza dell'instituzionalizzazione. Minerva 
Psichiatrica, 32, 89-92. 
Campo-Arias A., Haydar-Ghidays R., Bermusdez-de-Leon A., et al (1998) 
Tabaquismo en pacientes psiquiatricos ambulatorios. Revista ABP-APAL, 20, 
71-74. 
 115
Capell PJ. (1978) Trends in cigarette smoking in the U.K. Health Trends, 10, 49-54. 
Carvajal C., Passig C., San Martin E., et al (1989) Prevalencia del consumo de 
cigarrillos en pacientes psiquiatricos. Acta Psiquiatrica y Psicologica de 
America Latina, 35, 145-151. 
Challis GB. (1999) Level of activity and prevalence of smoking in psychiatric 
patients. Canadian Journal of Psychiatry, 44, 711. 
Chambers RA., Krystal RH. & Self DW. (2001) A neurobiological basis for 
substance abuse comorbidity in schizophrenia. Biological Psychiatry, 50, 71-
83. 
Chapman J. (1966) The early symptoms of schizophrenia. British Journal of 
Psychiatry, 112, 225-251. 
Chatterton R., Sanderson L., Van Leent S., et al (1998) Does clozapine affect 
smoking rates? Australian and New Zealand Journal of Psychiatry, 32, 890-
891. 
Cherry N. & Kiernan K. (1976) Personality scores and smoking behaviour: A 
longitudinal study. British Journal of Preventive and Social Medicine, 30, 
123-131. 
Chiles JA., Cohen S., Maiuro R., et al (1993) Smoking and Schizophrenic 
Pathology. American Journal of Addictions, 2, 315-319. 
Chong SA. & Choo HL. (1996) Smoking among Chinese patients with 
schizophrenia. Australian and New Zealand Journal of Psychiatry, 30, 350-
353. 
Combs DR., A. C. (2000) Antipsychotic medication and smoking prevalence in 
acutely hospitalized patients with chronic schizophrenia. Schizophrenia 
Research, 46, 129-137. 
Cornblatt B., O. M. (1997) Update of high-risk research; 1987-1997. International 
Review of Psychiatry, 9, 437-447. 
Corrigall WA., Coen KM. & Adamson KL. (1994) Self-administered nicotine 
activates the mesolimbic dopmaine system through the ventral tegmental 
area. Brain Research, 653, 278-284. 
Corrigall WA., Franklin KBJ. & Coen KM., e. a. (1992) The mesolimbic 
dopaminergic system is implicated in the reinforcing effects of nicotine. 
Psychopharmacology, 285-289. 
Dalack GW., M.-W. J. (1996) Smoking, smoking withdrawal and schizophrenia: 
case reports and a review of the literature. Schizophrenia Research, 22, 133-
141. 
---- (1998) Nicotine Dependence in Schizophrenia: Clinical Phenomena and 
Laboratory Findings. American Journal of Psychiatry, 155. 
Dani JA. (2001) Overview of nicotinic recpetors and their roles in the central 
nervous system. Biological Psychiatry, 49, 166-174. 
Dani JA., H. S. (1996) Molecular and cellular aspects of nicotine abuse. Neuron, 16, 
905-908. 
Dawe S., G. C., Russell M., Gray A., (1995) Nicotine intake in smokers increases 
following a single dose of haloperidol. Psychopharmacology, 117, 110-115. 
De Amicis LE., Wagstaff DA. & Cromwell RL. (1986) Reaction time cross-over as 
a marker of schizophrenia and higher functioning. Journal of Nervous and 
Mental Disease, 174, 177-179. 
 116
De Leon J. (1996) Smoking and vulnerability for schizophrenia. Schizophrenia 
Bulletin, 22, 405-409. 
De Leon J., Dadvand M., Canuso C., et al (1995) Schizophrenia and smoking: An 
epidemiological survey in a state hospital. American Journal of Psychiatry, 
152, 453-455. 
De Leon J. & Diaz FJ. (2005) A meta-analysis of world-wide studies demonstrates 
an association between schizophrenia and tobacco smoking behaviours. 
Schizophrenia Research, 76, 135-157. 
De Leon J., Diaz FJ., Rogers T., et al (2002) Initiation of daily smoking and 
nicotine dependence in schizophrenia and mood disorders. Schizophrenia 
Research, 56, 47-54. 
De Leon., T. J., McCann E., McGrory A., Diaz FJ., (2002) Schizophrenia and 
tobacco smoking: a replication study in another US psychiatric hospital. 
Schizophrenia Research, 56, 55-65. 
De Luca V., Wong AH., Muller DJ., et al (2004) Evidence of association between 
smoking and alpha-7 nicotinic receptor subunit gene in schizophrenia 
patients. Neuropsychopharmacology, 29, 1522-1526. 
Decina P., Caracci G., Sandyk R., et al (1990) Cigarette smoking and neuroleptic-
induced parkinsonism. Biological Psychiatry, 28, 502-508. 
Degenhardt L. & Hall W. (2001) The association between psychosis and 
problematical drug use among Australian adults: findings from the National 
Survey of Mental Health and Well-being. Psychological Medicine, 31, 659-
668. 
Dewey SL., Brodie JD., Gerasimov M., et al (1999) A pharmacologic strategy for 
the treatment of nicotine addiction. Synapse, 31, 76-86. 
Dickerson FB., Pater A. & Origoni AE. (2002) Health behaviours and health status 
of older women with schizophrenia. Psychiatric Services, 53, 882-884. 
Diez-Manrique JF. (1996) Salud Urbana. Santander: Servicio de publicaciones de 
la Universidad de Cantabria. 
Dijkstra A. & Tromp D. (2002) Is the FTND a measue of physical as well as 
psychological tobacco dependence? Journal of Substance Abuse Treatment, 
23, 367-374. 
Diwan A., Castine M., Pomerleau CS., et al (1998) Differential prevalence of 
cigarette smoking in patients with schizophrenic vs mood disorders. 
Schizophrenia Research, 33, 113-118. 
Doll R. & Hill A. (1950) Smoking and carcinoma of the lung: preliminary report. 
British Medical Journal, 2, 739-748. 
Doll R., Peto R., Boreham J., et al (2004) Mortality in relation to smoking: 50 
years' observations in male british doctors. British Medical Journal, 328, 
1519. 
Dursun SM. & Kuchter S. (1999) B5 Smoking, nicotine and psychiatric disorders: 
evidence for therapeutic role, contoversies and implications for future 
research. Medical Hypotheses, 52, 101-109. 
Eissenberg T. (2004) Measuring the emergence of tobacco dependence: The 
contribution of negative reinforcement models. Addiction, 99(Suppl. 1), 5-29. 
El Guebaly N. & Hodgkins DC. (1992) Schizoprehnia and substance abuse: 
Prevalence issues. Canadian Journal of Psychiatry, 37, 704-710. 
 117
Eubanks JH., Djabali M., Selleri L., et al (1992) Structure and linkage of the D2 
dopamine receptor and neural cell adhesion molecule genes on human 
chromosme 11q23. Genomics, 14, 1010-1018. 
Eysenck HJ. (1973) Personality and the maintenance of the smoking habit. In 
Smoking Behaviour: Motives and Incentives (ed W. L. Dunn). Washington: 
Winston. 
Eysenck HJ. & Eaves EJ. (1980) The causes and effects of smoking. London: 
Maurice temple Smith. 
Fagerstrom K. (2002) The Epidemiology of Smoking. Health Consequences and 
Benefits of Cessation. Drugs, 1-9. 
Feighner JP., Gardner EA., Johnstone JA., et al (1991) Double-blind comparison 
of bupropion and fluoxetine in depressed outpatients. Journal of Clinical 
Psychiatry, 52, 329-335. 
Forchuk C., Norman R., Malla A., et al (2002) Schizophrenia and the Motivation 
for Smoking. Perspectives in Psychiatric Care, 38, 41-49. 
---- (1997) Smoking and schizophrenia. Journal of Psychiatric and Mental Health 
Nursing, 4, 355-359. 
Foulds J. (1999) The relationship between tobacco use and mental disorders. 
Current Opinion in Psychiatry, 12(3), 303-306. 
Foulds J. & Toone B. (1995) A case of nicotine psychosis? Addiction, 90, 435-437. 
Fowler IL., Carr VJ., Carter NT., et al (1998) Patterns of current and lifetime 
substance use in schizophrenia. Schizophrenia Bulletin, 24, 443-455. 
Fowler JS., Volkow ND., Wang G-J., et al (1996) Inhibition of monoamine oxidase 
B in the brains of smokers. Nature, 379, 733-736. 
Frank PI., Morris JA., Frank TL., et al (2004) Trends in smoking habits. A 
longitudinal population study. Family Practice, 21, 33-38. 
Freedman R., Adams CE. & Leonard S. (2000) The alpha7-nicotinic receptor and 
the pathology of hippocampal interneurones in schizophrenia. Journal of 
Chemical Neuroanatomy, 20, 299-306. 
Freedman R., Adler LE., Bickford P., et al (1994) Schizophrenia and Nicotinic 
Receptors. Harvard Review of PSychiatry, 2, 179-192. 
Freedman R., Coon H., Myles-Worsley M., et al (1997) Linkage of a 
neurophysiological deficit in schizophrenia to a chromosome 15 locus. 
Proceedings of the National Academy of Sciences USA, 94, 587-592. 
Freedman R., Hall M., Adler LE., et al (1995) Evidence of postmortem brain tissue 
for decreased num,bers of hippocampal nicotinic receptors in schizophrenia. 
Biological Psychiatry, 38, 22-33. 
Fung YK. (1988) Effects of chronic nicotine pretreatment on amphetamine and 
nicotine-induced synthesis and release of [3H]dopamine form [3H]tyrosine in 
rat nucleus accumbens. Journal of Pharmacy and Pharmacology, 41, 66-68. 
Fung YK., Schmid MJ., Anderson TM., et al (1996) Effects of nicotine withdrawal 
on central dopaminergic systems. Pharmacology, Biochemstry and 
Behaviour, 53, 635-640. 
Fuxe K., Janson AM., Jansson A., et al (1990) Chronic nicotine treatment increases 
dopamine levels and reduces dopamine utilisation in substantia nigra and in 
surviving forebrain dopamine nerve terminal systems after a partial 
dimesencephalic hemitransection. Naunyn Schmiedebergs Archives of 
Pharmacology, 341, 171-181. 
 118
George TP., S. M., Ziedonis DM., Woods SW., (1995) Effects of clozapine on 
smokingin chronic schizophrenic outpatients. Journal of Clinical Psychiatry, 
56, 344-346. 
Glass R. (1990) Blue mood, blackened lungs: depression and smoking. Jounral of 
the American Medical Association, 264, 1583-1584. 
Glassman AH. (1993) Cigarette smoking: Implications for Psychiatric Illness. 
American Journal of Psychiatry, 150, 546-553. 
Glautier S. (2004) Measures and models of nicotine dependence: positive 
reinforcement. Addiction, 99(Suppl. 1), 30-50. 
Glautier S., Clements K., White JA., et al (1996) Alcohol and the reward value of 
smoking. Behavioural Pharmacology, 7, 144-154. 
Glynn SM. & Sussman S. (1990) Why patients smoke. Hospital and Community 
Psychiatry, 41, 1189-1194. 
Goff DC., H. D., Amico E., (1992) Cigarette smoking in schizophrenia: relationship 
to psychopathology and medication side effects. American Journal of 
Psychiatry, 149, 1189-1194. 
Grenhoff J., Jannson AM., Svensson TH., et al (1991) Chronic continuous nicotine 
treatment causes decreased burst firing of nigral dopamine neurons in rats 
partially hemitransected at the meso-diencephalic junction. Brain Research, 
562, 347-351. 
Griffith JD., Cavanaugh J., Held J., et al (1972) Dextroamphetamine: evaluation 
of psychotomimetic properties in man. Archives of General Psychiatry, 26, 
97-100. 
Gurpuegui M., Martinez-Ortega JM., Aguilar MC., et al (2005) Smoking 
intiation and schizophrenia: a replication study in a Spanish sample. 
Schizophrenia Research, 76, 113-118. 
Hafner H., Riecher A., Maurer K., et al (1989) How does gender influence age at 
first hospitalisation for schizophrenia. A transnational case register study. 
Psychological Medicine, 19, 903-918. 
Hall RG., Duhamel M., McClanahan R., et al (1995) Level of functioning, severity 
of illness and smoking status among chronic psychiatric patients. Journal of 
Nervous and Mental Disease, 183, 468-471. 
Hamera E., Schneider JK. & Deviney S. (1995) Alcohol, cannabis, nicotine and 
caffeine use and symptom distress in schizophrenia. Journal of Nervous and 
Mental Disease, 183, 559-565. 
Hasselmo ME., Schnett E. & Barkai E. (1995) Dynamics of learing and recall at 
excitatory recurrent synapses and cholinergic modulation in rat hippocampal 
region CA3. Journal of Neuroscience, 15, 5249-5262. 
Hatsukami D., Fletcher L., Morgan S., et al (1989) The effects of varying cigarette 
deprivation duration on cognitive and performance tasks. Journal of 
Substance Abuse, 1, 407-416. 
Heath AC., Cates RC., Martin NG., et al (1993) Genetic contribution to risk of 
smoking initiation: comparisons across birth cohorts and across cultures. 
Journal of Substance Abuse, 5, 221-246. 
Heatherton T., Kozlowski LT., Frecker RC., et al (1991) The Fagerstrom Test for 
Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire. 
British Journal of Addiction, 86, 1119-1127. 
 119
Hecker E. (1871) Die Hebephrenie. Virchows Archiv fur Pathologie and Anatomie, 
52, 394-429. 
Helton DR., Tizzano JP., Monn JA., et al (1997) LY354740: A metabotropic 
glutamate receptor agonist whcih ameliorates symptoms of nicotine 
withdrawal in rats. Neuropsychopharmacology, 113, 205-210. 
Henningfield JE., Stapleton JM., Benowitz NL., et al (1993) Higher levels of 
nicotine in arterial than in venous blood aftre cigarett smoking. Drug and 
Alcohol Dependence, 33, 23-29. 
Herran A., Santiago A., Sandoya M., et al (2000) Determinants of smoking 
behaviour in outpatients with schizophrenia. Schizophrenia Research, 41, 
373-381. 
Herz A. (1997) Endogenous opioid systems and alcohol addcition. 
Psychopharmacology, 129, 99-111. 
Himelhoch S. & Daumit G. (2003) To whom do psychiatrists offer smoking-
cessation counselling? American Journal of Psychiatry, 160, 2228-2230. 
Hodges A., Byrne M., Grant E., et al (1999) People at risk of schizophrenia: 
Sample characteristics of the first 100 cases in the Edinburgh High-Risk 
Study. British Journal of Psychiatry, 174, 547-553. 
Hoffmann D., Hoffmann I. & El-Bayoumy K. (2001) The less harmful cigarette: A 
controversial issue. A tribute to Ernst L. Wynder. Chemical Research in 
Toxicology, 14, 767-790. 
Holzman PS., Kringlen E., Matthysse S., et al (1988) A single dominant gene can 
account for eye tracking dysfunctions and schizophrenia in offspring of 
discordant twins. Archives of General Psychiatry, 45, 641-647. 
Houdi AA., Pierzchala K., Marson L., et al (1991) Nicotine-induced alteration in 
try-gly-gly and met-enkephalin in discrete brain nuclei reflects altered 
enkephalin neuron activity. Peptides, 12, 161-166. 
Hu XT. & White FJ. (1996) Glutamate receptor regulation of rat nucleus 
accumbens in vivo. Synapse, 23, 208-218. 
Hughes JR. (1986) Genetics of smoking: A Brief Review. Behaviour Therapy, 17, 
335-345. 
Hughes JR., Gust SW., Skoog K., et al (1991) Symptoms of tobacco withdrawal: a 
replication and extension. Archives of General Psychiatry, 48, 52-59. 
Hughes JR., Hatsukami DK., Mitchell JE., et al (1986) Prevalence of Smoking 
Among Psychiatric Outpatients. American Journal of Psychiatry, 143, 993-
997. 
Hughes JR., Hatsukami DK., Pickens RW., et al (1984) Effects of  nicotine on the 
tobacco withdrawal syndrome. Psychopharmacology, 83, 82-87. 
Imperato A., Mulas A. & DiChiara G. (1986) Nicotine preferentially stimulates 
dopamine release in the limbic system of freely moving rats. European 
Journal of Pharmacology, 90, 468-470. 
Itkin O., Nemets B. & Einat H. (2001) Smoking habits in bipolar and schizophrenic 
outpatients in southern Israel. Journal of Clinical Psychiatry, 62, 269-272. 
Jablensky A. (1995) Schizophrenia. Recent epidemiologicl issues. Epidemiological 
reviews, 10-20. 
Jacobs MA., Knapp PH., Anderson LS., et al (1965) Relationship of oral 
frustration factors with heavy cigarette smoking in males. Journal of Nervous 
and Mental Disease, 141, 161-171. 
 120
Jann M., Saklad SR., Ereshefsky L., et al (1986) Effects of smoking on haloperidol 
and reduced haloperidol plasma concentrations and haloperidol clearance. 
Psychopharmacology, 90, 468-470. 
Janson AM., Agnati LF., Fuxe K., et al (1988) GM1 ganglioside protects against 1-
methyl-4-phenyl-1,2,3,6,tetrahydropyridine-induced degenration of 
nigrostriatal dopmaine neurons in the black mouse. Acta Physiologica 
Scandinavica, 132, 587-588. 
Jarvik ME. & Schneider NG. (1992) Nicotine. In Substance Abuse: A 
Comprehensive Textbook, 2nd ed (ed R. P. Lowinson JH., Millman RB.). 
Baltimore: Williams & Wilkins. 
Johnston JA., Schmidt G., Ascher JA., et al (2002) Pharmacokinetic optimisation 
of  bupropion SR for smoking cessation. Drugs, 62(suppl 2), 11-24. 
Johnstone EC., Abukmeil SS., Byrne M., et al (2000) Edinburgh high risk study - 
findings after four years: demographic attainment and psychopathological 
issues. Schizophrenia Research, 46, 1-15. 
Johnstone EC., Crow TJ., Frith CD., et al (1978) Mechanism of the antipsychotic 
effect in the treatment of acute schizophrenia. Lancet i, 848-851. 
Johnstone EC., Miller P., Ebmeier KP., et al (2005) Predicting schizophrenia: 
findings from the Edinburgh High-Risk Study. British Journal of Psychiatry, 
186, 18-25. 
Johnstone EC., Owens DGC., Bydder GM., et al (1989) The spectrum of structural 
brain changes in schizophrenia: age at onset as a predictor of cognitive and 
clincal impairments and their cerebral correlates. Psychological Medicine, 19, 
91-103. 
Kahlbaum K. (1863) Die gruppirung der psychichen Krankheiten. 
Kane JM., Honigfield G., Singer J., et al (1988) Clozapine for the treatment-
resistant schizophrenic. A double-blind comparison with chlorpromazine. 
Archives of General Psychiatry, 45, 789-796. 
Kaprio J., Sarna S., Koskenvuo M., et al (1978) The Finnish Twin Registry: 
Baseline Characteristics. Helsinki: University of Helsinki Press. 
Kapur S. (1998) A new framework for investigation antipsychotic action in humans: 
lessons from PET imaging. Molecular Psychiatry, 3, 135-140. 
Kavanagh DJ., Waghorn G., Jenner L., et al (2004) Demographic and clinical 
correlates of comorbid substance use disorders in psychosis: Multivariate 
analyses from an epidemiological sample. Schizophrenia Research, 66, 115-
124. 
Kay SR., Fiszbein A. & Opler LA. (1987) The Positive and Negative Syndrome 
Scale  (PANSS) for schizophrenia. Schizophrenia Bulletin, 13, 261-276. 
Kelly C. & McReadie RG. (1999) Smoking habits, current symptoms and 
premorbid characteristics of schizophrenic patients in Nithsdale, Scotland. 
American Journal of Psychiatry, 156, 1751-1757. 
Kendler KS. & Gardner CO. (1997) The Risk for Psychiatric Disorders in 
Relatives of Schizophrenic and Control Probands: A Comparison of Three 
Independent Studies. Psychological Medicine, 27, 411-419. 
Kendler KS., Mcguire M., Gruenberg A., et al (1993) The Roscommon Family 
Study: I. Methods, Diagnosis of Probands, and Risk of Schizophrenia in 
Relatives. Archives of General Psychiatry, 50, 527-540. 
 121
Kendler KS., Neale MC., MacLean CJ., et al (1993) Smoking and major 
depression: A causal analysis. Archives of General Psychiatry, 50, 36-43. 
Kendler KS., Thornton LM. & Pedersen NL. (2000) Tobacco consumption in 
Swedish twins reared apart and reared together. Archives of General 
Psychiatry, 57, 886-892. 
Kessler II. & Diamond DL. (1971) Epidemiologic studies of Parkinson's disease. 1. 
Smoking and Parkinson's disease: a survey and explanatory hypothesis. 
American Journal of Epidemiology, 94, 16-25. 
Khantzian EJ. (1985) The self-medication hypothesis of addictive disorders: focus 
on heroin and cocaine dependence. American Journal of Psychiatry, 142, 
1259-1264. 
---- (1997) The Self-Medication Hypothesis of Substance Use Disorders: A 
Reconsideration and Recent Applications. Harvard Review of Psychiatry, 4, 
231-244. 
Kirch DG., Gerhardt GA., Shelton RC., et al (1987) Effect of chronic nicotine 
administration on monoamine and monoamine metabolite concentrations in 
rat brain. Clinical Neuropharmacology, 10, 376-383. 
Klein C. & Andresen B. (1991) On the influence of smoking upon smooth pursuit 
eye movements of schizophrenics and normal controls. Journal of 
Psychophysiology, 5, 361-369. 
Koob GF. (1996) Drug addiction: the yin and yang of hedonic homeostasis. Neuron, 
16, 893-896. 
Koob GF. & Le Moal. (1997) Drug abuse: hedonic homeostatic dysregulation. 
Science, 278, 52-58. 
Kornhuber J., Riederer P., Reynolds GP., et al (1989) [3H]-Spiperone binding 
sites in post-mortem brains from schizophrenic patients: relationship to 
neuroleptic drug treatment, abnormal movements and positive symptoms. 
Journal of Neural Transmission, 75, 1-10. 
Kraeplin E. (1919/1971) Dementia Praecox. New York: Churchill Livingstone Inc. 
Krishan-Sarin S., Rosen MI. & O'Malley SS. (1999) Naloxone challenge in 
smokers: preliminary evidence of an opioid component in nicotine 
dependence. Archives of General Psychiatry, 56, 663-668. 
Kuehn BM. (2006) Link between smoking and mental illness may lead to 
treatments. JAMA, Vol 295. 
Lane A., Kinsella A., Murphy P., et al (1997) The anthopometric assessment of 
dysmorphic features in schizophrenia as an index of its developmental 
origins. Psychological Medicine, 27, 1155-1164. 
Langsley N., Miller P., Byrne M., et al (2005) Dermatoglyphics and Schizophrenia: 
findings from the Edinburgh high risk study. Schizophrenia Research, 74, 
122-124. 
Lapin EP., Maker HS., Sershen H., et al (1987) Dopamine-like action of nicotine: 
lack of tolerance and reverse-tolerance. Brain Research, 407, 351-363. 
---- (1989) Action of nicotine on accumbens dopamine and attenuation with repeated 
administration. European Journal of Pharmacology, 160, 53-59. 
Larrison-Faucher AL., Matorin AA. & Sereno AB. (2004) Nicotine reduces 
antisaccade errors in task impaired schizophrenic subjects. Progress in 
Neuro-Psychopharmamcology and Biological Psychiatry, 28, 505-516. 
 122
Laruelle M. & A, A.-D. (1999) Dopamine as the wind of psychotic fire: new 
evidence form brain imaging studies. Journal of Psychopharmacology, 13, 
358-371. 
Lawn SJ., Pols RG. & Barber JG. (2002) Smoking and quitting: a qualitative study 
with community-living psychiatric clients. Social Science and Medicine, 54, 
93-104. 
Lawrie SM., Buckley LA., Ulyatt BC., et al (1995) Cigarette smoking in 
psychiatric inpateints. Journal of The Royal Society of Medicine, 88, 59. 
Lawrie SM., McIntosh A. & Rao S. (2000) Critical Appraisal for Psychiatry: 
Churchill Livingstone. 
Leonard S. (2003) Consequence of low levels of nicotinic acetylcholine receptors in 
schizophrenia for drug development. Drug Development Research, 60, 127-
136. 
Leonard S., Adams C., Breese CR., et al (1996) Nicotinic Receptor Function in 
Schizophrenia. Schizophrenia Bulletin, 22, 431-445. 
Leonard S., Adler LE., Benhammou K., et al (2001) Smoking and mental illness. 
Pharmcacology, Biochemistry and Behaviour, 70, 561-570. 
Leonard S., Gault J., Hopkins J., et al (2002) Promoter variants in the alpha-7 
nicotinic acetylcholine receptor subunit gene are associated with an 
inhihbitory deficit found in schizophrenia. Archives of General Psychiatry, 
59, 1085-1096. 
Levin ED., Conners CK., Silva D., et al (1998) Transdermal nicotine effects on 
attention. Psychopharmacology, 140, 135-141. 
Levin ED. & Resvani AH. (2002) Nicotinic treatment for cognitive dysfunction. 
Current Durg Targets: CNS and Neurological Disorders, 1, 423-431. 
Levin ED. & Simon BB. (1998) Nicotinic acetylcholine involvement in cognitive 
function in animals. Psychopharmacology, 138, 217-230. 
Levin ED., Westman EC., Stein RM., et al (1994) Nicotine skin patch treatment 
increases abstinence, decreases withdrawal and attenuates rewarding effects 
of smoking. Journal of Clinical Psychopharmacology, 14, 41-49. 
Levin ED., Wilson W., Rose JE., et al (1996) Nicotine-haloperidol interactions and 
cognitive performance in schizophrenics. Neuropsychopharmacology, 15, 
429-436. 
Levy DL., Holzman PS., Matthysse S., et al (1994) Eye tracking and 
schizophrenia: a selective review. Schizophrenia Bulletin, 20, 47-62. 
Liao D-H., Yang J-Y., Lee S-M., et al (2002) Smoking in Chronic Schizophrenic 
Inpatients in Taiwain. Neuropsychobiology, 45, 172-175. 
Lieberman JA. (2004) Dopamine partial agonists: a new class of antipsychotic. CNS 
Drugs, 18, 251-267. 
Lieberman JA., Kinon BJ. & Loebel AD. (1990) Dopaminergic mechanism in 
idiopathic and drug-induced psychoses. Schizophrenia Bulletin, 16, 97-100. 
Llerena A., De La Rubia A., Pen~as-Lledo EM., et al (2003) Schizophrenia and 
tobacco smoking in a Spanish psychiatric hospital. Schizophrenia Research, 
60, 313-317. 
Lohr JB. & Flynn K. (1992) Smoking and Schizophrenia. Schizophrenia Research, 
8, 93-102. 
Lyon ER. (1999) A review of the effects of nicotine on schizophrenia and 
antipsychotic medications. Psychiatric Services, 50, 1346-1350. 
 123
Lyons MJ., Kremen WS., Eisen SA., et al (2002) Nicotine and Familial 
Vulnerability to Schizophrenia: A Discordant Twin Study. Journal of 
Abnormal Psychology, 111, 687-693. 
Lysaker PH., Bell MD., Bioty SM., et al (1995) The frequency of associations 
between positive and negative symptoms and dysphoria in schizophrenia. 
Comprehensive Psychiatry, 36, 113-117. 
Masterson E. & O'Shea B. (1984) Smoking and malignancy in schizophrenia. 
British Journal of Psychiatry, 145, 429-432. 
McConnell J. (2004) First Minister's Statement to Parliament. 
McCreadie RG. (2002) Use of drugs, alcohol and tobacco by people: case-control 
study. British Journal of Psychiatry, 181, 321-325. 
---- (2003) Diet, smoking and cardiovascular risk in people with schizophrenia: 
Descriptive study. British Journal of Psychiatry, 181, 534-539. 
McCreadie RG., Paterson JR., Blacklock C., et al (2000) Smoking habits and 
plasma lipid peroxide and vitamin E levels in never- treated first-episode 
patients with schizophrenia. British Journal of Psychiatry, 176, 290-293. 
McEvoy JP. & Brown S. (1999) Smoking in first-episode patients with 
schizophrenia. American Journal of Psychiatry, 156, 1120-1121. 
McEvoy JP., Feudenreich O., Levin ED., et al (1995) Haloperidol increase 
smoking in patients with schizophrenia. Psychopharmacology, 119, 124-126. 
McEvoy JP., Freudenreich O., McGee M., et al (1995) Clozapine decreases 
smoking in patients with chronic schizophrenia. Biological Psychiatry, 37, 
550-552. 
McEvoy JP., Rose JE., Levin ED., et al (1994) Clozapine decreases drives to 
smoke. Schizophrenia Research, 11, 104. 
McGehee DS., Heath MJS., Gelber S., et al (1995) Nicotine enhancement of fast 
excitatory synaptic transmission in the CNS by presynaptic receptors. 
Science, 269, 1692-1696. 
McGuffin P., Farmer A. & I., H. v. (1991) A polydiagnostic application of 
operational criteria in studies of psychotic illness. Archives of General 
Psychiatry, 764-770. 
McIntosh AM., Forrester A., Lawrie SM., et al (2001) A factor model of the 
functional psychoses and the relationship of factors to clnical variables and 
brain morphology. Psychological Medicine, 31, 159-171. 
McReadie RG., o. b. o. t. S. C. S. G. (2002) 90 Use of drugs, alcohol and tobacco 
by people: case-control study. British Journal of Psychiatry, 181, 321-325. 
Meehl PE. (1962) Schizotaxia, schizotypy, schizophrenia. American Psychologist, 
17, 827-838. 
Meltzer HY. (1991) The mechanism of action of novel antipsychotic drugs. 
Schizophrenia Bulletin, 127, 263-287. 
Menza MA., Grossman N., Van Horn M., et al (1991) Smoking and movement 
disorders in psychiatric patients. Biological Psychiatry, 30, 109-115. 
Mester RE., Toren P., Ben-Moshe Y., et al (1993) Survey of smoking habits and 
attitudes of patients and staff in psychiatric hospitals. Psychopathology, 26, 
69-75. 
Mexal S., Frank M., Berger R., et al (2005) Differential modulation of gene 
expression in the NMDA postsynaptic density of schizophrenic and control 
smokers. Molecular Brain Research, 139, 317-332. 
 124
Miller DD., Kelly MW., Perry PJ., et al (1990) The influence of cigarette smoking 
on haloperidol pharmacokinetics. Biological Psychiatry, 28, 529-531. 
Milner PM. (1991) Brain-stimulation reward: a review. Canadian Journal of 
Psychology, 45, 1-36. 
Moghaddam B. & Bunney BS. (1990) Acute effects of typical and atypical 
antipsychotic drugs on the release of dopamine from prefrontal cortex, 
nucleus accumbens and striatum of the rat: an in vivo microdialysis study. 
Journal of Neurochemistry, 54, 1755-1760. 
Morel BA. (1860) Traite des malades mentales. 
Morens DM., Grandinetti A., Reed D., et al (1995) Cigarette smoking and 
protection from Parkinson's disease: false association or etiologic clue? 
Neurology, 45, 1041-1045. 
Mori T., Sasaki T., Iwanami A., et al (2003) Smoking habits in Japanese patients 
with schizophrenia. Psychiatry Research, 120, 207-209. 
Myrsten AL., Andersson K., Frankenhauser M., et al (1975) Immediate effects of 
cigarette smoking related to different smoking habits. Perceptual and Motor 
Skills, 40, 515-523. 
Nagamoto HT., Adler LE., Hea RA., et al (1996) Gating of auditory P50 in 
schizophrenics: unique effects of clozapine. Biological Psychiatry, 40, 181-
188. 
Nemeroff CB., DeVane CL. & Pollock BG. (1996) Newer antidepressants and they 
cytochrome P450 system. American Journal of Psychiatry, 153, 311-320. 
Nemeth-Coslett R. & Griffiths RR. (1986) Naloxone does not affect cigarette 
smoking. Psychopharmacology, 89, 261-264. 
Newhouse PA., Potter A. & Levin Ed. (1997) Nicotinic system involvement in 
Alzheimer's and Parkinson's diseases. Implications for therapeutics. Drugs 
and Aging, 11, 206-228. 
Nissel M., Nomikos GG. & Svensson TH. (1994) Systemic nicotine induced 
dopmaine release in the rat nucleus accumbens is regulated by the nicotine 
receptors in the ventral tegmental area. Synapse, 16, 36-44. 
Noble EP. (2000) Addiction and its reward process through polymorphisms of the 
dopamine D2 receptor gene: a review. European Psychiatry, 15, 79-89. 
Nokikos GC., Damsma G., Wenkstern D., et al (1989) Acute effects of bupropion 
on extracellular dopamine concentrations in rat striatum and nucleus 
accumbens studied by in vivo microdialysis. Neuropsychopharmacology, 
273-279. 
O'Farrell TJ., Connors GJ. & Upper D. (1983) Addictive behaviors among 
hospitalized psychiatric patients., 8, 329-333. 
Olincy A., Ross RG., Young DA., et al (1998) Improvement in smooth pursuit eye 
movements after cigarette smoking in schizophrenic patients. 
Neuropsychopharmacology, 18, 175-185. 
Olincy A., Young DA. & Freedman R. (1997) Increased levels of the nicotine 
metabolite cotinine in schizophrenic smokers compared to other smokers. 
Biological Psychiatry, 42, 1-5. 
Orford J. (1985) Excessive appetites: A psychological view of addicitions. 
Chichester, England.: Wiley. 
 125
Orlando M., Ellickson PL. & Jinnett K. (2001) The temporal association between 
emotional distress and cigarette smoking during adolescence and young 
adulthood. Journal of Consulting and Clinical Psychology, 69, 959-970. 
Osler M., Holst C., Prescott E., et al (2001) Influence of genes and environment on 
adult smoking behaviour assessed in an adoption study. Genetic 
Epidemiology, 21, 193-200. 
Overall JE. & Gorham DR. (1962) The Brief Psychiatric Rating Scale. 
Psychological Reports, 10, 799-812. 
Owen F., Cross AJ., Crow TJ., et al (1978) Increased dopamine receptor sensitvity 
in schizophrenia. Lancet ii, 223-225. 
Owens DGC., Miller P., Lawrie SM., et al (2005) Pathogenesis of schizophrenia: a 
psychopathological perspective. British Journal of Psychiatry, 186, 386-393. 
Patkar AA., Alexander RC., Lundy A., et al (1999) Changing patterns of illicit 
substance abuse among schizophrenic patients 1984-1996. American Journal 
of Addictions, 8, 65-71. 
Patkar AA., Gopalakrishnan R., Lundy A., et al (2002) Relationship between 
tobacco smoking and positive and negative symptoms in schizophrenia. 
Journal of Nervous and Mental Disease, 190, 604-610. 
Peto R., Lopez AD., Boreham J., et al (1996) Mortality from smoking worldwide. 
British Medical Bulletin, 12-21. 
Pidoplichko VI., DeBias M., Williams JT., et al (1997) Nicotine activates and 
desensitizes midbrain dopamine neurons. Nature, 401-404. 
Poirier M-F., Canceil O., Bayle F., et al (2002) Prevalence of smoking in 
psychiatric patients. Progress in Neuro-Psychopharmamcology and 
Biological Psychiatry, 26, 529-537. 
Pomerleau OF. & Pomerleau CS. (1992) Euphoriant effects of nicotine in smokers. 
Psychopharmacology, 108, 460-465. 
Prasad C., Spahn SA. & Hiromasa I. (1989) Chronic nicotine use blocks 
haloperidol-induced increase in striatal D2-dopamine receptor density. 
Biochemical and Biophysical Research Communications, 159, 48-52. 
Procyshyn RM., Ihsan N. & Thompson D. (2001) A comparison of smoking 
behaviours between patients treated with clozapine and depot neuroleptics. 
International Clinical Psychopharmacology, 16, 291-294. 
Procyshyn RM., Patel K. & Thompson DL. (2004) Smoking, anticholinergics and 
schizophrenia. Schizophrenia Research, 67, 313-314. 
Rasmussen K., Kallman MJ. & Helton DR. (1997) Serotonin-1A antagonists 
attenuate the effects of nicotine withdrawal on the auditory startle response. 
Synapse, 27, 145-152. 
Revzani AH. & Levin ED. (2001) Cognitive effects of nicotine. Biological 
Psychiatry, 49, 258-267. 
Reynolds GP. (1983) Increased concentration and lateral assymetry of amygdala 
dopamine in schizophrenia. Nature, 305, 527-529. 
Riala K., Hakko H., Isohanni M., et al (2005) Is initiation of smoking associated 
with the prodromal phase of schizophrenia? Journal of Psychiatry and 
Neurosciences, 30, 26-32. 
Ripoll N., Bronnec M. & Bourin M. (2004) Nicotinic receptors and schizophrenia. 
Current Medical Research and Opinions, 20, 1057-1074. 
 126
Rose JE., Behm FM., Westman EC., et al (2003) PET studies of the Influences of 
Nicotine on Neural Systems in Cigarette Smokers. American Journal of 
Psychiatry, 160, 323-333. 
Russell MA. (1989) Subjective and behavioural effects of nicotine in humans: some 
sources of individual variation. Progress in Brain Research, 79, 289-302. 
Sahakian B., Jones G., Levy R., et al (1989) The effects of nicotine on attention, 
information processing and short-term memory in pateints with dementia of 
the Alzheimer type. British Journal of Psychiatry, 154, 797-800. 
Sandyk R. (1993) Cigarette smoking: effects on cognitive functions and drug-
induced parkinsonism in chronic schizophrenia. International Journal of 
Neuroscience, 70, 193-197. 
Sandyk R. & Kay SR. (1991) Tobacco addiction as a marker of age at onset of 
schizophrenia. International Journal of Neuroscience, 57, 259-262. 
Sato M., Numachi Y. & Hamamura T. (1992) Relapse of paranoid psychotic state 
in methamphetamine model of schizophrenia. Schizophrenia Bulletin, 18, 
115-122. 
Schelling TC. (1992) Addictive drugs: The cigarette experience. Science, 255. 
Seguela P., Wadiche J., Dinely-Miller K., et al (1993) Molecular cloning, 
functional properties and distribution of rat brain alpha7: a nicotinic cation 
channel highly permeable to calcium. Journal of Neuroscience, 13, 596-604. 
Shafari M. (2005) Comparison of classical and clozapine treatment on schizophrenia 
using the positive and negative symptom scale (PANSS) and SPECT 
imaging. International Journal of Medical Sciences, 2, 79-86. 
Siegel C., Waldo M., Mizner G., et al (1984) Deficits in sensory gating in 
schizophrenic patients and their relatives. Archives of General Psychiatry, 41, 
607-612. 
Silvestri S., Negrete JC., Seeman MV., et al (2004) Does nicotine affect D2 
receptor upregulation? A case-control study. Acta Psychiatrica Scandinavica, 
109, 313-318. 
Smith GL. (1996) Schizophrnia, Smoking and Boredom. American Journal of 
Psychiatry, 153, 583. 
Solomon RL. & Corbit JD. (1973) An opponent-process thoery of motivation. II. 
Cigarette addiction. Journal of Abnormal Psychology, 81, 158-171. 
Spitzer RL., Williams VBW., Gibbon M., et al (1987) User guide for the 
Structured Clinical Interview for DSM III-R. New York: Department of 
Psychiatry, Columbia University Biometrics Research, New York State 
Psychiatric Institute. 
Srinavasan TN. & Thara R. (2002) Smoking in schizophrenia - all is not 
biological. Schizophrenia Research, 56, 67-74. 
Stahl SM., Pradko JF., Haight BR., et al (2004) A review of the 
neuropharmacology of Bupropion, a dual norepinephrine and dopamine 
reuptake inhibitor. Primary Care Companion Journal of Clinical Psychiatry, 
6, 159-165. 
Stassen HH., Bridler R., Hagele S., et al (2000) Schizophrenia and Smoking: 
Evidence for a Common Neurobiological Basis? American Journal of 
Medical Genetics (Neuropsychiatric Genetics), 96, 173-177. 
 127
Stein EA., Pankiewiz J., Harsch HH., et al (1998) Nicotine-induced limbic cortical 
activation in the human brain: a functional MRI study. American Journal of 
Psychiatry, 155, 1009-1015. 
Svensonn T. & Enberg G. (1980) Effect of nicotine on single cell activity in the 
noradrenergic locus coeruleus. Acta Physiologica Scandinavica, S479, 31-34. 
Svensson TH., Grenhoff J. & Enberg G. (1990) Effect of nicotine on dynamic 
function of brain catecholamin neurons. In The Biology of Nicotine 
Dependence 
 (ed G. Bock), pp. 169-185. New York: New York. 
Swett CJ. (1974) Drowsiness due to chlorpromazine in relation to cigarette smoking: 
a report from the Boston Collaborative Drug Surveillance Program. Archives 
of General Psychiatry, 31, 211-213. 
Taiminen TJ., Salokangas RKR., Saarijarvi S., et al (1998) Smoking and 
cognitive deficits in schizophrenia: A pilot study. Addictive Behaviours, 23, 
263-266. 
Tracy JI., De Leon J., Qureshi G., et al (1996) Repetitive behaviors in 
schizophrenia: A single disturbance or discrete symptoms? Schizophrenia 
Research, 20, 221-229. 
Tregellas JR., Tanabe JL., Miller DE., et al (2004) Neurobiology of smooth 
pursuit eye movement deficits in schizophrenia: an fMRI study. American 
Journal of Psychiatry, 161, 315-321. 
Turecki G., Grof P., Grof E., et al (2000) A genome scan using a pharmacogenetic 
approach indicates a susceptibility locus for bipolar disorder at 15q14. 
Biological Psychiatry, 47, 69S-70S. 
Ucok A., Polat A., Bozkurt O., et al (2004) Cigarette smoking among patients with 
schizophrenia and bipolar disorders. Psychiatry and Clinical Neurosciences, 
58, 434-437. 
Uzun O., Cansever A., Basoglu C., et al (2003) Smoking and substance abuse in 
outpatients with schizophrenia: a 2 year follow up study in Turkey. Drug and 
Alcohol Dependence, 70, 189-192. 
Van Dongen CJ. (1999) Smoking and Persistent Mental Illness: An Exploratory 
Study. Journal of Psychosocial Nursing, 37, 26-34. 
Van Kammen DP. & Boronow JJ. (1988) Dextro-amphetamine diminishes 
negative symptoms of schizophrenia. International Journal of Clinical 
Psychopharmacology, 3, 111-121. 
Vanable PA., Carey MP., Carey KB., et al (2003) Smoking among Psychiatric 
Outpatients: Relationship to Substance Use, Diagnosis, and Illness Severity. 
Psychology of Addictive Behaviours, 17, 259-265. 
Venables P. (1964) Input dysfunction in schizophrenia. New York: Academic Press. 
Vezina P., Blanc Glowinsk J. & Tassin J. (1992) Nicotine and morphine 
differentially activate brain dopamine in prefrontocortical and subcortical 
terminal fields: effect of acute and repeated injections. Journal of 
Pharmacology and Experimental Therapeutics, 261, 484-490. 
Waldo MC., Carey G., Myles-Worsley M., et al (1991) Codistribution of a sensory 
gating defict and schizophrenia in multi-affected families. Psychiatry 
Research, 39, 257-268. 
 128
Waldo MC., Cawthra E., Adler LE., et al (1994) Auditory sensory gating, 
hippocampal volumes and catecholamine metabolsim in shcizophrenics and 
their siblings. Schizophrenia Research, 12, 93-106. 
Walker A., Maher J., Coulthard M., et al (2001) Living in Britiain. Results from 
the 2000-01 General Household Survey. London: The Stationery Office. 
Watkins S., Koob GF. & Markou A. (2000) Neural mechanisms underlying 
nicotine addiction: acute positive reinforcement and withdrawal. Nicotine and 
Tobacco Research, 2, 19-37. 
Watkins S., Stinus L., Koob GF., et al (2000) Reward and somatic changes during 
precipitated nicotine withdrawal in the rat: central and peripheral 
mechanisms. Journal of Phramacology and Experimental Therapeutics, 292, 
1053-1064. 
Weiland S., Betrand D. & Leonard S. (2000) Neuronal nicotinic aceylcholine 
receptors: from the gene to the disease. Behavioural Brain Research, 43-56. 
Weinberger DR. (1987) Implications of normal brain development for the 
pathogenesis of schizophrenia. Archives of General Psychiatry, 44, 660-669. 
---- (1995) From neuropathology to neurodevelopment. Lancet, 346. 
Weiss AP., DeWitt I., Goff D., et al (2005) Anterior and posterior hippocampal 
volumes in schizophrenia. Schizophrenia Research, 73, 103-112. 
Wikipedia (2005a) Cigarettes. 
---- (2005b) Tobacco. 
---- (2006) Bupropion. 
Williams AF. (1973) Personality and other characteristics assoicated with cigarette 
smoking among young teenagers. Journal of Health and Social Behaviour, 
14, 374-380. 
Wing JK., Cooper JE. & Sartorius N. (1974) The Description and Classification of 
Psychiatric Symptoms: an Instruction Manual for the PSE and Catego 
Systems. Cambridge: Cambridge University Press. 
World Health Organisation (1992) International Classification of Diseases -10. 
---- (2003) Factsheet on gender, health and tobacco. 
World Health Organisation. (2004). 
www.cnsforum.com (2005a) Distribution of acetylcholine receptors in the brain. 
---- (2005b) The nicotinic type cholinergic receptor. 
---- (2005c) The noradrenaline pathways in the brain. 
---- (2005d) The serotonin pathways in the brain. 
Yassa R., Samarthji L., Korpassy A., et al (1987) Nicotine exposure and tartdive 
dyskinesia. Biological Psychiatry, 22, 67-72. 
Yoshimasu K. & Kiyohara C. (2003) Genetic Influences on Smoking Behaviour 
and Nicotine Dependence: a Review. Journal of Epidemiology, 13, 183-192. 
Ziedonis DM. & George TP. (1997) Schizophrenia and nicotine use: report of a 
pilot smoking cessation program and review of neurobiological and clinical 
issues. Schizophrenia Bulletin, 23, 247-254. 
Ziedonis DM., Kosten TR., Glazer WM., et al (1994) Nicotine dependence and 
schizophrenia. Hospital and Community Psychiatry, 45, 204-206. 
 
 
